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COMMON ABBREVIATIONS 
α1-AT  Alfa-1-antitrypsin 
AGC  Automatic gain control 
ALAT  Alanine aminotransferase 
Apo C-III Apolipoprotein C-III 
ARCLII Autosomal recessive cutis laxa type II 
ASAT  Aspartate aminotransferase 
AT-III  Anti-thrombin III 
CDG  Congenital disorder of glycosylation 
CHCA  Alfa-Cyano-4-hydroxycinnamic acid 
CNS   Central nervous system 
COG  Conserved oligomeric Golgi (complex) 
CPS  Crystal positioning system 
DHB  2,5-dihydroxybenzoic acid 
DMA  N,N-dimethyl aniline 
Dol  Dolichol 
Dol-PP Dolichol-pyrophosphate 
ER  Endoplasmic reticulum  
ESI-MS Electrospray ionisation mass spectrometry 
Gal  Galactose 
Glc  Glucose 
GlcNAc N-acetyl-glucosamine 
HUS  Hemolytic uremic syndrome 
IEF  Isoelectric focusing 
LC-MS  Liquid chromatography mass spectrometry 
LIT  Linear ion trap 
LLO  Lipid-linked oligosaccharide 
MALDI-MS Matrix assisted laser desorption/ionization mass spectrometry 
Man  Mannose 
MS  Mass spectrometry 
MSn  Multistage mass spectrometry 
NeuAc  Sialic acid 
OST  Oligosaccharyltransferase 
PNGase F Peptide-N4-(acetyl-β-glucosaminyl)-asparagine amidase 
pNP-GlcNAc p-nitrophenyl-N-acetyl-β-D-glucosamine  
RSD  Relative standard deviation 
TBG   Thyroxin binding globulin 
Tf  Transferrin 
TIEF  Transferrin isoelectric focusing  
TOF  Time-of-flight 
V-ATPase Vacuolar H+-ATPase 
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GENERAL INTRODUCTION 
Glycosylation and congenital disorders of glycosylation 
Glycosylation is one of the most important and diverse modifications of 
proteins and lipids: it has been estimated that over 50% of all human proteins are 
glycosylated, and that glycoproteins represent the majority of secreted and cell 
surface proteins [1,2]. Glycans serve many different functions including the 
modulation of protein structure and stability, sorting and targeting of proteins within 
the cell, mediation of cell-cell interactions, and modulation of enzyme activity [3-6]. 
Several types of glycosylation can be distinguished: N-, O- and C-glycosylation of 
proteins, lipid glycosylation, and glycosylphophatidylinositol anchor glycosylation. 
Defects have been described in all types of glycosylation invidually, as well as 
combined defects in different glycosylation routes. These defects are grouped under 
the common denominator ‘congenital disorders of glycosylation’ (CDGs) [7-11]. The 
family of CDGs is rapidly growing, with up to 50 different defects currently known 
[12]. Nevertheless, the prevalance of known CDG patients is very low: PMM2-CDG, 
ALG6-CDG and MPI-CDG are the most common types of CDG reported, with >700 
patients, >30 patients and >20 patients affected worldwide, respectively. With the 
recent diagnosis of several patients, DOLK-CDG and SRD5A3-CDG are becoming more 
prominent types of CDG. Other CDG subtypes, such as COG7-CDG, occur in low 
numbers of patients, and some subtypes have only been described in single patients 
[11]. For the purpose of this thesis, we will focus on defects in the N-glycosylation of 
proteins.  
Originally, CDGs were divided into two distinct groups: CDG type I and CDG 
type II. The distinction was made based on the localisation of the defect along the N-
glycan biosythesis pathway: defects occurring before transfer of the glycan onto the 
protein were classified as type I, whereas defects affecting the processing of the 
protein-bound glycan were classified as type II. Accordingly, two different patterns 
are obtained when performing isoelectric focusing of transferrin, the most common 
first-line diagnostic test for the detection of CDG. With the appearance of defects in 
other pathways and combined defects, a new classification was proposed: defects of 
protein N-glycosylation, defects of protein O-glycosylation, defects in lipid 
glycosylation and glycosylphosphatidylinositol anchor glycosylation, and defects in 
multiple glycosylation pathways. Different subtypes of CDG are named after the 
defective gene, followed by ‘-CDG’ [12-14]. Nevertheless, the use of the original 
classification in CDG type I and type II still remains common among the CDG 
community (Table 1.1).  
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Table 1.1: Known defects affecting N-glycosylation of proteins.  
Human 
Gene 
CDG-name Former  
CDG-name 
Protein name OMIM  
Defective genes of the cytosol and cytosolic side of the ER 
SRD5A3 SRD5A3-CDG  Steroid 5-α-reductase 3 612379 
PMM2 PMM2-CDG CDG Ia Phosphomannomutase 2 212065 
MPI MPI-CDG CDG Ib Mannose-6-phosphate isomerase 602579 
ALG1 ALG1-CDG CDG Ik Beta-1,4-mannosyltransferase 608540 
ALG2 ALG2-CDG CDG Ii Alpha-1,3/1,6-mannosyltransferase 607906 
ALG11 ALG11-CDG CDG Ip Glycolipid 2-alpha-mannosyltransferase 613661 
DPAGT1 DPAGT1-CDG CDG Ij N-acetylglucosamine-1-phosphate transferase 608093 
DOLK DOLK-CDG CDG Im Dolichol kinase 610768 
DPM1 DPM1-CDG CDG Ie Dolichol-phosphate mannose synthase 608799 
DPM3 DPM3-CDG CDG Io Dolichol-phosphate mannose synthase subunit 3 612937 
MPDU1 MPDU1-CDG CDG If Man-P-dolichol utilization defect 1 protein 609180 
Defective genes of the ER lumen 
RTF1 RFT1-CDG CDG In RNA polymerase-associated protein RTF1 
homolog (accessory unit of flippase) 
612015 
ALG3 ALG3-CDG CDG Id Alpha-1,3-mannosyltransferase 601110 
ALG9 ALG9-CDG CDG IL Alpha-1,2-mannosyltransferase 608776 
ALG12 ALG12-CDG CDG Ig Alpha-1,6-mannosyltransferase 607143 
ALG6 ALG6-CDG CDG Ic Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-
glucosyltransferase 
603147 
ALG8 ALG8-CDG CDG Ih Probable dolichyl pyrophosphate 
Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase 
608104 
TUSC3 TUSC3-CDG  Tumor suppression candidate 3 
subunit of the oligosaccharyltransferase 
611093 
MAGT1 MAGT1-CDG  Magnesium transporter protein 1 
subunit of the oligosaccharyltransferase 
300716 
GLS1 GLS1-CDG CDG IIb Glucosidase 1 606056 
Defective genes of the Golgi  
MGAT2 MGAT2-CDG CDG IIa Beta-1,2-N-acetylglucosaminyltransferase II 212066 
B4GALT1 B4GALT1-
CDG 
CDG IId Beta-1,4-galactosyltransferase 1 607091 
SLC35C1 SLC35C1-CDG CDG IIc GDP-fucose transporter 1 266265 
SLC35A1 SLC35A1-CDG CDG IIf CMP-sialic acid transporter  603585 
ATP6V0A2 ATP6V0A2-
CDG 
CDG IIk V-type proton ATPase 116kDa subunit a isoform 2 219200 
278250 
COG1 COG1-CDG CDG IIg Component of oligomeric Golgi complex subunit 1 611209 
COG4 COG4-CDG CDG IIj Component of oligomeric Golgi complex subunit 4 613489 
COG5 COG5-CDG CDG IIi Component of oligomeric Golgi complex subunit 5 613612 
COG6 COG6-CDG CDG IIL Component of oligomeric Golgi complex subunit 6 606977 
COG7 COG7-CDG CDG IIe Component of oligomeric Golgi complex subunit 7 608779 
COG8 COG8-CDG CDG IIh Component of oligomeric Golgi complex subunit 8 611182 
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Because of the ubiquitous requirement of glycoproteins, CDGs usually present 
as multi-system diseases. Neurologic involvement, failure to thrive, liver dysfunction, 
coagulation abnormalities and dysmorphic features are frequent in both CDG type I 
and CDG type II [10,15,16]. Typical CDG type I features include inverted nipples, 
abnormal fat pads, muscle hypotonia and strabismus (Figure 1.1). Ataxia and epilepsy 
are common as well. Congenital vermis hypoplasia and cerebellar atrophy are 
characteristic signs on brain imaging. Most patients develop mental retardation and 
have delayed speech development, however, normal intellectual development does 
not rule out CDG. Additional features of CDG type II patients include hematologic 
involvement and frequent infections. Some CDGs occur with a recognisable clinical 
pattern, helping early diagnosis. For example, PMI-CDG is characterized by hepatic-
intestinal problems [17,18], DPM3-CDG leads to a dystroglycanopathy [19] and 
ATP6V0A2-CDG patients always present with sagging skin [20,21]. The severity of 
clinical presentation can vary from very mild symptoms to a severe multisystem 
presentation. Lethality in CDG patients is usually due to cardiac disease (progressive 
pericardial effucsion or cardiomyopathy), sepsis or bleeding anomalies. Among 
PMM2-CDG, two thirds of the patients survive to adulthood.  
Defects in the N-glycan biosynthesis 
The N-glycosylation pathway is well-understood, and different types of defects 
have been described along the N-glycan biosynthesis route. The pathway starts in the 
cytosol where nucleotide sugars and dolichol are synthesized. In the endoplasmic 
reticulum (ER), a lipid-linked oligosaccharide is assembled and transferred en bloc to 
a nascent protein. After trimming, the glycoprotein is transferred to the Golgi, where it 
is further processed (Figures 1.2, 1.3 and 1.4).  
The sugars needed for glycan biosynthesis are mostly originating from dietary 
sources. Transfer of monosaccharides onto the nascent glycans occurs through the use 
of activated nucleotide sugars: GDP-Man, UDP-Glc, UDP-GlcNAc, GDP-Fuc, UDP-Gal and 
CMP-NeuNAc. Fructose-6-phosphate can be transformed into mannose-1-phosphate 
through the action of mannose-6-phosphate isomerase and phosphomannomutase 2, 
the first enzymes which were known to be deficient in CDG [16,22]. The biosynthesis 
of CMP-NeuNAc requires UDP-GlcNAc 2-epimerase/N-acetylmannosamine kinase 
(GNE). This enzyme is deficient in GNE-CDG, also known as recessive hereditary 
inclusion body myopathy or Nonaka myopathy [23,24]. The activated sugars may then 
be incorporated in the glycans directly at the cytosolic side of the ER, inside the ER 
lumen after flipping over the ER membrane on a dolichol carrier, or inside the Golgi 
lumen. Transfer into the Golgi requires specific transport proteins [25-27]. 
 
Chapter 1 
~ 16 ~ 
 
Figure 1.1: A. inverted nipple; B. strabismus; C. generalized bruising after delivery due to a coagulation 
defect; D. cutis laxa. 
N-glycan biosynthesis starts at the cytosolic side of the ER, where an 
oligosaccharide is built upon a dolichol (Dol) carrier. For each N-glycan, eight dolichol 
molecules are necessary, coming from recycling of Dol-P and Dol-PP, or from de novo 
synthesis (Figure 1.2 and 1.3) [28]. Two defects are known in the dolichol biosynthetic 
pathway, causing glycosylation defects: SRD5A3-CDG and DOLK-CDG (DK1-CDG). 
SRD5A3 catalyses the conversion of polyprenol to dolichol, which is then 
phosphorylated by dolichol kinase (DOLK). Lack of one of these enzymes leads to a 
reduction of the general level of glycosylation rather than structural abnormalities 
[29-32]. A mutation in the dehydrodolichol diphosphate synthase, DHDDS, results in 
eye dysfunction, without further known glycosylation abnormalities in CDG screening 
[33,34]. 
Following phosphorylation of Dol to Dol-P, the lipid linked oligosaccharide 
(LLO) Man5GlcNAc2-PP-Dol is built stepwise at the cytosolic side of the ER . Several 
defects are known in the different enzymes involved in this biosynthesis. The LLO is 
then transferred inside the ER lumen by a flippase. It has been thought that RFT1 was 
(part of) the flippase, yet recent studies suggest that it may only have an accessory 
role [35-38], and the exact mechanism of transfer of the LLO across the membrane is 
not yet understood. Once in the lumen, the LLO is further assembled to the final 
General introduction and purpose of this study 
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Glc3Man9GlcNAc2-PP-Dol molecule which will be transferred to the nascent protein. 
Defects were described in RFT1, and in the three mannosyltransferases and two of the 
glycosyltransferases involved in this build-up, all causing CDG type I (Figure 1.3) [39-
41]. 
 
Figure 1.2: Biosynthetic route of dolichol. Dolichol branches from the mevalonate pathway through a 
number of condensation steps of isoprenoid units, followed by loss of phosphates. In the last step, the 
polyprenol reductase SRD5A3 is required to reduce the terminal isoprene unit, resulting in dolichol.  
The monosaccharide residues necessary for the LLO biosynthesis inside the 
lumen are transferred from dolichylphosphate-bound mannose and glucose which are 
synthesized at the cytosolic side of the ER and then transferred across the membrane 
[42]. DPM1-CDG, DPM3-CDG, and MPDU1-CDG result in a lack of available 
monosaccharides inside the ER lumen, therefore slowing down the build-up of the 
LLO [19,43-46]. 
The oligosaccharyltransferase complex (OST) transfers the Glc3Man9GlcNAc2 
from the dolichol pyrophosphate carrier onto an asparagine residue of a nascent 
protein. The asparagine must be located within an Asn-Xxx-Ser/Thr sequon, with Xxx 
being any amino acid except proline. This transferase is a heptameric ER membrane 
protein. Mutations in two of the subunits are known: TUSC3-CDG and MAGT1-CDG 
[47-50], but no abnormal CDG screening was observed. The latter is the only CDG 
known to be inherited in an X-linked manner. After transfer, the three glucoses and a 
mannose are trimmed off the protein-bound oligosaccharide by glucosidases and a 
mannosidase. A defective GLS1, one of the glucosidases, causes the first CDG type II 
along the biosynthesis pathway [51]. The trimming steps are of importance for the 
protein quality control cycle [52]. After trimming, the protein with a Man8GlcNAc2 
oligosaccharide attached is transferred from the ER to the cis-Golgi for further 
processing.  
  
 
 
 
 
 
 
Figure 1.3: N-glycan biosynthesis in the ER. Activated nucleotide sugars are incorporated into a lipid-linked oligosaccharide, which is transferred en bloc onto the 
nascent protein by the oligosaccharyltransferase. After trimming of terminal glucoses and mannoses, the glycoprotein exits the ER. Known disorders of glycosylation 
are indicated by old nomenclature. = fructose,  = N-acetyl glucosamine,  = mannose,  = glucose. 
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In the Golgi, the Man8GlcNAc2 moiety of the glycoprotein can be modified into a 
Man 6-P capped high-mannose structure, after which the protein is directed to the 
lysosome. The majority of the glycoproteins, however, undergo a trimming to a 
trimannosyl core which can then be reprocessed into complex glycans. In the medial 
Golgi, the trimannosyl core is extended by GlcNAc-transferases using UDP-GlcNAc to 
form two antennae (Figure 1.4). Additional glucosaminyltransferases may allow for 
further branching of the complex structure, or transfer of a bisecting GlcNAc onto the 
core mannose. This results in tri-, tetra-, penta- or even hexa-antennary N-glycans. 
MGAT2-CDG is caused by a defect in glucosaminyltransferase II and leads to formation 
of monoantennary N-glycans. This was the first identified CDG type II, described in 
1994 by Jaeken et al. [53,54]. After transfer to the trans Golgi, the antennae of the N-
glycan are extended by addition of galactose residues by galactosyltransferases using 
UDP-Gal, followed by termination with sialic acid residues. A first patient with 
B4GALT1-CDG was described in 2001 [55,56].  
Within the Golgi, glycans may be subject to further modifications such as the 
addition of polylactosamine extensions or polysialic acid chains, sulfation, 
phosphorylation, addition of glucuronic acid, or, more commonly, fucosylation 
[57,58]. Fucosylation can occur on the core GlcNAc, or GlcNAc residues in the 
antennae. Once fully processed, glycoproteins leave the Golgi apparatus, to be 
expressed on the cell surface, or released outside the cell.  
The availability of nucleotide sugars in the Golgi, such as UDP-GlcNAc, GDP-Fuc, 
UDP-Gal and CMP-NeuAc is dependent on active transporters. These transfer the 
activated sugars from the cytosol into the Golgi lumen and are therefore essential for 
successful glycosylation. Transport of GDP-Fuc is deficient in SLC35C1-CDG, whereas a 
defective CMP-NeuAc transporter causes SLC35A1-CDG. SLC35C1-CDG patients show 
a normal TIEF pattern, as the fucoses do not influence the isoelectric point of the 
glycan. These patients present a leukocyte adhesion deficiency type II syndrome 
[26,59,60], a clinical presentation that should trigger clinicians to request mass 
spectrometric analysis of serum N-glycans in order to confirm the hypofucosylation of 
proteins. The SLC35A1-CDG patient also presented a normal TIEF. This is suprising 
because low levels of sialylation would be expected [61,62]. 
In addition to the proteins directly involved in glycosylation, such as the 
glycosyl-transferases and sugar transporters, a new category of proteins was 
described to cause CDG. These proteins are involved in trafficking, structure and 
environment of the Golgi complex. They are of crucial importance for N-glycosylation, 
yet defects also affect other glycosylation routes, such as mucin-type O-glycosylation.  
  
  
 
Figure 1.4: N-glycan processing in the cis, medial and trans-Golgi. The COG complex and the v-ATPase are represented schematically, with all subunits. Known 
disorders of glycosylation are indicated.  = N-acetyl glucosamine,  = mannose,  = galactose,  = fucose,  = sialic acid. 
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The conserved oligomeric Golgi (COG) complex is a peripheral Golgi 
heterooctameric complex which is required for the trafficking and stability of Golgi 
glycosyltransferases. The eight subunits are arranged in two lobes: lobe A (Cog1-4) 
and lobe B (Cog5-8) interact through Cog1 and Cog8. To date, defects of 6 COG units 
were found in CDG type II, Cog1 and Cog4 through Cog8 [63-70]. The COG complex 
plays an essential role in retrograde Golgi vesicular transport, which is important for 
efficient maturation of glycans. Although all known COG defects result in glycosylation 
defects, there seem to be two distinct mechanism causing hypoglycosylation, 
depending on the affected lobe: extensive Golgi fragmentation or diminished levels of 
glycosyltransferases [71]. The glycosylation abnormalities in COG-CDG patients vary, 
although in all COG-CDG patients, a decrease in sialylation of the N-glycans is obvious 
by MS-analysis. COG1, COG6 and COG7 patients also present high levels of 
undergalactosylation. In addition, COG1 and COG7 present a demannosylation defect 
which results in elevated high-mannose glycan structures. In COG8-CDG, intact 
transferrin missing one or two terminal sialic acids was measured, without evident 
undergalactosylation [67,70].  
In a group of patients, presenting with a combined defect in N- and O-
glycosylation and autosomal recessive cutis laxa type II (ARCL II), genetic analysis led 
to the discovery of mutations in ATP6V0A2 [20,72]. This gene encodes the a2 subunit 
of the vacuolar H+-ATPase complex, a proton pump present in the Golgi membrane, 
which influences the lumenal pH [73]. It has been shown that even minor differences 
in pH may disturb the activity of glycosylation enzymes and, more importantly, their 
correct localization along the Golgi [74-77]. As a result, these patients have a 
decreased galactosylation and sialylation of their N-glycans.  
The discovery of COG and vacuolar H+-ATPase defects had raised awareness 
that a wide range of proteins that regulate trafficking of the Golgi may be accountable 
for glycosylation defects when affected.  
Diagnosis of CDG 
Transferrin isoelectric focusing (TIEF) is the most common screening method 
for detection of N-glycan biosynthesis deficiencies. Transferrin carries two complex N-
glycans, attached to Asn432 and Asn630 (Figure 1.5). These are mostly biantennary, 
and terminated by negatively charged sialic acids. Thus, the most abundant form in 
controls is the tetrasialotransferrin. Loss of the sialic acids, or increased branching of 
the glycans, result in a shift of the protein pI. Most CDGs can be detected because they 
will lead to an abnormal TIEF pattern, with increased amounts of undersialylated 
transferrin (Figure 1.6). Two types of abnormal TIEF profiles can be distinguished. 
Type 1 TIEF is characterized by decreased amounts of tetrasialotransferrin, along 
with increased amounts of di- and asioalo-transferrin, as a result of defects in the 
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early N-glycan biosynthetic pathway. The transferrin will then lack one or two full N-
glycan chains (Figure 1.5 and 1.6). Defects in the processing of the protein-bound N-
glycans may result in a CDG type 2 TIEF pattern, which shows increased tri-, di-, 
mono- and asialotransferrin and decreased tetrasialotransferrin. In this case, 
transferrin does present the N-glycans, yet they are not fully processed and therefore 
not completely sialylated, as in MGAT2-CDG (Figure 1.5 and 1.6) 
 
Figure 1.5: Schematic representation of the transferrin molecule, with N-glycans attached to the 
asparagines N432 and N630. A. Fully glycosylated, tetrasialylated transferrin; B. Disialylated 
transferrin, as seen in CDG type I; C. Disialylated transferrin carrying two monoantennary N-glycans, as 
seen in MGAT2-CDG. GlcNAc(), Man(), Gal (), NeuNAc (), Fuc () moieties are indicated.  
 
 
Figure 1.6: A. Transferrin isofocusing profiles of a healthy control, different CDG type II and a 
secondary cause of hypoglycosylation (HUS). The defect is indicated above the lanes. B. TIEF of a 
healthy control and a CDG type I. Numbers left of figure indicate the amount of sialic acids on 
transferrin. 
In a few cases of known CDG, transferrin isofocusing presents a normal profile. 
Whereas CDG subtypes MGAT2-CDG, B4GALT1-CDG and COG-CDG are known to 
present typical type 2 profiles, subtypes GLS1-CDG, SLC35C1-CDG and SRD5A3-CDG 
do not necessarily result in hyposialylation of transferrin on IEF (Figure 1.6). On the 
other hand, abnormal TIEF patterns may be caused by conditions independent of CDG, 
such as alcohol abuse, fructosemia, galactosemia, liver pathology or the presence of 
plasma sialidase in hemolytic uremic syndrome associated with a streptococcus 
pneumonia infection [78,79]. An additional challenge is caused by transferrin protein 
polymorphisms which may cause pI differences of the polypeptide chain. 
Heterozygous combinations of two variants may lead to misinterpretation of the 
isofocusing pattern [80-82].  
General introduction and purpose of this study 
~ 23 ~ 
After transferrin analysis, a number of subsequent analyses may be considered. 
When a type 1 pattern is obtained, the next step is measurement of PMM and PMI 
enzyme activity in fibroblasts. If normal, further investigation may include LLO 
analysis in fibroblasts, or plasma polyprenols. To confirm the defect, genetic analysis 
must reveal a pathogenic mutation. A type 2 pattern should be followed by mucin O-
glycan analysis by apolipoprotein C-III IEF [83-85]. Apolopoprotein C-III (apo C-III) is 
a characteristic marker for core 1 mucin type O-glycans. Three apo C-III isoforms can 
be separated on IEF, apo C-III0, apo C-III1 and apo C-III2, based on the number of sialic 
acids present on the O-glycan (Figure 1.7). In healthy individuals, apo C-III2  is the 
major isoform present, along with evident amounts of apo C-III1. In patients with a 
mucin O-glycosylation defect, the apo C-III0 and/or apo C-III1 fractions may be 
increased. The use of apo C-III IEF revealed that some patients present with a 
combined N- and O-glycosylation defect [83,85]. COG defect analysis by Western 
blotting, IEF of other plasma glycoproteins such as tyroxine binding globuline  or α1-
antitrypsin, and mutation analysis of genes known to be involved in glycosylation may 
provide additional knowledge of the exact cause of the disease.  
Nevertheless, elucidation of the glycosylation defect may require further 
information about the glycan structures which are present on glycoproteins. 
Transferrin and apo C-III are mainly processed in the liver, therefore a tissue-related 
defect, not affecting the liver, may be overlooked by IEF of these two proteins. 
Therefore, various other techniques have been developed for structural analysis of 
glycoproteins, including capillary electrophoresis, HPLC and mass spectrometry 
[78,86,87].  
 
Figure 1.7: A. Apo C-III isofocusing profile of a healthy control. B. Apo C-III1 profile, with elevated 
monosialo-apo C-III. C. Apo C-III0 profile with elevated mono- and asialo-apo C-III. Numbers on the left 
indicate the amount of sialic acids on apo C-III.  
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Mass spectrometry for diagnosis of CDG 
In the diagnostic track of CDG type I, mass spectrometric analysis was first 
used in 1992 when Wada et al. measured whole transferrin on ESI-MS and detected 
abnormally glycosylated forms of the protein [88,89]. The technique was later applied 
at the Mayo Clinic (Rochester, MN, USA) for screening of CDG patients [90,91]. Using 
liquid chromatography (LC)-MS/MS, Hülsmeier et al. developed a method to measure 
N-glycosylation site occupancy on transferrin glycopeptides [92]. Whereas a 98-100% 
occupancy was measured for all N-glycosylation sites on transferrin in controls, a 
reduced occupancy was observed in CDG type I, which correlated with disease 
severity. In the diagnosis of SRD5A3-CDG patients, LC-MS analysis of dolichol 
intermediates (polyprenols) in patient’s plasma samples was performed, revealing 
increased polyprenol-18,19,20/dolichol-18,19,20 ratios [29]. Garrett et al. tried to 
develop a mass spectrometric method to measure the fully synthesized LLO, Dol-PP-
(GlcNAc)2(Man)9(Glc)3, and confirm its structure [93]. Although their data were 
consistent with the proposed structure, endogenous levels of the compounds in cell 
lipid extract were too low, making the technique inapplicable to diagnosis purposes.  
Diagnosis of CDG type II requires a different approach. Different classes of 
defects may be distinguished: defects in nucleotide sugar transporters (as in SLC35C1-
CDG), defects in the glycosyltransferases (as in MGAT2-CDG), defects affecting Golgi 
trafficking (as in COG-CDG) or secondary causes of underglycosylation. These defects 
affect the processing of the protein-bound glycans, often resulting in glycans which 
miss a limited number of residues or present increased fucosylation.  
Analysis of intact glycoproteins often lacks the resolution necessary for 
detailed glycan analysis. At high-mass range, glycoforms which vary by one or a few 
monosaccharides cannot be distinguished. Therefore, structural analysis of the 
glycans isolated from specific glycoproteins, whole serum or tissues should help in 
finding the glycosylation defect [94,95]. Due to its high sensitivity and potential for 
high-throughput analysis, MALDI is the preferred ionization method for glycan mass 
fingerprinting [86,96]. Nowadays, most protocols for glycan mass fingerprinting 
describe enzymatic release of N-glycans by PNGase F digestion, purification, and 
optional derivatization of the glycans [97-100]. Permethylation, which is often the 
choice of derivatization, is usually performed as described by Ciucanu and Kerek 
[101]. The modification increases the stability of sialic acids, improves the ionization 
efficiency and facilitates spectral interpretation since both acidic and neutral 
structures can be measured in positive ion mode [96,98-102]. Comparison between 
HPLC quantitation of fluorescently labeled glycans and analysis of permethylated 
glycans has shown that MALDI analysis is a reliable method for relative quantitation 
of glycan profiles [100,102]. The possibility for multistage MS is an important asset of 
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linear ion trap detectors. MSn fragmentation allows structural assignment of glycans, 
allowing, for example, distinction between core and antennal fucosylation.  
The application of MS for the diagnosis of CDG type II was first demonstrated in 
2002, when N-glycans cut and purified from transferrin were measured by MALDI-
TOF MS, revealing abnormal structures, lacking the terminal galactoses and sialic 
acids [55]. In 2003, two publications addressed the relevance of MS analysis of N-
glycans in the diagnosis of CDG type II [103,104]. Butler et al. described a strategy for 
detailed analysis of serum N-glycans, and N-glycans from transferrin or IgG. These 
glycans were fluorescently labeled and separated by HPLC and the structures were 
then confirmed by MALDI-TOF measurement. Mills et al. developed a protocol for 
MALDI-TOF measurement of N-glycans after enzymatic release from total serum 
proteins and purification [104]. Since then, various strategies have been developed to 
improve N-glycan fingerprinting and reduce the amount of biological material needed 
for the analysis [98,105,106].  
A number of disorders are known which result in a glycosylation defect in 
specific cell types or tissues. In such case, knowledge of glycan structures present in 
serum or on the affected cells might provide more insight into the pathomechanism. 
For example, Morelle et al. describe the changes in the N-glycome of serum 
glycoproteins in patients with cirrhosis: increase in N-glycans with bisecting GlcNAc 
and α1,6-fucosylated oligo-saccharides could be related to modifications of the 
relevant glycosyltransferases, leading to lipid accumulation in the liver [107]. 
Glycogen storage disease type-Ib and defects of the glucose-6-phosphatase give rise to 
a clinical presentation including neutropenia and neutrophil dysfunction, resulting in 
higher sensitivity to infections. In patients with these defects, mass spectrometric 
analysis of neutrophil complex N-glycans revealed severly truncated antennae, which 
may explain the effects on the cell’s function [108]. HEMPAS, hereditary erythroblastic 
multinuclearity with positive acidified-serum test (also called congenital 
dyserythropoietic anemia type II, CDA II), leads to abnormal N-glycosylation of 
membrane glycoproteins of the erythrocytes. Originally, fast atom bombardment MS 
analysis of the N-glycans in different patients showed either short hybrid structures 
or an accumulation of high-mannose oligosaccharides, implying a genetically 
heterogeneous disease [109-111]. Improved measurements by MALDI-TOF MS and 
ESI-MS/MS in 2008 showed unprocessed high mannose glycans, hybrid glycans and 
an increase in truncated complex glycans, suggesting that HEMPAS was probably 
caused by a Golgi trafficking defect, comparable to COG defects [112]. Moreover, 
analyses of protein glycosylation in liver diseases and various forms of cancer have 
been described [107,113-119], providing potential means of diagnosis through 
measurement of tissue or serum glycosylation.  
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All these investigations illustrate the importance of knowing more about the 
overall N-glycosylation state in order to provide insight into the glycosylation defect, 
confirm the biochemical consequences, or explain the ensuing pathology. Therefore, 
mass spectrometry should be applied in the diagnostic tract of CDG patients, as the 
first step following TIEF, when a type 2 pattern is obtained. 
PURPOSE OF THIS STUDY AND OUTLINE OF THIS THESIS 
To this day, approximately 10 % of the patients with CDG type I and two thirds 
of the patients with CDG type II are still unsolved. Although some specific clinical 
features may be indicative, the diversity of presentation is often not sufficient to 
pinpoint the genetic defect. This is, however, of great importance, in order to be able 
to develop a proper course of action for treatment of the disease and to provide 
genetic counseling. In addition, the presence of secondary causes of glycosylation may 
complicate the diagnostic process.  Understanding of the glycosylation pathways and 
development of analytical instrumentation led to improved diagnosis of patients with 
an unsolved CDG. In this study, mass spectrometry was developed as a diagnostic tool. 
In parallel, careful observation and description of the patients’ clinical presentation 
should support clinicians in the recognition of the disorder.  
PART I: GLYCAN ANALYSIS BY MASS SPECTROMETRY 
In order to improve diagnosis of patients, we introduce mass spectrometry as a 
tool in the diagnostic tract of CDG.  
In Chapter 2, we describe how we used serum N-glycan samples from healthy 
individuals to set up and optimize the automation of data collection on a MALDI linear 
ion trap mass spectrometer. First, we optimized sample processing, using only 10 to 
20 microliters of sample. Next, sample measurement on a MALDI linear ion trap mass 
spectrometer and data processing were developed. The unique features of this 
instrument, including crystal positioning system, automatic gain control and MSn 
sequencing possibilities, allowed data collection on large numbers of samples, as well 
as confirmation of the glycans’ structure. In addition, a script was developed to 
process the data. Chapter 3 describes how this technique was further improved and 
applied to a number of samples from patients with known CDG defect. Characteristic 
glycan profiles allowed the distinction between different patient groups, including 
secondary causes of CDG type II.  
The importance of mass spectrometry in the diagnosis of CDG type I is 
highlighted in Chapter 4: mutations at the glycosylation sites of transferrin cause a 
TIEF pattern very suggestive of CDG type I. Mass spectrometry of the tryptic peptides 
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of transferrin, however, unambiguously confirmed that the protein part was affected, 
not the glycosylation itself.  
Part II: Clinical and biochemical investigation of CDG patients 
In 2008, a mutation was identified in a subunit of the vacuolar H+-ATPase, 
resulting in abnormal glycosylation in patients presenting with cutis laxa. Chapter 5 
reviews the structure and function of this proton pump, and discusses the relationship 
between the mutations, the glycosylation deficiency, and the clinical presentation of 
the patients.  
Besides the vacuolar H+-ATPase, a wide array of Golgi-related proteins may 
cause CDG type II. In Chapter 6, eleven children with a suspected Golgi-related 
glycosylation defect were assessed clinically and biochemically. We searched for 
discriminative features that should trigger clinicians to consider CDG and set up a 
diagnostic guideline, which should be applied to all patients with a type 2 TIEF 
pattern.  
The use of mass spectrometry and careful clinical investigation allowed the 
diagnosis of a novel patient with a galactosyltransferase defect. In Chapter 7, we 
describe this patient, who presented with quite mild clinical features.  
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 ABSTRACT 
The use of N-glycan mass spectrometry for clinical diagnostics requires the 
development of robust high-throughput profiling methods. Still, structural assignment 
of glycans requires additional information such as MS2 fragmentation or 
exoglycosidase digestions. We present a setting which combines a MALDI ionization 
source with a linear ion trap analyzer. This instrumentation allows automated 
measurement of samples thanks to the crystal positioning system, combined with MSn 
sequencing options. 2,5-Dihydroxybenzoic acid, commonly used for the analysis of 
glycans, failed to produce the required reproducibility due to its non-homogeneous 
crystallization properties. In contrast, α-cyano-4-hydroxycinnamic acid provided a 
homogeneous crystallization pattern and reproducibility of the measurements. Using 
serum N-glycans as a test sample, we focused on the automation of data collection by 
optimizing the instrument settings. Glycan structures were confirmed by MS2 analysis. 
Although sample processing still needs optimization, this method provides a 
reproducible and high-throughput approach for measurement of N-glycans using a 
MALDI-linear ion trap instrument.  
INTRODUCTION 
Protein glycosylation is one of the most common and complex post-
translational modifications. Changes in the glycosylation pattern of specific or total 
serum proteins have proven to be useful as biomarkers for several diseases, including 
congenital disorders of glycosylation and several forms of cancer [1-4]. For example, 
altered sialylation and fucosylation of N- and O-glycans, as determined by mass 
spectrometric profiling, have been related to disease state [4]. Mass spectrometric 
analyses can either focus on global profiling of complex glycan mixtures or on 
structural determination of individual carbohydrates, including MSn sequencing and 
linkage analysis [5]. For application of glycan profiling in a medical setting, 
reproducible, high-throughput methods are required to differentiate disease groups. 
Carbohydrate deficient transferrin is used as biomarker for CDG [6]. Although iso-
electric focusing of plasma transferrin is a convenient high-throughput method, the 
use of mass spectrometry of immunopurified transferrin provides increased 
sensitivity and additional structural information [7-9]. In a similar way, it can be 
expected that glycan profiling by mass spectrometry may prove helpful to determine 
the exact defect in patients with an unsolved CDG [8-11]. 
Mass spectrometry using MALDI has been applied successfully to glycan 
analysis because of its high sensitivity and the potential for high-throughput analysis 
[12]. It is less sensitive to residual contaminants such as salts compared to other 
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ionization methods. Also, the ease of spectral interpretation facilitates unambiguous 
data analysis, as only singly charged ions are formed. Sialylated glycans have been 
analysed in native form [13,14], after reductive amination [9,15,16], or after sialic acid 
methylesterification [11,17]  or permethylation [17-20]. Permethylation of glycans, 
usually performed as described by Ciucanu and Kerek [21] has several advantages, 
including increased stability of sialic acids, improved ionization efficiency and ease of 
spectral interpretation since both acidic and neutral structures can be measured in 
positive ion mode [12,20,22,23]. A recent comparative study suggested that MALDI 
analysis of permethylated N-glycans and the analysis of reductively aminated glycans 
by HPLC can be correlated and are both reliable for the elucidation of glycan profiles 
[22]. 
Most studies on N-glycan analysis by MALDI described the use of a MALDI 
ionization source with a time-of-flight analyzer, with the advantages of large mass 
range, high sensitivity and high resolution. Structural assignment of glycans relies on 
MS2 fragmentation options, as has been shown by the use of, for example, MALDI-TOF-
TOF [24,25], MALDI-QTOF for CDG type II patients [9], MALDI-FTMS [26-29], and 
MALDI-Ion Trap [30]. The combination of soft ionization by MALDI with multi-stage 
MS is particularly well suited for the analysis of post-translationally modified peptides 
[31,32] and oligosaccharides [2,30,33,34]. Disassembly through a number of 
consecutive MSn stages allows structural distinction between ions with similar mass. 
For example, thirteen methylated high mannose isomers were distinguished from 
bovine ribonuclease B [5]. Fragmentation has also been used in order to gain insight 
in branching level, fucosylation site and linkage of sialic acid [24,25,34]. MALDI 
analysis of carbohydrates has been extensively reviewed by Harvey [4,35-37]. 
The matrix used for MALDI measurements is crucial for optimal signal-to-noise 
levels and the quality of data. 2,5-Dihydroxybenzoic (DHB) acid is most commonly 
used for measurement of permethylated glycans. It typically crystallizes as needle-
shaped crystals along the border of the target spot. Luxembourg et al. [38] described 
that some crystals consist of matrix exclusively, while others contain mainly sodium 
and analyte or only sodium and little matrix. Different groups have tried to disrupt the 
large crystal formation by mixing DHB with other compounds such as aniline, N,N-
dimethylaniline or glycerol [39,40], or by recrystallization of the matrix using ice-cold 
ethanol [41]. α-Cyano-4-hydroxycinnamic acid (CHCA) is widely used as matrix for 
protein and peptide analysis, although Stephens et al. [42] described the use of CHCA 
to analyze fragmentation of native and permethylated oligosaccharides. Its 
crystallization pattern is much more homogeneous which could be an advantage with 
respect to automated analysis. Various groups have analyzed the influence of matrix 
on glycan profile acquisition. Stephens et al. [42] showed that CHCA induces mainly 
fragmentation along the glycosidic bonds, whereas fragmentation using DHB as matrix 
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causes a wide range of fragmentations. Creaser et al.[44] compared the efficiency of 
esculetin, CHCA, 2-(4’-hydroxypehnylazo)benzoic acid (HABA), DHB and 2,4,6-
trihydroxyacetophenone (THAP) in a quadrupole ion trap mass spectrometer. The use 
of HABA and esculetin provided increased sensitivity and a lesser degree of 
fragmentation compared to measurements using the other matrices.  
In this study, we explored the potential of MALDI combined with a linear ion 
trap (LIT) (vMALDI-LTQ, Thermo Fisher Scientific) for the glycoprofiling of serum N-
glycans with a focus on automated data acquisition. Apart from its advantage of 
possible MSn analysis, a number of unique features allows automated data collection 
of large numbers of samples, as required in a medical diagnostic setting. The crystal 
positioning system (CPS) automatically identifies matrix crystals on the target spot 
based on the image generated by a camera inside the MALDI source. It then generates 
an ideal path along the matrix crystals for the laser, in order to collect sample data, 
avoiding places on the spot containing no crystals. This circumvents the need to 
manually scout the surface in order to hit the crystal-rich spots. In addition, the 
automatic gain control (AGC) adjusts the number of laser shots needed to fill the ion 
trap. 
Development of an efficient diagnostic workflow by means of mass 
spectrometry includes three steps: (i) optimization of sample processing prior to MS 
analysis, using very small amounts of biological material, (ii) accuracy, sensitivity, 
robustness and high-throughput applicability of the measurement on the mass 
spectrometer, and (iii) automation of data processing. Here, we focused on the 
possibilities for automated data collection using a MALDI-LIT for measuring serum N-
glycans. 
RESULTS AND DISCUSSION 
Choice of matrix for analysis of permethylated serum N-glycans 
Permethylated N-glycans from total serum proteins were prepared as 
described in the experimental section. In initial experiments, DHB was used as matrix 
for measurement on the MALDI-LIT mass spectrometer. The detected glycan profile 
(Figure 2.1a) showed the presence of major glycan ions at m/z 2432 and 2794, 
corresponding to mono- and disialylated biantennary N-glycans. Their fucosylated 
counterparts (m/z 2606 and 2968) were detected as well, along with a number of less 
abundant glycans. In addition, we observed an ion series with m/z values of 2739, 
2494, 2132, 1914 and 1669 of unknown origin. The intensity of these ion peaks 
relative to each other remained fairly constant, while their collective appearance 
compared to the known glycans was highly variable within one spot. Optimization of 
instrument settings such as laser intensity did not result in elimination of these 
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signals. The appearance of these unknown ions was unexpected since these ions were 
not detected when analyzing samples using DHB on a MALDI-TOF instrument in 
reflectron mode (Figure 2.1b), which suggests that they do not reflect sample or 
matrix contamination. The same peak series was detected for the commercial core 
fucosylated biantennary disialylated A2F glycan (Figure 2.1c).  
 
Figure 2.1: Analysis of permethylated N-glycans using DHB. A chosen set of glycan structures are 
assigned, fragment ion m/z values are boxed. a. Serum N-glycans measured on MALDI-LIT, average of 
100 spectra b. Serum N-glycans measured by MALDI-TOF, fragment ions not detected c. MALDI-LIT 
spectrum of the A2F glycan standard showing fragment ions (  = GlcNAc,  = Man, = Gal,  = sialic 
acid, = Fuc). 
A second observation with DHB was the irreproducibility of the signal intensity 
within one spot. Recording of 50 spectra within a single spot showed highly variable 
glycan ratios and a limited number of spectra with sufficient signal-to-noise. Possibly, 
the needle-like crystallization pattern of DHB (Figure 2.2) resulted in heterogeneous 
sample distribution along the spot, as has been described by Luxembourg et al. [38]. 
Re-dissolving the crystallized matrix in ice-cold ethanol followed by recrystallization 
or addition of glycerol to DHB, as described by Soltwilsch et al. [39], did not improve 
the homogeneity of the spot sufficiently. 
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Figure 2.2: Crystallization pattern of different matrices. a. Crystallization as detected by the charge-
coupled camera of the MALDI. b. Signal of the crystal positioning system and generated path along the 
crystal surface.  
 
In conclusion, automated data acquisition of permethylated serum N-glycans 
on the MALDI-LIT was not possible with DHB as matrix. Therefore, other matrices 
were taken into consideration to obtain a homogeneous crystallization. Of these 
matrices, CHCA is commonly used for analysis of proteins and peptides and is known 
for its homogeneous analyte distribution. 
Measurements of permethylated N-glycans using CHCA on a MALDI-LIT 
yielded spectra with specific glycan ion signals and high signal-to-noise ratio, whereas 
undesirable in- and post-source fragmentation ions were not observed. Of note, when 
using CHCA on a Bruker Biflex III MALDI-TOF instrument, no glycan signals could be 
observed using the same sample. To improve the homogeneity of the crystallization 
for use of the CPS, different spotting methods were studied. Premixing of dissolved 
analyte and CHCA-matrix before spotting, mixing of the two solutions on the plate or 
the dried droplet method resulted in the formation of scattered crystal clusters. When 
the matrix was first spotted and allowed to dry before addition of the sample on top of 
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it, a homogeneous crystal distribution was observed (Figure 2.2), providing a larger 
surface area for measuring. The use of CPS still proved useful as empty spaces on the 
spot were not scanned by the laser, thereby avoiding the recording of spectra without 
glycan signal. In this way, data could be automatically acquired. 
Optimization of data collection on the MALDI-LIT instrument 
To optimize the automated measurement of permethylated serum N-glycans, 
several instrumental parameters of the MALDI-LIT were adjusted. We investigated the 
path followed by the laser over the spot surface, the number of spectra recorded for 
each step, the number of sweep shots and the use of automatic gain control. To assess 
the quality of a set of parameters, 50 spectra of one spot were recorded and screened 
manually. Settings were judged based on reproducibility of the spectra, signal-to-noise 
ratio, quality of the final averaged spectrum, and duration of analysis per spot. This 
led us to the following optimized measurement method. As the laser skims the surface 
of the spot, one spectrum was recorded for every step along the path as determined by 
the CPS. Each laser shot generating a spectrum is preceded by 5 unrecorded sweep 
shots in order to eliminate excess matrix. The spectra were recorded as survey scans 
in the high-mass mode (m/z 1500-4000) with 2 microscans and the automatic gain 
control enabled. An increased number of microscans or of recorded spectra for each 
step did not improve the reproducibility of the results, while it increased the overall 
measurement time. For each spot, 50 spectra were recorded and averaged. This 
improved the reliability of the averaged spectrum, as well as the signal-to-noise ratio. 
Using the optimized conditions (1 spectrum per step, 5 sweep shots, 2 microscans per 
spectrum for a total of 50 spectra), the analysis of one spot took 3 to 4 minutes.  
The serum N-glycan profile 
The final averaged spectrum reflects the general N-glycan profile of serum in 
line with previous publications [9,19,20,23] (Figure 2.3). Glycan structures were 
confirmed on basis of MS2 fragmentation patterns and common knowledge of the N-
glycan biosynthetic pathway. The most abundant glycans included the disialylated 
(m/z 2794) and monosialylated biantennary complex glycan (m/z 2432) and their 
fucosylated equivalents (m/z 2967 and 2606), as well as the trisialylated triantennary 
glycan (m/z 3606). Additional MS2 fragmentation of minor signals revealed the 
presence of up to 40 additional glycan ions. The ratio of monosialo/disialo 
biantennary N-glycan (about 44%) and fucosylation levels were higher than those in 
published MALDI-TOF profiles of permethylated serum N-glycans [19,20,23]. Yet, the 
study of Ruhaak et al. [15] measuring 2-AA labeled glycans in negative ion mode, also 
showed ratios of monosialo/disialo biantennary glycan higher than 40%. A 
comparative study on immunopurified transferrin [22] showed an estimated 
occurrence of roughly 10 to 45% monosialylated biantennary N-glycan compared to 
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the total amount of disialylated diantennary N-glycan, as measured in seven different 
laboratories. The higher level of undersialylation in some laboratories was explained 
by a probable sialic acid loss during sample preparation. Possibly, the use of different 
instrumentation results in slight variation of individual glycan ion intensities. Most 
previous studies were performed with time-of-flight analyzers, whereas we use a 
linear ion trap. Possibly, specific features of the ion trap may lead to differences in the 
data. In addition, although we found similar profiles for several control samples, 
variation in N-glycan composition between individuals could also partly explain the 
differences between studies. By HPLC, it has been shown that age, gender and 
environmental determinants may affect the total serum N-glycan composition [43]. 
Glycan profiling of a larger number of individuals must be conducted to study the 
variability of glycans in healthy controls.  
MS2 spectra were generated by fragmenting selected precursor ions using 
collision induced dissociation. This led to fragmentation of the glycan structures along 
the glycosidic bond, generating sodium-cationized B, C, Y and Z ions (nomenclature 
according to Domon and Costello [44]). Analysis of the fragment ions confirmed the 
glycan nature of the precursor ions shown in Figure 2.3a. Fragmentation of the glycan 
ion with m/z 2968 (MS2, Figure 2.3b) generates essentially B or Y fragment ions. Also, 
Yα/β-ions, resulting from cleavage in both antennae, can be detected at e.g. m/z 
1317.45 Da (Y4α/4β) and 1592.45 Da (Y4α/6β). This MS2 spectrum shows that 
fucosylation of the biantennary disialylated N-glycan occurs on both core and antenna 
N-acetyl-glucosamine residues. The non-reducing end B-ions at 1022.55 Da (B4α) and 
2690.09 Da (B6) and the reducing end Y-ion at 1968.82 Da (Y4α) are indicative of 
antenna fucosylation. In contrast, the Yα/β-ions at 1113.36 Da (Y3α/4β) and 1317.45 Da 
(Y4α/4β), as well as the B-ion at 2516.09 Da (B6), indicate fucosylation of the chitobiose 
core. The MS3 spectrum of m/z 1022 Da shows loss of sialic acid (m/z 646.18 Da) and 
antenna fucose (m/z 815 Da), thereby confirming the composition of this low 
abundant MS2 ion.  
Reproducibility 
To assess the reproducibility of our methods, we individually processed 10 
aliquots of a control serum sample, as described in the experimental section. These 10 
aliquots were each spotted four times on the MALDI target plate. Data acquisition was 
performed by measuring each spot 50 times and averaging these spectra after outlier 
removal. A subset of ten specific glycan ions (Table 2.1) was selected to assess 
reproducibility, in addition to the 2794 ion used for normalization. The intensity of 
these glycan ions, relative to the 2794 ion, was used for the calculation of the intra-
spot variability, the inter-spot variability and the inter-assay variability.  
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Figure 2.3: a. Serum N-glycome as measured by MALDI-LIT using CHCA as matrix. Average of 50 
spectra. Prominent glycans are assigned. b. MS2 CID spectrum of [M + Na]+ precursor ion with m/z 
2968. A number of potential fragment ions are labelled, loss of fragments from the precursor ion are 
indicated on the right side of the spectrum. Fragments with m/z 1022, 1143 and 2690 are indicative of 
antenna fucosylation, whereas fragments with m/z 1113, 1317and  2516 implicate core fucosylation. 
MS3 of the m/z 1022 ion confirms its proposed structure with terminal sialic acid and antenna 
fucosylation ( = GlcNAc,  = Man, = Gal,  = sialic acid, = Fuc). 
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Table 2.1: Relative glycan ion intensities (to m/z 2794) and relative standard deviation (RSD) of serum 
N-glycans used for reproducibility assessment. 
Ion signal (m/z) Glycan structure Average relative 
ion signal 
Average intra-
spot RSD (n = 6) 
Average inter-
spot RSD (n = 10) 
Inter-assay RSD  
(n = 10) 
1837 
 
0.21 15% 9.6% 29% 
2041 
 
0.26 15% 8.8% 23% 
2245 
 
0.15 13% 9.0% 32% 
2432 
 
0.44 8.5% 5.7% 17% 
2606 
 
0.18 5.8% 4.7% 20% 
2968 
 
0.21 4.7% 3.8% 8.2% 
3212 
 
0.09 9.2% 8.0% 28% 
3242 
 
0.09 7.8% 7.4% 27% 
3606 
 
0.26 7.3% 5.4% 11% 
3778 
 
0.07 7.8% 9.8% 36% 
 
 
The intra-spot variability, or variability between measurements within one 
spot, was assessed by acquiring four data sets per spot on six spots of the same 
sample. For each spot, the relative intensities of the four acquisition sets were 
averaged and the relative standard deviation (RSD) calculated for our subset of glycan 
ions. The average RSD over the six spots was smaller than 10%, with slightly higher 
variability for small glycans (Table 2.1, column 4).  
The inter-spot variability, or variability between data of four spots of the same 
aliquot measured on the same day, is represented in Figure 2.4. For each of the ten 
glycan ions, the average intensity over the four spots was calculated with the RSD. In 
almost all cases, the inter-spot RSD was lower than 10%. Incidentally, mostly for low 
abundant glycans, more variable intensities were found, with RSD ranging from 1.7% 
to 31%. This likely reflects the influence of higher background signals for these 
glycans. When averaged over the ten aliquots, the RSD was lower than 10% for all 
glycan ions in our subset (Table 2.1 column 5). Comparable results have been 
reported in a study conducted by the HUPO Human Disease Glycomics/Proteome 
Initiative on transferrin and IgG N-glycans from human serum. Variability (n = 5) for 
analysis of permethylated N-glycans on these proteins using MALDI-TOF was less than 
10% for major oligosaccharides and up to 34% for minor ones [22]. 
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Figure 2.4: 10 aliquots of one serum sample were processed independently and each measured on four 
spots. For a chosen subset of glycan ions, average relative intensities are presented with standard 
deviation (n = 4), in each one of these aliquots. 
 
Finally, the inter-assay variability, or variability between 10 aliquots processed 
from the same serum, was analyzed. For each aliquot, the ion intensities over the four 
spots were averaged. These intensities were then compared between the 10 aliquots, 
revealing inter-assay RSD’s ranging from 8% to 36% (Table 2.1 column 6). 
Considering the high reproducibility of the MALDI measurement itself, this variability 
must be due to sample processing. Degradation and peeling reactions might be 
associated with high pH during the permethylation reaction of glycans [17], while 
other steps in the purification of glycans may cause sialic acid loss or degradation of 
glycans. After processing serum N-glycans 9 times independently, Kang et al. showed 
an average inter-assay RSD of 20% for the measurement of serum N-glycans [23], 
ranging from 4.3% to 39%.  
Overall, these results indicate that while intra- and inter-spot variability are 
within acceptable range, sample processing still needs attention to further increase 
robustness and decrease inter-laboratory variability, as required for a diagnostic test. 
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Conclusion 
We have optimized a method for automatic data acquisition of serum N-glycans 
on a MALDI-LIT. Homogeneous matrix crystallization has been proven essential for 
the reproducibility of the measurements. Although DHB is usually the matrix of choice 
for glycans, its needle-shaped crystal structure did not generate the desired level of 
reproducibility. However, by using CHCA, a highly reproducible measurement of 
serum N-glycans was set up. The crystal positioning system, along with other 
optimized instrument parameters, allowed the automation of data collection. 
Although the processing of glycans prior to measurement still needs optimization, this 
method provides a sensitive, robust, reproducible and high-throughput method for 
analysis of N-glycans using a MALDI-LIT.  
MATERIALS AND METHODS 
Materials 
Serum was obtained from a healthy volunteer. HPLC-grade MeCN and MeOH 
were purchased from LabScan (Gliwice, Poland). NaOH pellets, CH3I and chloroform 
were from Sigma-Aldrich (Saint-Louis, USA), anhydrous DMSO was from Aldrich 
(Steinheim, Germany) and NaOAc.3H2O from Merck (Darmstadt, Germany). 
Trifluoroacetic acid (TFA) was from Riedel-deHaën (Saint-Louis, USA). Porous 
graphitized carbon SPE columns (3 ml, 250 mg) were purchased from Supelco 
(Steinheim, Germany) and the SepPak C18 columns from Waters (Milford, USA). Mass 
spectrometry grade 2,5-dihydrobenzoic acid (DHB) and α-cyano-4-hydroxycinnamic 
acid (CHCA) were from Fluka (Steinheim, Germany). PNGase F kit was from New 
England Biolabs (Ipswich, USA). All water used was ultrapure. 
Processing of glycans 
N-glycans were released from serum glycoproteins using PNGase F [peptide-
N4-(acetyl-β-glucosaminyl)-asparagine amidase] mainly as described in the 
manufacturer’s guide: a serum aliquot (10 μL) was diluted five times in saline, 
denaturing solution (11 μL) was added and the sample was boiled (10 min). After 
addition of phosphate buffer (10x, 12 μL), NP40 (10x, 50 μL) and PNGase (5 μL), the 
mixture was incubated (37oC, overnight). Released glycans were purified on porous 
graphitized carbon SPE columns as described [45]. The glycans were permethylated 
based on the method of Ciucanu and Kerek [21]: 10 NaOH pellets were crushed in 
DMSO (3 mL). To the dried glycans, 0.5 mL of the NaOH suspension and CH3I (0.2 mL) 
were added. After incubation with shaking (10 min), the reaction was stopped by 
addition of water (1 mL). Water soluble reagents were removed by liquid-liquid 
extraction with chloroform and permethylated glycans were purified on a C18 Sep-
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Pak cartridge, which was preconditioned using MeOH (5 mL), water (5 mL), MeCN (5 
mL) and water (15 mL) subsequently prior to loading the sample. The sample was 
diluted in 50 % aqueous MeOH and loaded onto the Sep-Pak column. After washing 
with water and 15% aqueous MeCN, the glycans were eluted using 75% aqueous 
MeCN and dried. Spotting and measurement of each aliquot was performed 
immediately after processing. 
Spotting 
CHCA matrix was prepared by dissolving CHCA (5 mg/mL) in 1:1 (v/v) 
MeCN:20 mM aqueous NaOAc. DHB was dissolved (20 mg/mL) in 1:1 (v/v) MeOH:20 
mM aqueous NaOAc. Fully processed permethylated glycans from 10 µl serum were 
dissolved in 50 µl MeOH, then mixed 1:1 with 20 mM aqueous NaOAc. NaOAc was 
added to ensure generation of sodiated ions exclusively. First, matrix (0.5 μL) was 
spotted on one of the 384 sample wells of a stainless steel MALDI target plate. After 
crystallization, the sample (0.5 μL) was deposited on top of the matrix and allowed to 
dry at ambient temperature. 
vMALDI-LTQ , measurements and data analysis 
Glycan analyses were performed on a linear ion trap fitted with an 
intermediate pressure matrix assisted laser desorption ionization source (vMALDI 
LTQ, Thermo Fisher Scientific, San Jose, USA). The 337 nm N2 laser (20 Hz, 250 μjoules 
per pulse) is located outside the instrument in a separate unit and the laser beam is 
directed to the vMALDI source through a fiber-optic cable. Its power could be adjusted 
through an iris attenuator. As transmission may degrade over time due to build-up of 
material in the fibre optic cable, the laser power was optimized before each set of 
measurements. The mass analyzer is a standard LTQ with vMALDI source 
modifications that include a camera, x,y-table, sample plate, quadrupole q00 with 
auxiliary rods, and skimmer. Ions generated by the MALDI process are guided to the 
linear ion trap via a differentially pumped multipole assembly. It is important to note 
that the intermediate pressure of the vMALDI source is several orders of magnitude 
higher compared to traditional vacuum MALDI [46]. Ions generated by traditional 
vacuum MALDI have high internal energies that may lead to in- or post- source decay 
(ISD / PSD) of excited ions. Although both ISD and PSD are useful techniques to 
characterize ions, unwanted fragmentation of analyte ions makes the analyses of 
labile molecules (f.e. phosphopeptides) rather ambiguous. It has been shown 
previously that elevated pressures reduce source fragmentation of analyte ions by a 
process called collisional cooling: ions generated by MALDI have relatively high 
internal energies (influenced by the matrix type) but are cooled down by gas phase 
collisions that lower the internal energy of the analyte ion and return its internal 
energy level back to the ground state [46,47].  
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In the optimized setting, CPS and AGC were enabled. One spectrum was 
recorded for each step along the CPS-pathway. To improve the signal-to-noise ratio 
and the reliability of this spectrum, two measurements, or so-called microscans, were 
averaged each time. Only ions with m/z between 1500 and 4000 were measured, 
smaller ions were removed by the q00 octopole before reaching the ion trap. Mass 
spectra were acquired automatically, based on a sequence of spots programmed into 
the control software Xcalibur 2.0 SR2 (Thermo Fisher Scientific, 1998-2006). MS2 data 
were generated for selected precursor ions using collision induced dissociation at 
35% laser power. Assignment of the fragment structures was calculated based on 
differences of molecular weight between ions. GlycoWorkBench [48] was used for 
support in the annotation of fragments and fragments were assigned using the 
nomenclature by Domon and Costello [44]. MALDI-TOF measurements were 
performed on a Bruker III mass spectrometer set to reflectron mode. A malto-
oligosaccharide mixture was used for calibration. The number of spectra summed 
depended on signal intensity.  
Spectral data were parsed from raw data files as comma separated CSV files 
using the MASIC software tool developed by Monroe et al. [49]. The MASIC software 
(version 2.5.3050.16636, Richland, USA) was used as parser since this publicly 
available software tool is capable of handling data formats from mass spectrometers 
developed by different manufacturers. An in-house developed Perl script was used to 
process the exported data for further analysis. This script imports all raw spectral 
points and (i) extracts intensities for peaks of interest, (ii) normalizes the intensity of 
each m/z value of interest to a preselected m/z value within each spectrum, (iii) 
iteratively performs a Grubbs’ test for selected m/z values to remove outliers at a 95% 
confidence level, and (iv) reports the average intensities and standard deviations for 
selected m/z values (before and after outlier removal) as well as average signal to 
noise ratios after outlier removal. On average, 5 to 10% of the spectra were removed 
by the outlier removal tool, improving the reliability of the remaining spectra. These 
spectra usually showed very low signal-to-noise ratios, due to lack of analyte, excess 
of matrix or bad crystallization at a certain place on the spot. 
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ABSTRACT 
Determination of the genetic defect in patients with a congenital disorder of 
glycosylation is challenging because of the wide clinical presentation, the large 
number of gene products involved, and the occurrence of secondary causes of 
underglycosylation. Transferrin isoelectric focusing has been the method of choice for 
CDG screening; however, improved methods are required for the molecular diagnosis 
of patients with CDG type II. Plasma samples with a typical transferrin isofocusing 
profile were analyzed. N-glycans were released from these samples by PNGase F 
digestion, permethylated and purified, and measured on a MALDI linear ion trap mass 
spectrometer. A set of 38 glycans was used for quantitative comparison and to 
establish reference intervals for such glycan features as the number of antennae, the 
level of truncation, and fucosylation. Plasma N-glycans from control individuals, 
patients with known CDG type II defects, and patients with a secondary cause of 
underglycosylation were analyzed. MGAT2-CDG, B4GALT1-CDG, and SLC35C1-CDG 
could be diagnosed directly from the N-glycan profile. CDGs due to defects in proteins 
involved in Golgi trafficking, such as COG7-CDG and ATP6V0A2-CDG caused a loss of 
triantennary N-glycans and an increase of truncated structures. Secondary causes 
with liver involvement were characterized by increased fucosylation, whereas the 
presence of plasma sialidase produced isolated undersialylation. MALDI ion trap 
analysis of plasma N-glycans documents features that discriminate between primary 
and secondary causes of underglycosylation and should be applied as the first step in 
the diagnostic track of all patients with an unsolved CDG type II. 
INTRODUCTION 
Congenital disorders of glycosylation constitute a group of inherited metabolic 
defects caused by abnormalities in protein and/or lipid glycosylation [1]. The clinical 
phenotype ranges from a severe multi-system presentation with early death to 
relatively mild neurological symptoms [2,3]. Because clinical features are not 
diagnostic and cannot be used as exclusion criteria, identification of CDG patients 
relies on the diagnostic screening by isoelectric focusing of plasma transferrin, 
carrying two complex N-glycans [3]. This method is an efficient method to identify N-
glycosylation defects and to discriminate a genetic cause in the cytoplasm or 
endoplasmic reticulum (CDG type I) or in the Golgi apparatus (CDG type II). 
Particularly the elucidation of CDG type II defects is very challenging. O-
glycosylation analysis by isoelectric focusing of plasma apolipoprotein C-III allows 
differentiation between patients with an isolated N-glycosylation abnormality and 
patients with a combined N- and O-glycosylation defect [4,5]. The clinical 
Chapter 3 
~ 58 ~ 
heterogeneity in these patients prevents the straightforward identification of 
causative genes. An additional complicating factor is the occurrence of secondary 
causes of type 2 TIEF profiles, including the hemolytic uremic syndrome (HUS) with 
the presence of pneumococcal sialidase in plasma [6] or severe liver pathology [7-9]. 
Given that some of the CDG type II defects present with severe hepatopathy as well, 
these factors may delay diagnosis. Finally, no proper diagnostic assay is available for 
Golgi glycosylation defects with normal TIEF pattern, as seen in SLC35C1-CDG [10] 
with defective fucosylation. 
Clearly, there is a need for additional diagnostic tools in a medical setting to 
facilitate gene identification in CDG type II patients. HPLC and mass spectrometry 
provide structural information and have been applied in individual cases [11,12]. N-
glycome fingerprinting by MS has been successful in other classes of disease, including 
liver fibrosis and ovarian cancer [13,14]. In the field of CDG, Butler et al. described 
HPLC analysis of purified glycoproteins and whole-serum N-glycans, followed by mass 
spectrometric confirmation of glycan structures [15]. Mills et al. applied MALDI-TOF 
analysis of unmodified N-glycans in positive and negative ion mode providing an 
overview of neutral and acidic glycans, respectively [16]. Permethylated glycans have 
better ionization properties in MALDI-MS, and additional structural information is 
obtained from fragmentation. In addition, their signal strength reflects the relative 
amounts of glycans in the sample [17,18].  
Our goal was to develop a fast and robust method for plasma N-glycan profiling 
in a single measurement. Using permethylated glycans and appropriate matrix, all N-
glycans could be measured together in positive ion mode and relative quantification 
was achieved. In addition, the MALDI-linear ion trap allowed MSn-glycan sequencing, 
revealing detailed information on glycan structures [19]. It was applied to samples 
from healthy individuals and patients with a Golgi-related CDG and with a secondary 
cause of N-glycan hypoglycosylation. Through identification and quantification of the 
ions, factors were identified to discriminate patient groups. 
MATERIALS AND METHODS 
All chemical reagents were acquired with the highest level of purity available. 
Unless otherwise stated, they were purchased from Sigma Aldrich. 
Plasma samples 
Plasma samples were collected from EDTA- or heparin-treated blood by 
centrifugation and were stored at –20 °C. Plasma samples from healthy adults (>18 
years, n = 10) and children (0–14 years; n = 9) with a normal TIEF profile were used 
to establish reference ranges. We obtained samples from patients with the following 
Plasma N-glycan profiling as a diagnostic tool 
~ 59 ~ 
defects: MGAT2-CDG (CDG-IIa, provided by Prof.  Jaeken, Belgium [11]), B4GALT1-
CDG (CDG-IId)[12], SLC35C1-CDG (CDG-IIc)[10], SLC35A1-CDG (CDG-IIf, provided by 
Dr. Mollicone, France [20]), four COG7-CDG (CDG-IIe)[21] and two ATP6V0A2-CDG 
[22]. Samples with a secondary cause of underglycosylation were from 1 patient with 
severe liver failure of unknown etiology, 1 patient with citrullinemia type I with liver 
failure, 1 patient with hemophagocytic lymphohistiocytosis (HLH), and 1 patient with 
hemolytic uremic syndrome (HUS) due to Streptococcus pneumoniae infection and 
positive for plasma sialidase (specific activity: 41100 pmol.h-1.mL-1 at pH 7.0; 
undetectable in controls). 
Transferrin isofocusing 
We incubated 5 μL of plasma was incubated for 30 minutes with the same 
volume of 6.7 mmol/L ferric citrate and 0.17 mmol/L NaHCO3 (Fluka) in water and 
then diluted the mixture with 9 volumes of saline solution (9 g/L NaCl in ultrapure 
water; this saline solution was used through the procedure). We transferred 4 μL of 
each sample to a hydrated immobilin dry gel (ampholyte: Servalyt, pH 5-7; GE 
Healthcare) and ran them on PhastSystem (GE Healthcare) according to the 
manufacturer’s conditions and protocol. Transferrin isoforms were detected by 
immunoprecipitation in the gel with 60 μL rabbit-anti-human transferrin antibody per 
gel (8.5 g/L; Dako) for 30 minutes, followed by overnight washing in saline, fixation 
with 20% trichloroacetic acid, and Coomassie blue staining. 
Mass spectrometry 
Glycan release by PNGaseF (peptide-N4-(acetyl-β-glycosaminyl)-asparagine 
amidase, New England Biolabs) was performed by adding 90 μL saline and 11 μL 
Denaturation Buffer to 10 μL plasma before incubation at 95oC for 5 minutes. After 
cooling, we added 40 μL 10% NP40 (Roche), 15 μL reaction buffer and 2 μL PNGase F 
and incubated the mixture at 37oC overnight. Released glycans were purified on 3-mL 
graphitized carbon columns (Supelco) [23]. All N-glycans were eluted in a single 2 mL 
fraction of 25% acetonitrile (Biosolve)/0.1% aqueous trifluoroacetic acid and dried. 
Permethylation was performed as previously described [24, 17], with the following 
improvements. No specific precautions were taken to prevent moisture. Four air-dried 
NaOH pellets (approximately 375 mg) were crushed in 10 mL anhydrous DMSO, 0.5 
mL of this slurry and 0.2 mL CH3I were added to the dried glycans and the mixture 
was shaken vigorously for 1 hour. Permethylated glycans were extracted in a 
chloroform layer, which was washed 4 times with water and dried under nitrogen 
flow. Further purification was performed by C18-StageTips instead of with C18-
SepPak cartridges [25]. The tips were pre-washed with 100 μL methanol (LabScan) 
and washed with 100 μL 20 mmol/L aqueous sodium acetate (Fluka). The glycans, 
diluted in 50 μL 50% aqueous methanol, were loaded onto the tip, washed 
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consecutively with 100 μL 20 mmol/L aqueous sodium acetate and 50 μL 15% 
aqueous acetonitrile, and eluted in 50 μL 75% aqueous acetonitrile. The glycans were 
dried, then resuspended in 5 to 10 μL 50% methanol/50% 20 mmol/L aqueous 
sodium acetate for spotting. The matrix consisted of 100 mg/mL 2,5-
dihydroxybenzoic acid (DHB, Fluka) in 50% acetonitrile/50% 20 mmol/L aqueous 
sodium acetate, to which 20 μL N,N-dimethyl aniline (DMA) was added per mL of 
DHB-solution. 0.5 μL sample and 0.5 μL matrix were mixed on the MALDI plate and 
left to dry at ambient temperature. 
Measurement of permethylated glycans on a vMALDI-LTQ (Thermo Scientific) 
and data acquisition were performed as described [19]. Spectra are averages of 50 
scans. Processed samples were considered unfit for further analysis when the average 
spectrum had a background signal exceeding 5% of the relative intensity of the 
highest peak. In these cases, a new serum aliquot was processed. 
A set of 38 glycans was chosen for quantitative analysis. There intensities were 
normalized to the sum of all those peaks, because control individuals and patients do 
not always share the same main peak (Table 3.1). For all samples, 4 spots were 
measured, and peak intensities were averaged.  
For comparative analyses between samples, we chose a set of glycan features 
including the following: nonreducing end monosaccharide; number of antennae; 
proportion of complex, hybrid or oligomannosidic glycans; fraction of fucosylated 
structures; and level of undersialylation. For each feature, we summed the relative ion 
intensities for all glycan peaks presenting that feature. Truncated structures included 
all complex N-glycans with at least 1 antenna without a terminal sialic acid (NeuNAc) 
and may therefore have a non-reducing end mannose (Man), N-acetyl glucosamine 
(GlcNAc) or galactose (Gal). The level of undersialylation was calculated as the ratio 
between the intensities of biantennary monosialylated (|A1|, m/z 2433) and the 
biantennary disialylated (|A2|, m/z 2794) complex glycans, with their fucosylated 
equivalents (|A1F| m/z 2606 and |A2F| m/z 2968, respectively): 
FAA
FAA
levellationUndersialy
22
11


   
For tetra-antennary glycans, only undersialylated species could be analyzed 
because the m/z values of the fully sialylated forms were out of range for this mass 
spectrometer. 
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Table 3.1: Measured masses of the 38 sodiated glycan ions used for quantitation. Structures 
were assigned on basis of molecular weight and confirmed by MSn fragmentation. Signal intensity is 
normalized to the sum of all quantified glycan peaks. The 10 most abundant glycans are highlighted in 
gray. 
Mass 
Assigned 
structure 
Glycan composition 
 
Signal intensity 
in adult controls,  
n = 10, average % 
(interval) 
Signal intensity in 
pediatric controls,  
n = 9, average % 
(interval) 
1581 
 
Hex5HexNAc2 
0.3%  
(0.0% - 0.8%) 
0.3%  
(0.0% - 0.7%) 
1592 
 
Hex3HexNAc3dHex1 
0.8% 
(0.2% - 1.5%) 
0.1% 
(0.0% - 0.3%) 
1663 
 
Hex3HexNAc4 
0.1% 
(0.0% - 0.6%) 
0.0% 
(0.0% - 0.1%) 
1785 
 
Hex6HexNAc2 
1.6% 
(0.9% - 2.7%) 
0.7% 
(0.2% - 1.2%) 
1837 
 
Hex3HexNAc4dHex1 
2.0% 
(0.3% - 4.6%) 
0.8% 
(0.1% - 1.8%) 
1867 
 
Hex4HexNAc4 
0.5% 
(0.1% - 1.1%) 
0.2% 
(0.0% - 0.4%) 
1908 
 
Hex3HexNAc5 
0.3% 
(0.0% - 0.7%) 
0.1% 
(0.0% - 0.2%) 
1983 
 
NeuAc1Hex4HexNAc3 
1.1% 
(0.6% - 1.7%) 
0.5% 
(0.3% - 0.6%) 
2041 
 
Hex4HexNAc4dHex1 
3.1% 
(1.1 – 5.2%) 
1.5% 
(0.7% - 3.3%) 
2071 
 
Hex5HexNAc4 
1.0% 
(1.1% - 5.2%) 
0.4% 
(0.2% - 0.7%) 
2082 
 
Hex3HexNAc5dHex1 
0.6% 
(0.2% - 1.1%) 
0.2% 
(0.0% - 0.4%) 
2157 
 
NeuAc1Hex4HexNAc3dHex
1 
1.0% 
(0.6% - 1.5%) 
0.3% 
(0.1% - 0.5%) 
2228 
 
NeuAc1Hex4HexNAc4 
1.0% 
(0.7% - 1.4%) 
1.0% 
(0.8% - 1.2%) 
2245 
 
Hex5HexNAc4dHex1 
2.1% 
(1.3% - 2.9%) 
1.5% 
(0.8% - 3.6%) 
2286 
 
Hex4HexNAc5dHex1 
1.2% 
(0.9% - 1.4%) 
0.5% 
(0.3% - 0.8%) 
2392 
 
NeuAc1Hex6HexNAc3 
0.6% 
(0.3% - 0.9%) 
0.5% 
(0.4% - 0.6%) 
2403 
 
NeuAc1Hex4HexNAc4dHex
1 
1.3% 
(1.0% - 1.5%) 
0.8% 
(0.5% - 1.1%) 
2433 
 
NeuAc1Hex5HexNAc4 
5.3% 
(3.0% - 7.6%) 
7.3% 
(4.1% - 10.1%) 
2474 
 
NeuAc1Hex4HexNAc5 
0.9% 
(0.7% - 1.3%) 
0.5% 
(0.3% - 0.8%) 
2607 
 
NeuAc1Hex5HexNAc4dHex
1 
2.9% 
(2.3% - 4.0%) 
3.0% 
(1.9% - 4.6%) 
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2648 
 
NeuAc1Hex4HexNAc5dHex
1 
0.8% 
(0.5% - 1.2%) 
0.4% 
(0.2% - 0.5%) 
2794 
 
NeuAc2Hex5HexNAc4 
39.2% 
(34.8% - 43.7%) 
52.4% 
(44.6% - 60.3%) 
2852 
 
NeuAc1Hex5HexNAc5dHex
1 
3.3% 
(2.3% - 4.2%) 
2.4% 
(1.3% - 3.7%) 
2882 
 
NeuAc1Hex6HexNAc5 
2.1% 
(1.5% - 2.5%) 
1.5% 
(1.0% - 2.3%) 
2968 
 
NeuAc2Hex5HexNAc4dHex
1 
5.5% 
(2.6% - 7.0%) 
5.5% 
(4.0% - 7.2%) 
3039 
 
NeuAc2Hex5HexNAc5 
1.3% 
(0.9% - 2.1%) 
0.7%  
(0.4% - 1.2%) 
3056 
 
NeuAc1Hex6HexNAc5dHex
1 
1.4% 
(0.9% - 2.2%) 
0.7% 
(0.4% - 1.3%) 
3142 
 
NeuAc2Hex5HexNAc4dHex
2 
0.9% 
(0.6% - 1.5%) 
0.4% 
(0.2% - 0.6%) 
3213 
 
NeuAc2Hex5HexNAc5dHex
1 
2.2% 
(1.1% - 2.7%) 
1.0% 
(0.7% - 1.3%) 
3231 
 
NeuAc1Hex6HexNAc5dHex
2 
1.2% 
(0.9% - 1.7%) 
0.7% 
(0.5% - 1.0%) 
3244 
 
NeuAc2Hex6HexNAc5 
1.8% 
(1.3% - 2.3%) 
1.5% 
(1.1% - 2.1%) 
3332 
 
NeuAc1Hex7HexNAc6 
0.6% 
(0.3% - 1.1%) 
0.2% 
(1.1% - 2.1%) 
3418 
 
NeuAc2Hex6HexNAc5dHex
1 
0.8% 
(0.3% - 1.6%) 
0.5% 
(0.3% - 1.3%) 
3506 
 
NeuAc1Hex7HexNAc6dHex
1 
0.4% 
(0.1% - 1.3%) 
0.1% 
(0.0% - 0.3%) 
3605 
 
NeuAc3Hex6HexNAc5 
6.3% 
(4.2% - 9.3%) 
6.4% 
(4.3% - 9.3%) 
3693 
 
NeuAc2Hex7HexNAc6dHex
2 
0.7% 
(0.3% - 1.5%) 
0.5% 
(0.3% - 0.8%) 
3779 
 
NeuAc3Hex6HexNAc5dHex
1 
2.7% 
(0.7% - 5.4%) 
3.9% 
(1.4% - 11.4%) 
3867 
 
NeuAc2Hex7HexNAc6dHex
1 
0.4% 
(0.0% - 1.2%) 
0.3% 
(0.0% - 1.0%) 
 
The reproducibility was assessed similarly to the method that we described in 
our previous publication [19]. We individually processed 10 aliquots of a control 
serum sample and spotted each 4 times; we also measured 10 spots 4 times (Table 
3.2). The 10 most abundant glycan ions were selected, with the intensity of these ions 
normalized to the sum of all 38 glycan ions previously defined. Intra-spot CV was 
calculated by measuring four data sets per spot on ten spots. The relative intensities 
on the four data sets were averaged and their corresponding CV’s calculated. The CV’s 
Plasma N-glycan profiling as a diagnostic tool 
~ 63 ~ 
on the ten spots were averaged. The inter-spot variability was calculated by 
measuring the average intensity and corresponding CV of the peaks in four spots of 
the same aliquot. This represents the variability between data of four spots of the 
same aliquot, measured on the same day. The inter-assay variability, or variability 
between 10 aliquots of the same sample, was calculated by averaging the ion 
intensities of four spots for each aliquot and calculating the CV between the 10 
aliquots. 
Table 3.2: Reproducibility of sample processing and measurement.  
Ion signal 
(m/z) 
Average intra-spot CV (n = 
10) 
Average inter-spot CV (n = 
10) 
Inter-assay CV (n = 10) 
2041 7.1% 7.4% 17% 
2245 7.4% 13% 22% 
2433 5.4% 8.8% 23% 
2607 5.1% 7.4% 24% 
2794 3.2% 5.9% 20% 
2852 3.4% 7.1% 13% 
2968 2.8% 4.7% 17% 
3213 7.9% 8.1% 26% 
3605 4.9% 9.6% 34% 
3779 7.1% 11% 15% 
RESULTS  
Plasma N-glycan analysis of control samples 
For comparative purposes, we analyzed plasma N-glycans from 19 samples 
with normal TIEF pattern. We optimized sample processing by using a smaller amount 
of NaOH with an increased reaction time to facilitate sample work-up. The use of C18-
StageTips instead of C18-SepPak cartridges greatly increased the throughput. Use of a 
DHB/DMA mixture as the matrix permitted good measurement reproducibility (Table 
3.2). The reproducibility of sample processing was comparable to that of our previous 
method, with the inter-assay CV varying from 13 to 34% [19]. 
Figure 3.1 presents a representative N-glycan spectrum for controls. We 
quantified 38 glycan ions (Table 3.1) and confirmed assigned glycan structures by MSn 
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sequencing. Unless explicitly addressed, adult and pediatric controls were pooled for 
establishment of reference intervals. The dominant ions are biantennary and 
triantennary fully sialylated complex N-glycans (m/z 2794 and 3605) with their 
fucosylated equivalents (m/z 2968 and 3779). The mean level of undersialylation was 
18% (reference interval 12% - 28%). The degree of fucosylation was higher for 
truncated structures than for fully assembled glycans. For example, the ratio of the 
major glycan at m/z 2794 to its fucosylated equivalent (m/z 2968) was about 8, while 
the ratio for truncated structure, i.e., (m/z 2071)/(m/z 2245), was only about 0.5. A 
small fraction of oligomannosidic glycans was detected (Table 3.1; sum of m/z 1581 
and m/z 1785, reference interval 0.0% - 1.7%).  
The quantitative analysis of glycan features in control samples, as described in 
Materials and Methods, revealed the presence of 78% biantennary (reference interval 
67% - 84%) and 16% triantennary glycans (reference interval 11% - 26%) (Figure 
3.2, Table 3.3). Truncated structures, such as ions with m/z values 1837, 2041 and 
2245, account for one-third of all complex N-glycans (reference interval 21% - 44%).  
Among the controls, no significant distinction could be made between age 
groups, except for the fucosylation status. In the pediatric group, <30% of the N-
glycans were fucosylated (reference interval 17% to 28%, with 1 sample at 34%), 
whereas > 30% was fucosylated in adults (reference interval 31% - 37%). MSn 
sequencing revealed the occurrence of both core and antenna fucosylation in both age 
groups.  
Plasma N-glycan analysis in patient samples 
After establishing reference intervals for glycan features, we compared 
controls with a comprehensive panel of patient samples. Known defects included 
deficiencies in glycosyltransferases (MGAT2 and B4GALT1), nucleotide sugar 
transporters (SLC35C1 and SLC35A1) and Golgi transport proteins (COG7 and 
ATP6V0A2), whereas secondary causes included severe liver pathology and the 
presence of plasma sialidase.  
Glycosyltransferase defects 
Samples from the two known CDG type II subtypes with a glycosyltransferase 
defect, MGAT2-CDG and B4GALT1-CDG were processed and measured (Figure 3.3). 
The N-glycan spectrum of the MGAT2-CDG patient was dominated by ions with 
m/z values of 1983 and 2157, corresponding to the monoantennary complex N-glycan 
and its fucosylated equivalent. Biantennary glycans were strongly reduced, and 
triantennary glycans were completely absent from the spectrum. This is in accordance 
with an enzymatic deficiency of N-acetyl-glycosaminyltransferase II [11].  
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Figure 3.1: Representative plasma N-glycan profile of control samples indicating the major glycans. All 
38 glycan structures (Table 3.1) were confirmed by MSn fragmentation. For clarity of the pictures only a 
selection of glycans is shown. GlcNAc(), Man(), Gal (), NeuNAc (), Fuc () moieties are 
indicated. Inset, right: control TIEF profile with numbers of sialic acids on transferrin (0-5). 
 
 
Figure 3.2: Comparison of glycan features between control and patient samples. Glycan features 
represent summed data of individual glycan ions as described in Materials and Methods. *Controls (n = 
19), *COG7 (n = 4) and *ATP6V0A2 (n = 2) values are presented as means; error bars indicate the range 
of all samples. Citrul, sample from a patient with type I citrullinemia; HLH, sample from a patient with 
hemophagocytic lymphohistiocytosis.  
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Table 3.3: Comparison of glycan features between control and patient samples. Undersialylation level 
is defined as described in the Materials and Methods section. All other data are expressed as average % 
of the total glycan pool. *Controls, COG7 (n = 4) and ATP6V0A2 (n = 2), values are shown as mean and 
full interval of measurements.  
 Truncated Undersialylation 
level 
Triantennary Terminal Gal Terminal 
GlcNAc 
Fucosylated 
Control, 
adults* 
38% 
(30% -44%) 
18% 
(13% - 24%) 
16% 
(12% - 22%) 
29% 
(25% - 31%) 
19% 
(14% - 24%) 
34% 
(31% - 37%) 
 
Control, 
pediatric* 
27% 
(21% - 36%) 
18% 
(12% - 28%) 
15% 
(11% - 26%) 
23% 
(18% - 30%) 
10% 
(8% - 14%) 
24% 
(17% - 34%) 
 
MGAT2 86% 141% 1% 17% 14% 39% 
 
B4GALT1 91% 83% 1% 11% 88% 40% 
 
SLC35C1 29% 19% 27% 24% 10% 11% 
 
SLC35A1 31% 15% 23% 24% 15% 30% 
 
 
COG7* 
61% 
(57% – 67%) 
64% 
(49% – 83%) 
8% 
(4% – 13%) 
44% 
(39% – 50%) 
28% 
(25% – 
30%) 
37% 
(34% – 40%) 
ATP6V0A2* 
 
54% 
(50% – 58%) 
48% 
(43% – 53%) 
11% 
(10% – 12%) 
38% 
(36% – 40%) 
27% 
(23% – 
32%) 
35% 
(31% – 39%) 
 
HUS 74% 181% 12% 65% 12% 28% 
 
HLH 61% 63% 7% 42% 34% 51% 
 
Citrullinemia 60% 65% 12% 47% 25% 52% 
 
Liver failure 47% 37% 25% 39% 19% 55% 
 
The N-glycans of the B4GALT1-CDG patient [12] showed a different profile 
with a high proportion of structures with terminal GlcNAc (m/z 1663, 1823, 1837, 
1908 and 2082) and truncated bi- and triantennary structures missing 1 or 2 NeuNAc-
Gal moieties (m/z 2228, 2403, 2474 and 2648). Overall, 88% of the quantified glycans 
had at least 1 terminal GlcNAc residue (12% in controls), corresponding to a deficient 
transfer of Gal to terminal GlcNAc residues by β1,4-galactosyltransferase 1. 
Nucleotide sugar transporter defects  
Nucleotide sugars must be actively transported from the cytosol to the Golgi 
lumen by highly specific nucleotide-sugar transporters. Malfunctioning of the GDP-Fuc 
transporter and CMP-NeuNAc transporter have been described in SLC35C1-CDG 
[10,26] and SLC35A1-CDG patients [20]. Both presented a normal TIEF pattern. Mass 
spectrometry of SLC35C1-CDG revealed an evident decrease of the fucosylation status 
to 11% (33% in controls; Figures 3.2 and 3.3). In the MS profile, the prominent 
fucosylated ions at m/z 2606, m/z 2968 and m/z 3779 were not observed. MSn 
fragmentation showed that both core and antenna fucosylation were affected. This 
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Figure 3.3: N-glycan profile of CDG type II patients, with major glycans indicated. All glycan structures 
were confirmed by MSn. GlcNAc(), Man(), Gal (), NeuNAc (), Fuc () moieties are indicated. The 
corresponding plasma TIEF profile is shown on the right, the number of sialic acids on transferring (0-
6) are indicated. 
 
example illustrates the use of mass spectrometry to identify glycosylation defects with 
normal TIEF pattern. In accordance with the normal isofocusing pattern, the mass 
spectrum of whole plasma N-glycans of the SLC35A1-CDG patient was comparable to 
that of the controls.  
Defects in Golgi trafficking 
Besides deficient transfer and transport of sugars, abnormal glycosylation may 
be caused by impaired Golgi trafficking, as seen in COG-CDG [27] and ATP6V0A2-CDG 
[28]. Plasma N-glycan profiling of 4 COG7-CDG and 2 ATP6V0A2-CDG patients showed 
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a reduction in triantennary glycans along with an increase of truncated structures 
(Figures 3.2 and 3.4). For both CDG-types, the undersialylation level was 2 to 3 times 
higher than the reference range. Overall, the total fraction of truncated structures was 
increased from 33% (reference interval 21% - 44%) to 61% in COG7-CDG patients 
(reference interval 57% - 67%) and 50% and 58% in the ATP6V0A2-CDG patients 
(Figure 3.2). The truncation occurred at various levels of the antenna: the fraction of 
glycans with terminal Gal (including m/z values 2041, 2433 and 2607) increased from 
26% in controls (reference interval 21% - 34%) to 44% in COG7-CDG patients 
(reference interval 39% - 50%) and 36% and 40% in ATP6V0A2-CDG. The fraction of 
glycans with terminal GlcNAc was significantly higher in both patient groups (e.g. m/z 
1837 and 2228; Figure 3.4), from 15% in controls (reference interval 8% - 24%) to 
28% in COG7-CDG patients (range 25% - 30%) and 22% and 31% in the ATP6V0A2-
CDG patients. In three of the four COG7-CDG samples, oligomannosidic structures 
were increased compared to controls (m/z 1581 and 1785). These data confirm that 
trafficking defects affect several steps in the processing of N-glycans along the Golgi 
biosynthetic route. 
Secondary causes of hypoglycosylation 
One of the challenges in the diagnostics of CDG type II patients is the exclusion 
of secondary causes of hypoglycosylation. We carried out a detailed analysis of the N-
glycome to search for glycan features that discriminate between primary and 
secondary glycosylation abnormalities.  
Plasma N-glycan profiling of HUS patients with sialidase in the blood was in 
agreement with the undersialylated transferrin isoforms revealed by isoelectric 
focusing; the most prominent ion was the monosialylated biantennary N-glycan 
(Figure 3.3). The undersialylation level is 10-fold higher than in controls, and all 
observed ion peaks with m/z values > 2800 Da represented undersialylated tri- and 
tetra-antennary structures, most of which were not observed in controls (Figure 3.4). 
In contrast to COG7- and ATP6V0A2-CDG glycomes, the percentage of triantennary 
glycans was not decreased, and there was no increase in ions with terminal GlcNAc or 
oligomannosidic glycans. This finding is in agreement with a normal N-glycan 
biosynthesis followed by extracellular sialidase cleavage. TIEF and MS of a sample 
from a HUS patient after treatment showed normal profiles (data not shown).  
Three other patients presented a type 2 TIEF pattern, although their diagnosis 
was not directly related to a genetic glycosylation disorder. One patient had isolated 
liver failure, one patient had citrullinemia type I and one patient had HLH. All patients 
had severe liver abnormalities according to their liver enzyme activities. 
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Figure 3.4: MS1 spectra of plasma N-glycans of 2 patients with a defect in Golgi trafficking (top 2 
panels) and 4 patients with secondary glycosylation defect (bottom 4 panels). GlcNAc(), Man(), Gal 
(), NeuNAc (), Fuc () moieties are indicated. The corresponding plasma TIEF profile is shown on 
the right, the number of sialic acids on transferring (0-6) are indicated. 
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The patient with isolated liver failure presented a slightly abnormal type 2 
TIEF profile. The mass spectrum revealed mainly undersialylation of tri- and tetra-
antennary N-glycans, an increase in fucosylated glycans, and increased 
undergalactosylated biantennary structures (Figures 3.2 and 3.4). The transferrin 
isofocusing pattern of the citrullinemia patient was also slightly abnormal, yet the 
mass spectrum of plasma N-glycans showed a more prominent increase in truncated, 
fucosylated structures than in the other patients with liver failure. The TIEF pattern of 
the HLH patient was clearly abnormal before treatment, a finding that was confirmed 
by an N-glycan profile with strongly elevated truncated and fucosylated structures 
and a decrease of triantennary glycans. The TIEF profile and N-glycan spectrum 
normalized after 13 days of chemo-immunotherapy (data not shown). Our overall 
analysis of the glycan features in these three patients revealed that their fucosylation 
status was significantly different from patients with a Golgi-trafficking defect. 
DISCUSSION 
The lack of proper diagnostic tools to exclude secondary causes of 
underglycosylation in patients with CDG type II and to highlight the genetic defect 
stimulated us to test the diagnostic potential of MALDI ion trap profiling of plasma N-
glycans. Particular glycan features, such as fucosylation, the terminal monosaccharide, 
and the level of undersialylation, were used to compare patient groups. 
Glycosyltransferase defects (MGAT2-CDG and B4GALT1-CDG) resulted in very 
distinct plasma N-glycan profiles that pointed directly to the defect. Plasma 
transferrin analysis by 1H-NMR and electrospray MS of purified disialotransferrin of 
the MGAT2-CDG patient had previously revealed two monoantennary N-glycans on 
the protein [11]. MALDI-MS showed that the fucosylated equivalent was also present. 
HPLC and mass spectrometric analysis of transferrin glycans of the B4GALT1-CDG 
patient previously showed 3 glycans: the fully sialylated biantennary N-glycan, and 
truncated equivalents missing 1 or 2 NeuNAc-Gal moieties [12]. Whole-plasma 
profiling showed a much wider spectrum of N-glycans, including fucosylated N-
glycans and glycans with a bisecting GlcNAc or truncated third antenna. A minor 
fraction of fully sialylated mono- and biantennary glycans was still present, in line 
with the transferrin isoform distribution on TIEF. These N-glycan MALDI fingerprints 
are directly indicative of the genetic defect.  
The two transporter defects do not lead to an abnormal TIEF profile. In the 
GDP-Fuc transporter defect (SLC35C1-CDG), the lack of fucose residues does not 
influence the isoelectric point of transferrin. Our MS data confirmed a significant 
decrease in fucosylated structures as compared to controls and other CDG patients. 
Thus, a clinical suspicion of SLC35C1-CDG as Leukocyte Adhesion Deficiency type II 
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(LAD-II) should trigger clinicians to request plasma N-glycan profiling for diagnostics. 
In the patient with a deficient Golgi CMP-NeuNAc transporter, the normal sialylation 
of transferrin was explained by the leakiness of the mutation or by sample 
contamination owing to frequent transfusions [20,29].  
Defects in the Golgi secretory pathway can affect both N- and O-glycosylation, 
as seen in COG-CDG and ATP6V0A2-CDG. The conserved oligomeric Golgi (COG) 
complex is involved in the control of intracellular trafficking and stability of Golgi-
associated glycosylation enzymes. Defects have been found in various subunits (COG1 
and COG4 through COG8) [27,30]. Previously published serum N-glycan spectra for 4 
different COG defects were mainly characterized by decreased sialylation [31]. COG1- 
and COG7-CDG showed the most severe underglycosylation with strongly decreased 
galactosylation and increased oligomannosidic glycan at m/z 1582. Our findings in 
COG7-CDG confirm the reduction of sialylation and galactosylation. We also observed 
an increase in oligomannosidic glycans from 0.7% (reference interval 0.0% - 1.7%) to 
2.0%, 2.8% and 2.9% in three COG7-CDG patients. The fourth COG7-CDG patient 
showed a normal percentage (1.2 %). The increased occurrence of oligomannosidic 
glycans has been explained by mislocalization of the 1,2-N-
acetylglucosaminyltransferase1 (GlcNAcT1) and mannosidase II (ManII) enzymes in 
the medial-Golgi [32]. Mutations in the a2 subunit of the vacuolar H+-ATPase 
(ATP6V0A2) [33,34] cause impaired Golgi trafficking via altering the intracellular pH 
gradient and glycosylation abnormalities at several levels. Unlike MGAT2 and 
B4GALT1 mutations, Golgi-trafficking defects affect multiple steps in the N-glycan 
processing pathway, as can be observed by the wide range of truncated glycan 
structures. 
Exclusion of secondary causes of underglycosylation still presents a major 
challenge in the diagnosis of CDG type II. Separate measurement of plasma sialidase in 
case of HUS or repetitive blood sampling in case of liver failure are required to obtain 
insight in the nature of the abnormal TIEF profile. Therefore, we searched glycan 
profiles for specific ions or general glycan features that could discriminate between 
primary and secondary defects. None of the individual glycan ions showed significant 
difference; however, analysis of general glycan features showed that the level of 
fucosylation carries such discriminating power. In patients with a glycosyltransferase 
or Golgi-trafficking defect, the fucosylation status was increased (31% to 40%) 
compared to pediatric controls (reference interval 17% to 34%). This can be 
explained by the increase in truncated structures, for which the fucosylation status is 
higher than for fully assembled structures. A much larger increase was observed in 
patients with liver disease as a secondary cause of underglycosylation. In this category 
of patients, >50% of all quantified glycans were fucosylated. The N-glycan profiles of 
these patients were characterized by decreased sialylation, by an increase in 
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structures truncated at various levels, but in particular by this increase in fucosylated 
ions (m/z values 1837, 2041, 2245, 2607, 2968, 3779) (Figures 3.2 and 3.4). In 
contrast, the plasma N-glycans of the HUS patient were characterized solely by 
undersialylation, whereas fucosylation was not affected. This finding is in agreement 
with a loss of sialic acid residues due to plasma sialidase action [6] after a normal 
biosynthesis and secretion of fully processed glycoproteins. 
In summary, our improved method for plasma N-glycan profiling allows 
distinguishing between primary genetic defects in the N-glycosylation process, Golgi-
trafficking disorders, and secondary causes of underglycosylation. Therefore, plasma 
N-glycan profiling by MS should be applied as a first diagnostic step in all patient 
samples presenting with a type 2 TIEF profile. This step should greatly facilitate 
further biochemical and genetic confirmations in CDG type II. 
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ABSTRACT 
Congenital Disorders of Glycosylation form a group of metabolic disorders 
caused by deficient glycosylation of proteins and/or lipids. Isoelectric focusing of 
serum transferrin is the most common screening method to detect abnormalities of 
protein N-glycosylation. On the basis of the IEF profile, patients can be grouped into 
CDG type I or CDG type II. Several protein variants of transferrin are known that result 
in a shift in isoelectric point (pI). In some cases, these protein variants co-migrate with 
transferrin glycoforms, which complicates interpretation. 
In two patients with abnormal serum transferrin IEF profiles, neuraminidase 
digestion and subsequent IEF showed profiles suggestive of the diagnosis of CDG type 
I. Mass spectrometry of tryptic peptides of immunopurified transferrin, however, 
revealed a novel mutation at the N-glycan attachment site. In case 1, a peptide with 
mutation p.Asn630Thr in the 2nd glycosylation site was identified, resulting in an 
additional band at disialotransferrin. After neuraminidase digestion, a single band was 
found at the asialotransferrin position, indistinguishable from CDG type I patients. In 
case 2, a peptide with mutation p.Asn432His was found. These results show the use of 
mass spectrometry of transferrin peptides in the diagnostic track of CDG type I. 
INTRODUCTION  
Congenital Disorders of Glycosylation comprise a group of rare inherited 
metabolic disorders caused by deficient glycosylation of proteins and/or lipids. For N-
glycan biosynthesis, a lipid-linked oligosaccharide is synthesized in the endoplasmic 
reticulum, and transferred en bloc to a nascent protein. N-glycans are exclusively 
transferred to an asparagine in the consensus sequence Asn-Xxx-Ser/Thr, where Xxx 
is any amino acid except proline. The glycosylated protein is then transferred to the 
Golgi for further processing of the glycans. Defects in the biosynthesis and transfer of 
the lipid-linked oligosaccharide result in the loss of whole N-glycans on glycoproteins, 
resulting in a CDG type I. 
Diagnostic screening of CDG is performed by isoelectric focusing of transferrin. 
In its most abundant form, this serum glycoprotein carries two complex N-glycans 
attached to Asn432 and Asn630. Each N-glycan is terminated by two negatively 
charged sialic acids. Defects in the biosynthesis of N-glycans in the endoplasmic 
reticulum cause a loss of one or two complete N-glycans, resulting in a typical IEF 
pattern of CDG type I, characterized by increased asialo- and disialotransferrin bands, 
and decreased tetrasialotransferrin. Secondary causes of hypoglycosylation such as 
galactosemia or fructosemia may cause an identical pattern and therefore must be 
excluded. Several transferrin protein polymorphisms result in a shifted IEF pattern, 
Chapter 4 
~ 80 ~ 
caused by pI differences of the polypeptide chain [1,2]. Variant Tf C is the most 
common form of transferrin, the anodic variant B and cathodic variant D are less 
common. In particular, heterozygous combinations of C and D variants may lead to 
misinterpretation in CDG diagnosis [1,3]. Nevertheless, these polymorphisms can be 
identified by neuraminidase treatment of serum, resulting in an IEF pattern with two 
distinct asialotransferrin bands (Figure 4.1, lane 5).  
 
Figure 4.1: Transferrin isoelectric focusing profiles before and after neuraminidase incubation. Lane 1 
and 1’: control, lane 2 and 2’: PMM2-CDG, lane 3 and 3’: case 1, lane 4 and 4’: mother of case 1, lane 5 
and 5’: case 2, lane 6 and 6’: mother of case 2, lane 7 and 7’: patient with a known “D variant” 
polymorphism. Left and right of the figure are the numbers of sialic acids present on transferrin C 
variant. 
 
To improve diagnostics of CDG, mass spectrometric methods for glycoprotein 
analysis are being developed because of its higher sensitivity and specificity [4-7]. 
Liquid chromatography-mass spectrometry (LC-MS) of immunopurified transferrin 
was proven to be a sensitive screening method for CDG type I, showing distinct peaks 
for fully glycosylated transferrin, and transferrin lacking one or two oligosaccharide 
chains [5,8,9]. For CDG type II with abnormal processing of glycans, analysis of 
enzymatically removed glycans can be diagnostic [10]. 
Here, we present the application of MS of transferrin peptides in the diagnosis 
of CDG and reveal two novel transferrin mutations in the N-glycan attachment site.  
PATIENTS AND METHODS 
IEF and SDS-PAGE of transferrin  
IEF of transferrin was performed as described in two cases. Case 1 was 
suspected of CDG due to a clinical presentation of cyclic vomiting accompanied with 
ketosis and metabolic acidosis and the appearance of atypical fat pads and inverted 
nipples at the age of seven. Hemoglobin and mean corpuscular volume were normal. 
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Case 2 was a healthy donor for blood transfusion, who participated in a large-scale 
screening for transferrin variants in populations of Japan and New Zealand [11]. His 
mother was also healthy. 
Five μL of plasma was incubated for 30 min. with equal volumes of 6.7 mM 
Fe(III)citrate and 0.17 mM NaHCO3 (Fluka, Buchs, Switzerland) in ultrapure water, 
then diluted ten times in saline. Two μl of each sample was transferred to a hydrated 
immobilin dry gel (GE Healthcare, Buckinghamshire, UK) with Servalyt, pH 5-7 (Serva, 
Heidelberg, Germany) and run on a PhastSystem (GE Healthcare). Different isoforms 
of transferrin were detected by immunoprecipitation in the gel with 60 μl rabbit-anti-
human transferrin antibody per gel (8.5 g/L; Dako, Glostrup, Denmark) for 30 min., 
followed by overnight washing in saline, fixation with 20% trichloroacetic acid and 
Coomassie blue staining. 
Removal of sialic acids was achieved by incubating 3 μL of plasma for 30 min. 
with the same volume of 6.7 mM Fe(III)citrate and 0.17 mM NaHCO3 (Fluka) in water, 
prior to addition of 15 mU of neuraminidase (Roche diagnostics, Mannheim, Germany) 
and incubation for two hours at 37oC. IEF was then performed identically to non-
treated samples.  
Prior to SDS-PAGE analysis, plasma samples were centrifuged and diluted 100-
fold with ultrapure water. Three μL diluted sample was mixed with 100 μl sample 
buffer (10 mM Tris–HCl, pH 8.0, 1 mM EDTA, 2.5% SDS, 2% DTT, and 0.01% 
bromophenol blue) and heated for 5 minutes at 95oC. The samples were then applied 
to a 12.5% Phastgel (GE Healthcare) and the proteins separated on a Phastsystem (GE 
Healthcare). After separation, the proteins were detected by western blotting using a 
primary rabbit anti-human transferrin antibody (Dako) and a secondary goat anti-
rabbit peroxidase conjugated antibody, followed by electrochemiluminescence 
detection. 
MALDI-MS of transferrin 
The purified transferrin was desalted by a ZipTip C4 (Millipore, Bedford, MA) 
and analysed by MALDI mass spectrometry using a Voyager DE Pro MALDI-time-of-
flight mass spectrometer with a nitrogen pulsed laser (337 nm) (Applied Biosystems, 
Foster City, CA) [10].  The sample matrix was 10 mg/mL sinapinic acid in a 0.1% (v/v) 
TFA and 30% (v/v) acetonitrile solution.  The measurements were carried out in 
positive ion and linear TOF mode.   
For electrospray MS of peptides, transferrin was dissolved in a solution of 6M 
guanidine, 0.25M Tris-HCl, pH 8.0, reduced with 0.13 M dithiothreitol at 50˚C for 1 h 
and then S-carbamidomethylated with 0.22 M iodoacetamide for 30 min at room 
temperature. Tryptic peptides were desalted by ZipTip C18 (Millipore), dissolved in a 
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0.1% formic acid and 50% (v/v) acetonitrile solution and were directly infused into an 
LTQ XL ion trap mass spectrometer (Thermo-Fisher Scientific, San Jose, CA) using a 
nanospray tip. The CID MS/MS was carried out with helium gas and the spectra were 
acquired by 100 scans. 
Genetic analysis 
DNA from case 1 and his mother was isolated from whole blood samples by the 
commonly used salt-out method for DNA isolation. DNA of other family members was 
isolated from archived dried blood spots on filter paper using the QIAamp DNA Micro 
Kit (Qiagen, Valencia, CA).  The isolation process was performed according to the 
recommended manufacturer protocols. The primers were designed to the intronic 
regions surrounding the 17 protein coding exons of the transferrin gene (TF gene: 
OMIM 190000; NCBI gene ID: 7018; NG_013080.1; ENSG00000091513). Primer 
sequences are available upon request. The fragments were amplified using the Combi 
PPP Master Mix (Top-Bio s.r.o; Praha, Czech Republic) and purified by gel extraction 
using Wizard SV Gel and PCR clean-Up System (Promega, Madison, WI). All fragments 
were sequenced on ABI PRISM 3100-Avant Genetic Analyzer (Applied Biosystems, 
Carlsbad, CA) using the Big Dye Terminator v.3.1 Cycle Sequencing Kit (Applied 
Biosystems) according the recommended manufacturer protocols. Sequence analyses 
were performed using SeqScape Software v2.5 (Applied Biosystems). The nucleotide 
numbering follows cDNA numbering with +1 corresponding to the A of the ATG 
translation codon in the reference sequence. The initiation codon is codon 1. For 
restriction analyses of the c.1889A>C mutation, the HpyCH4IV (New England BioLabs, 
Ipswich, MA) restriction endonuclease was used according to the manufacturer 
protocols of the enzyme. 
RESULTS  
Clinical suspicion of CDG in case 1 triggered us to perform IEF of transferrin, 
which showed a type I profile (Figure 4.1, lane 3) with increased disialotransferrin 
and decreased tetrasialotransferrin. Neuraminidase treatment resulted in a single 
band corresponding to asialotransferrin, suggesting that the double band in the 
untreated sample was not the result of a protein variant (Figure 4.1, lane 3’). IEF of 
serum transferrin from case 2 and his mother showed two major bands in a 1:1 ratio 
with one band at the level of tetrasialotransferrin and one band just below 
disialotransferrin (Figure 4.1, lanes 5 and 6). After neuraminidase treatment, two 
bands were visible at the asialotransferrin position (Figure 4.1, lanes 5’ and 6’). The 
distance between these two bands is much smaller than between the bands of 
sialylated transferrin.  
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Additional information was obtained by SDS-PAGE analysis of transferrin. In 
controls, transferrin SDS-PAGE shows a single band around 79 kDa corresponding to 
the glycoprotein with two N-glycans (Figure 4.2). The transferrin of a PMM2-CDG 
(CDG-Ia) patient showed bands with nonglycosylated transferrin at 75 kDa, 
transferrin with one N-glycan at 77 kDa and the fully glycosylated transferrin at 79 
kDa [12]. In cases 1 and 2, two bands of equal intensity were observed at 77 kDa and 
79 kDa. This finding was confirmed by MALDI-MS of whole transferrin [12]. Instead of 
a single peak at 79.6 kDa, peaks were observed at 77.3 kDa and 79.6 kDa, 
corresponding to transferrin with one and two N-glycans, respectively (Figure 4.2).  
 
Figure 4.2: MALDI-TOF profile of immunopurified transferrin, carrying 1 (m/z 77.3 kDa) or 2 (m/z 79.6 
kDa) N-glycan chains. Dotted line: control, continuous line: case 1. The gray boxes represent the 
glycosylation consensus sequences of the transferrin protein. Right: SDS-PAGE of serum transferrin: C = 
control, C1 = case 1, C1.M. = mother of case 1.  
 
Despite these indications for true CDG 1 profiles, a number of clues suggested 
otherwise. On transferrin IEF, the disialio- and tetrasialotransferrin bands were 
present in a 1:1 ratio, while asialotransferrin was normal (< 3%). In CDG type I 
patients, such severe profiles are commonly associated with an increase of 
asialotransferrin. IEF of thyroxin binding globulin (TBG), another serum glycoprotein 
used for screening of CDG, showed a normal pattern (data not shown). Additionally, 
transferrin IEF and SDS-PAGE in serum of the healthy mothers revealed similar 
patterns to their children’s (Figure 4.1, lanes 4 and 6; Figure 4.2). In contrast to the 
results after neuraminidase digestion, these findings were indicative of a protein 
variant.  
In order to obtain more insight into the structure of the transferrin protein in 
cases 1 and 2, transferrin was immunopurified from serum, trypsinized, and the 
peptides were analyzed by mass spectrometry. Glycopeptides, known to be present in 
the normal transferrin, were detected. In addition, a thus-far unreported 
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nonglycosylated peptide was found in case 1 as doubly charged ion at m/z 1252.1 and 
triply charged ion at m/z 835.0. MS/MS analysis revealed the peptide sequence 622-
QQQHLFGSTVTDCSGNFCLFR-642, corresponding to the non-glycosylated 
glycopeptide 2 with a heterozygous p.Asn630Thr change (Figure 4.3). This asparagine 
is the second N-glycosylation site of transferrin (underlined). In case 2, an unknown 
doubly charged ion with m/z 750.4 was found. MS/MS sequencing indicated a 
p.Asn432His change in the first glycosylation site: 421-CGLVPVLAENYHK-433 (Figure 
4.4).  
 
Figure 4.3: Analysis of transferrin peptides in case 1. A. identification of doubly- and triply charged 
species, not present in controls. B. MS/MS analysis of m/z 1252.1 indicates a p.N630T mutation in the 
second transferrin glycosylation site, thus peptide 622-QQQHLFGSNVTDCSGNFCLFR-642 is mutated to 
622-QQQHLFGSTVTDCSGNFCLFR-642. 
 
Thus, in both cases, MS/MS analysis of transferrin peptides showed a 
heterozygous amino acid change in one of the N-glycan attachment sites, resulting in a 
transferrin molecule with a single N-glycan. As a result, the mutated transferrin will 
lack two sialic acids and therefore be located at the disialotransferrin level on IEF. The 
imidazole group of the histidine in case 2 causes a slight pI difference between the 
common disialotransferrin and the mutated form. 
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Figure 4.4. Identification of a protein polymorphism in case 2. MS/MS analysis of m/z 750.4 indicated a 
p.N432H mutation in the first transferrin glycosylation site in case 2, thus peptide 421-
CGLVPVLAENYNK-433 is mutated to 421-CGLVPVLAENYHK-433. 
 
For case 1, sequencing of the TF gene revealed the heterozygous c.1889A>C 
mutation, thereby confirming the p.Asn630Thr alteration at the amino acid level. 
RFLP analysis in family members of case 1 showed the heterozygous mutation in the 
mother of case 1, her sister and the grandmother. This p.Asn630Thr mutation was not 
found in 130 controls. 
Case 2 was not available for further investigations at the molecular level. Yet, 
based on the amino acid sequence, a c.1294A>C mutation may have occurred, 
resulting in the substitution from Asn (AAT) to His (CAT). 
DISCUSSION 
In the diagnosis of CDG, it is important to exclude secondary causes of 
hypoglycosylation of transferrin, as well as transferrin variants which show an IEF 
pattern suggestive of CDG. In this study, we showed that the current method to 
identify a protein variants by treatment of serum samples with neuraminidase can be 
misleading when the mutation is located in one of the amino acids of the consensus 
sequence of N-glycosylation for transferrin. The loss of the N-glycan in half of the 
transferrin proteins in serum resulted in a pattern with equal amounts of disialo- and 
tetrasialotransferrin. Although this resembles a type 1 pattern, the approximate 1:1 
ratio between the two isoforms in combination with low levels of asialotransferrin (< 
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3%), should trigger one to consider a mutation in one of the glycosylation sites. If 
neuraminidase treatment is inconclusive, IEF of another glycoprotein, like TBG, may 
provide additional information about a generalized glycosylation defect. When serum 
of the patient’s parents is available, IEF of transferrin in these samples can also help to 
exclude such a mutation.  
Currently, mass spectrometry is increasingly used in diagnostics of inborn 
errors of metabolism. For CDG diagnosis, MS opportunities are growing [5,6,10]. Here, 
we show that the application of MS of transferrin (glyco)peptides reveals a non-
glycosylated peptide with a mutated N-glycosylation consensus sequence Asn-Xxx-
Thr/Ser. Alternatively, identification of non-glycosylated peptides with normal 
sequence will direct the diagnostics towards CDG type I. These analyses do not require 
additional serum sampling and provide unambiguous results.   
Our findings indicate the potential for mass spectrometric analysis of 
transferrin (glyco)peptides, not only in CDG type II, but also in the diagnostic track of 
CDG type I patients. It allowed the detection of two novel mutations in the consensus 
glycosylation sites, which influence the screening by transferrin IEF.  
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ABSTRACT 
Glycosylation of proteins is one of the most important post-translational 
modifications. Defects in the glycan biosynthesis result in congenital malformation 
syndromes, also known as congenital disorders of glycosylation (CDG). Based on the 
iso-electric focusing patterns of plasma transferrin and apolipoprotein C-III, a 
combined defect in N- and O-glycosylation were identified in patients with autosomal 
recessive cutis laxa type II (ARCL II). Disease-causing mutations were identified in the 
ATP6V0A2 gene, encoding the a2 subunit of the vacuolar H+-ATPase (V-ATPase). The 
V-ATPases are multi-subunit, ATP-dependent proton pumps located in membranes of 
cells and organels.  
In this article, we describe the structure, function and regulation of the V-
ATPase and the phenotypes currently known to result from V-ATPase mutations. A 
clinical overview of cutis laxa syndrome is presented with a focus on ARCL II. Finally, 
the relationship between ATP6V0A2 mutations, the glycosylation defect and the 
ARCLII phenotype is discussed. 
INTRODUCTION 
Detailed clinical and laboratory characterization of autosomal recessive cutis 
laxa phenotypes has revealed a surprising connection between glycosylation defects 
and cutis laxa. The discovery of mutations in the ATP6V0A2 gene, encoding the a2 
subunit of the vacuolar H+-ATPase, in autosomal recessive cutis laxa type II further 
highlighted the crucial role of the V-ATPase in glycosylation processes within the Golgi 
[1]. In this article, we will review the current knowledge of V-ATPase complex 
composition, its function and regulation. Known diseases associated with V-ATPase 
malfunction will be described with a special focus on ARCL II. Finally, we will discuss 
the possible links between a2 dysfunction, aberrant glycosylation and the disease 
pathophysiology.  
 Vacuolar H+-ATPase 
Vacuolar H+-ATPases are ATP-dependent proton pumps composed of two 
multi-subunit domains, V1 and V0, containing eight (A through H, total of 640 kDa) 
and five different subunits (a, c, c’’, d and e in mammals, total of 260 kDa), 
respectively. The structural organization of the V-ATPase complex is shown in figure 
5.1. The cytoplasmic V1 domain carries out ATP hydrolysis whereas the V0 domain, 
embedded in the plasma or organel membrane, is responsible for transfer of protons 
across the membrane into vesicles or into the extracellular space. As shown in figure 
5.1, the two domains are connected by a central and two peripheral stalks, which 
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couple ATP hydrolysis to proton translocation through a rotary mechanism similar to 
the mitochondrial F-ATPase complex [2,3]. The detailed mechanism through which 
these processes are coupled has already been described extensively and will therefore 
not be repeated here [4-6].  
 
Figure 5.1: Structure and function of the V-ATPase. ATP binds to and is hydrolysed by the A and B 
subunits of the hexameric head (light grey). This generates a rotational movement of the head and the 
central stalk or rotor, composed of subunits D, F and d (dark grey), which is transferred to the 
proteolipid ring (subunits c and c”, white). Subunit a (black) and the peripheral stalks (subunits C, E, G 
and H, medium grey) are static. The conformational changes generated by the rotational movement 
stimulate the transfer of a proton along the a-subunit and the proteolipid ring. 
V-ATPases were originally described as intracellular membrane proteins, 
present in endosomes, lysosomes, Golgi-derived vesicles, clathrin-coated vesicles and 
secretory vesicles. However, they have also been identified at the surface of a variety 
of cell types such as renal intercalated cells and osteoclasts, where they play an 
essential role in proton transport across the membrane [2]. In mammalian cells, 
several subunits of the V1 and V0 domains are expressed as multiple isoforms. 
Subunits B, C, E, H and d are expressed as two isoforms and subunit G as three 
isoforms. Subunit a even exists in 4 different isoforms (Table 5.1) [7-11]. Expression 
analysis has revealed that in many cases one isoform is ubiquitously expressed while 
other isoforms are limited to certain cell types [12]. This isoform complexity is 
thought to be necessary for tissue- and organel specific targeting of the V-ATPase and 
may also contribute to the control of its activity. This chapter will focus on the 
structure of the V-ATPase domains, the function of the subunits, and the distribution 
of the subunit isoforms.  
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Structure of the V1 domain and function of the subunits 
The subunits of the V1 domain of the ATPase are organized in (i) a ring shaped 
hexameric head consisting of three copies of A and B, (ii) a central stalk composed of 
subunits D and F of V1 and subunit d of V0 and (iii) peripheral stalks composed of 
subunits C, E, G and H of V1 and the N-terminal domain of the V0 subunit a. The two 
types of stalks connect the V1 domain to the V0 domain (Figure 5.1 and Table 5.1) 
[13].  
Subunits A and B 
Three copies of A and three copies of B alternate in the ring-shaped head of V1. 
The six ATP binding sites are located at the interfaces between the A and B subunits, 
whereas the three catalytic sites are located solely on the A subunit. Some residues of 
the B subunit make contact with these sites, but this is not an essential interaction for 
catalysis. In the B subunit, several non-catalytic sites have been described that are 
hypothesized to play a role in the regulation of ATP hydrolysis [14-19]. A unique 
domain of the A subunit, called the “non-homologous region” plays an important role 
in the control of ATP-hydrolysis, associated with proton translocation, through the 
reversible dissociation of the two V-ATPase domains [20]. This non-homologous 
region forms a separate domain on the outer surface of V1 and may contribute to 
peripheral connection between V1 and V0, controlling the tightness of coupling of the 
two domains. Two isoforms of the B subunit are known in humans: the B1 isoform is 
present in kidney but has not been detected in pancreas, muscle, liver, lung, brain or 
heart, whereas the B2 isoform is expressed at a basal level in all tissues analyzed, with 
a higher level in the human brain and kidney [7].  
Peripheral stalk or stator: subunits a, C, E, G, and H 
The peripheral stalk, which spans nearly the entire length of the outer surface 
of V1, is composed of subunits C, E, G, H and the N-terminal region of V0 subunit a 
[21]. Cross-linking and electron microscopy studies have provided evidence that there 
are two peripheral stalks in the V-ATPase [22-24]. The E and G subunits are 
essentially structural elements. Whereas E spans the entire length of the V1 outer 
surface, the G subunit is present near the top of the complex [25,26]. Recent studies by 
Ohira et al. have shown that the two peripheral stalks connecting the two V-ATPase 
domains are both based on an EG dimer [24]. Venzke et al. suggested that the EG 
complexes could be bound to different sets of other stator subunits such as C and H, 
while Fethiere et al. provided evidence for a complex of E, G and C subunits. Thus, the 
first peripheral stalk contains an EGC complex and the second one an EGH complex, 
both interacting with the N-terminal domain of subunit a [22,23]. The E and G 
subunits are expressed as more than one isoform. G1 is ubiquitously expressed, while 
G2 is brain specific and G3 is detected exclusively in kidney [12,27]. Similarly, E2 is 
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expressed in all tissues, as opposed to E1 which is a testis-specific isoform [28]. 
Subunit C, which is located near the interface of the V1 and V0 domains is suggested to 
control the interaction between the two domains [29]. Whereas the C1 isoform of this 
subunit is expressed throughout several different tissues, the C2 isoform is specifically 
expressed in placenta and kidney [12]. Subunit H has also been shown to regulate V-
ATPase activity, as it suppresses the ATP hydrolytic activity of the soluble V1 domain 
[30]. Based on cross-linking and electron microscopy studies, subunit H is suggested 
to be localized to the peripheral stator near the interface between V1 and V0 [31]. 
Mutation analysis has demonstrated that subunit H bridges the peripheral and central 
stalks and serves as a mechanical brake to prevent ATP-driven rotation [32]. All 
subunit isoforms are encoded by different genes, except the two known H isoforms, 
which seem to be splice variants of the same mRNA [33,34]. 
Central stalk or rotor: subunits d, D, and F 
The main function of the central stalk, composed of D and F subunits of V1 and 
the d subunit of V0, is coupling of the ATP-hydrolysis and proton transport. Cross-
linking experiments have proven the strong interaction between these subunits in 
bovine V-ATPases [35,36]. In addition, cysteine-mediated cross-linking studies 
showed that D interacts with B subunits at sites predicted to be oriented toward the 
centre of the A3B3 hexameric head [21,25].  
Structure of the V0 domain and function of the subunits 
The proteolipid ring: subunits c and c’’ 
The main component of the V0 domain is a proteolipid ring, formed by 4 or 5 
copies of subunit c (17 kDa) and a single copy of subunit c’’ (23 kDa). These highly 
hydrophobic proteins contain a number of transmembrane helices with buried 
glutamic acids that are important for proton translocation across the membrane 
[13,37-40]. 
Subunits d and e 
Subunit d interacts directly with the D and F subunits of the central stalk, and is 
also known to associate with the proteolipid ring of the V0 domain [9,41]. Its specific 
shape provides the contact surface needed to couple the stalk to the proteolipid ring. 
Because of its location, the d subunit is likely to play the connecting role in the rotary 
mechanism of the ATPase [9]. In man, two isoforms of subunit d exist, a d1 isoform 
that is ubiquitously expressed and a d2 isoform essentially expressed in kidney and 
osteoclasts [12]. The membrane-bound subunit e is known to be essential for V-
ATPase function, yet its exact location and function within the V0 domain are still 
unknown [42,43].  
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Subunit a 
The V0 subunit a is a 100 kDa protein that presents a two-domain structure: an 
N-terminal, hydrophilic domain extending along V1, and a hydrophobic C-terminal 
domain containing multiple transmembrane helices [44]. The N-terminal domain is 
responsible for intracellular targeting of the V-ATPase towards the appropriate 
organel membrane. In addition, experiments have shown that in yeast, in vivo 
dissociation of V-ATPase in response to glucose deprivation is controlled by this N-
terminal domain [45]. The last two transmembrane helices of the C-terminal domain 
contain critical arginine residues that are required for proton transport. Through 
channels, the protons are allowed to access the buried glutamic acid residues of the 
proteolipid ring [44]. The models for the transmembrane topology of the a subunit 
either predict eight or nine transmembrane helices [46]. However, an uneven number 
of helices is suggested by the fact that residues at the C-terminus cannot be modified 
by membrane impermeable agents [47]. Leng et al. have shown in yeast that 
mutations of specific residues in this domain not only affect the assembly of the V-
ATPase, but also results in mistargeting of the subunit [48].  
Four isoforms of subunit a are known, and their role in targeting the V-ATPase 
to specific locations is supported by data from mammalian cells. Mammalian isoforms 
share about 50% overall identity, with higher conservation within the transmembrane 
regions [49]. Broad and overlapping mRNA expression patterns were demonstrated 
for a1, a2 and a3, but each of the subunits is known to predominate in special 
compartments of some cell types [49-51]. In contrast, the protein distribution is less 
well characterized and data are often contradictory due to the different specificity and 
sensitivity of the antibodies used. The a1 isoform has been described to be highly 
expressed in brain and to reside in synaptic vesicles, which was corroborated by mass 
spectrometric analysis [52]. However, a1 is not specific for this compartment as 
indicated by the fact that it was detected in the Golgi proteome, together with a2 [53]. 
In fractions enriched for kidney brush border, subunits a1, a2 and a4 are found [51]. 
In kidney-derived MDCK cells, a2 does not reside in the Golgi, but rather in early 
endosomes [50]. The a3 isoform is mostly expressed in late endosomes and lysosomes 
and in the osteoclast ruffled membrane that is derived from these vesicles [54]. Other 
data suggest a localisation of a3 in secretory granules in pancreatic beta cells [55]. In 
contrast to the other a- subunits, expression of a4 is highly restricted to the kidney 
and the inner ear. An apical localisation of the a4 isoform in α-intercalated cells is 
known [56,57]. Interestingly, the a4 and B1 distribution are highly similar [57]. 
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Localisation, function and regulation of V-ATPases 
Cellular and subcellular localisation of V-ATPases 
V-ATPases are present in various subcellular compartments in all mammalian 
cells. As described in the previous section, different isoforms of numerous subunits 
are known. The composition of these isoforms within the V-ATPase complex and the 
expression levels are varying in a cell type- and subcellular compartment-specific 
manner [58,59]. Thus, there are different levels of regulation to ensure the optimal 
fine tuning of the V-ATPase activity according to the needs of each subcellular 
compartment. 
High V-ATPase expression levels are found in some specialized cell types. The 
osteoclast is a prominent example, but also renal intercalated cells, macrophages, 
neutrophils and epididymal cells show strong V-ATPase expression. In osteoclasts, the 
vacuolar H+-ATPase is essential for bone resorption. The ATPase complex is recruited 
to the plasma membrane by fusion of late endosomes which leads to the formation of 
the ruffled border membrane (Figure 5.2) [54,60]. Renal intercalated cells strongly 
express V-ATPase to control acid-base balance by secretion of acid via the plasma 
membrane [59] (Figure 5.2). In rat epididymis and vas deference the V-ATPase 
complex is found on the apical membrane of epididymal clear cells. In neutrophils V-
ATPases are localised in intracellular vesicles and at the plasma membrane. Further 
cell types that express V-ATPases on their plasma membrane are the insect midgut 
cells and some invasive tumour cells [3]. Hence, the cell types with the most 
prominent expression are in most cases those that show a plasma membrane 
localisation of the V-ATPase complex. 
This plasma membrane localisation, however, is a more recent evolutionary 
invention since the vacuolar-type ATPases got their name because they were 
identified in the yeast vacuole. In contrast, the proton pumps localized at the yeast 
plasma membrane belong to the P-ATPase family. In mammalian cells, the V-ATPase 
was found in many intracellular compartments. Localisation in vesicles of the 
endocytic pathway like early, late and sorting endosomes as well as lysosomes is long 
known [61]. Many groups have shown that the V-ATPase is also localised in secretory 
and synaptic vesicles and in the Golgi compartment [50,53,55,62,63]. In all these 
intracellular compartments, V-ATPase is involved in regulation of pH-homeostasis, 
membrane trafficking and vesicle fusion. 
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Figure 5.2: Multiple roles of V-ATPase in pH regulation and vesicle function. The main function of 
V-ATPases is the regulation of the luminal pH of different intracellular compartments, the extracellular 
space and the cytoplasm. a) In osteoclasts, V-ATPase is recruited from late endosomes/lysosomes to 
the cell surface membrane where it acidifies the resorption lacuna, also called an “extracellular 
lysosome”. b) V-ATPase controls the acid-base balance by pumping protons via the plasma membrane 
of alpha-intercalated cells into the renal tubule. c) Receptor-mediated endocytosis: V-ATPase provides 
the acidic pH in endosomes necessary for the release of internalized ligands from their receptors and 
the recycling of the unoccupied receptors back to the cell surface. The sorting and trafficking of 
different kinds of endocytosed physiologically (e.g. growth factors) and pathologically (e.g. toxins) 
relevant cargo is also influenced by V-ATPases. d) The V0 domain is suggested to play a role in different 
exocytic events: d1) V-ATPase with a1-subunit has special importance for neurotransmitter release in 
neuronal cells. d2) The a3 subunit has been shown to be involved in insulin secretion. d3) Possible role 
of the a2 subunit for the secretion of extracellular matrix components as indicated by defective elastic 
fibres in patients with autosomal recessive cutis laxa type 2. 
 
Regulation of V-ATPases 
Several mechanisms are described for V-ATPase regulation, including V1/V0 
domain dissociation, change of their cellular localisation and the efficiency of proton 
transport and ATP hydrolysis. 
Reversible dissociation of the V1 and V0 domains takes place in response to 
different stimuli such as glucose depletion and activation of antigen processing [64]. It 
is suggested that dissociation and assembly are two independently controlled 
processes. A disruption of the microtubular network inhibits glucose-dependent 
dissociation of V-ATPase without affecting reassembly [65].  In contrast, reassembly 
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requires a novel protein complex called RAVE (regulator of the ATPase of vacuolar 
and endosomal membranes) [66]. RAVE interacts with dissociated V1 sectors via the 
subunits E and/or G [67]. 
Aldolase is also proposed to regulate the V1-V0 complex assembly in a glucose-
dependent fashion [68]. This function depends on the interaction of aldolase with the 
B subunit, but does not require enzymatic activity [69]. An interaction of the a-subunit 
of the V0 domain (possibly the N-terminal cytoplasmic domain) and the A subunit of 
the V1 domain has also been implicated in glucose sensing [70]. 
The density of proton pumps at the surface of several cell types is controlled by 
reversible exo- and endocytosis. In epididymal clear cells, recycling of V-ATPases 
between intracellular compartments and the apical membrane is regulated by 
adenylyl cyclase (sAC) [71]. The presence of a sAC in numerous secretory epithelia, 
including renal intercalated cells, suggests that this might represent a common 
mechanism for V-ATPase regulation. The actin cytoskeleton also appears to have an 
important role in the regulation of V-ATPase localisation. Modulation of the actin 
cytoskeleton via gelsolin is proposed to regulate V-ATPase recycling [72]. Alterations 
of the coupling efficiency between proton transport and ATP hydrolysis have been 
proposed to modulate acidification [61]. Although there is important evidence to 
support this hypothesis, the responsible in vivo mechanisms remain to be further 
investigated. 
Physiological functions of V-ATPases 
V-ATPases serve a number of functions in normal physiology mainly by 
regulating the pH of different intracellular compartments, the extracellular space and 
the cytoplasm. 
Functions of intracellular V-ATPases 
The acidic pH that V-ATPases produce in endosomes generated by receptor-
mediated endocytosis induces the release of internalized ligands from their receptors 
[61]. This facilitates the recycling of the unoccupied receptors back to the cell surface 
and the targeting of the released ligands to the lysosome for degradation [3]. Typical 
examples for this type of transport are, among others, the cholesterol carrier low 
density lipoprotein (LDL), asialoglycoproteins, peptide hormones (e.g. insulin) and 
growth factors (e.g. EGF) (Figure 5.2) [5]. The lysosomal enzymes synthesized in the 
Golgi compartment are transported to the lysosome partially by a similar mechanism 
by binding to the mannose-6-phosphate receptor [3,73].  
V-ATPases also appear to play a role in the formation of endosomal carrier 
vesicles from sorting endosomes that transport the uncoupled ligands to later 
endosomal compartments. Budding of these vesicles requires the binding of beta-COP 
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coat proteins to the early endosomal membrane, and is dependent upon the acidic 
lumenal pH generated by the V-ATPase [3].  
Hurtado-Lorenzo and colleagues suggested that the V-ATPase also operates as 
a scaffold protein to recruit factors involved in trafficking [50]. It was shown that 
ARNO (ARF nucleotide-binding site opener) binds to the N-terminus of subunit a2 of 
the V-ATPase, which localises to early endosomes and the Golgi compartment [53]. 
ARNO is the guanine exchange factor (GEF) for Arf6 (ADP-ribosylation factor 6) which 
in the same study was shown to bind to the subunit c of the V0 domain in a pH-
dependent manner. This interaction between V-ATPase, Arf6 and ARNO implicates a 
direct, pH-dependent influence of the V-ATPase on membrane budding for which 
Arf6-recruitment is a crucial step. After budding and uncoating, the vesicles are 
tethered to the acceptor compartment via tethering factors and v- and t-SNARE 
proteins [74]. After the vesicle membrane has been brought in close contact with the 
target membrane both membranes must fuse to form a pore. The V0 domain of V-
ATPases has been implicated in this fusion process according to studies about fusion 
between vacuoles in yeast [75]. It is suggested that the V0 domains of opposing 
membranes form pairs with each other, which leads to the assembly of fusion pores 
[76]. Furthermore, V-ATPases have been shown to play a role in exocytic processes 
like synaptic vesicle release in Drosophila [77], exosome release of Hedgehog-related 
proteins in Caenorhabditis elegans [78] and secretion of insulin by pancreatic islet 
cells [55]. In some of these studies, it was demonstrated that the effect of the loss of 
the a-subunit in the mutants was different from the effect of the V-ATPase inhibitor 
bafilomycin. This indicates that the V0 domain might be able to directly mediate 
vesicle fusion by catalyzing the mixing of the two lipid bilayers due to its highly 
hydrophobic subunit composition.  
Lumenal pH regulation is also crucial for posttranslational modification in the 
Golgi compartment. While the pH of the cis cisterna is close to neutral, the trans 
cisterna has a pH around 6. Like all enzymes, glycosyltransferases have a pH optimum 
for function and therefore disturbance of pH regulation in the Golgi could lead to 
glycosylation defects. The pH gradient formed by V-ATPases is also used for different 
types of secondary active transport. Several neurotransmitter-proton antiporters are 
essential for the transport of neurotransmitters into synaptic vesicles [79]. 
Functions of plasma membrane V-ATPases 
In a variety of cell types, particularly cells of epithelial origin, V-ATPases are 
present in the plasma membrane where their major function is acid secretion. In the 
kidney, this applies to proximal tubular cells, as well as both alpha- and beta-
intercalated cells of the distal tubule and the collecting duct [3]. Proximal tubule cells 
reabsorb bicarbonate, by first converting it into CO2 that can cross the apical 
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membrane. This conversion takes place when acid is secreted into the lumen by the 
proximal tubular cells. The secretion of acid is carried out by plasma membrane V-
ATPases and apical membrane Na+/H+ exchangers. In the distal tubule and the 
collecting duct, the V-ATPases are involved in secretion of acid or base equivalents 
into the urine. Alpha-intercalated cells contain V-ATPases at the apical membrane and 
Cl-/HCO-3 exchangers at the basolateral membrane. V-ATPases are responsible for 
proton secretion from the cytoplasm into the lumen, whereas the Cl-/HCO-3 exchanger 
releases HCO-3 across the basolateral membrane and prevents alkalinisation of the 
cytoplasm [60]. To the contrary, intercalated cells which express the V-ATPase 
basolaterally serve to reabsorb acid equivalents. 
In osteoclasts, V-ATPase complexes are found at the cell surface and have a 
crucial role in bone resorption [60]. Osteoclasts attach to the bone surface and seal off 
a portion of the extracellular space. Acid and digestive enzymes that dissolve the bone 
matrix are secreted into this space that thereby becomes a resorption lacuna. V-
ATPases in this domain of the osteoclast cell surface, called the ruffled border, are 
responsible for acid secretion [80]. The a3 subunit of the Vo domain is prerequisite to 
direct the V-ATPase complexes to the ruffled border [54]. Furthermore, V-ATPases 
present at the apical plasma membrane of clear cells in the vas deferens and 
epididymus play the main role in maintenance of luminal pH at a relatively low value. 
This low pH is important for sperm maturation [71]. In macrophages and neutrophils, 
V-ATPases provide proton efflux from the cell. This is necessary because these types 
of cells are often found in highly acidic environments such as infected regions or 
tumours. Thus, they demand great acid secretion capacity in order to maintain their 
neutral pH [13]. V-ATPases also seem to participate in angiogenesis for which 
invasion and migration of microvascular endothelial cells is essential. In these cells, 
plasma membrane V-ATPases have been identified at the leading edge, where they 
appear to play a role in both processes [81]. 
Pathophysiological aspects 
Envelope viruses and bacterial toxins, such as influenza virus, Semliki forest 
virus, vesicular stomatitus virus (VSV), diphtheria toxin and anthrax toxin, enter cells 
via acidic endosomal compartments (Figure 5.2). In these compartments low pH 
induces the formation of a membrane pore through which the viral mRNA or cytotoxic 
portions of the toxin molecules can be translocated into the cytoplasm [82]. For 
example, the binding of influenza virus to a cell surface receptor is followed by 
internalization via clathrin-coated vesicles. Reaching early endosomes, the acidic 
environment produced by the V-ATPase triggers the fusion of the viral and endosomal 
membranes, which create a fusion pore and results in release of the viral RNA into the 
cytoplasm of the host cell [61]. In the case of toxins, entry occurs either directly from 
sorting endosomes, or first into the vesicles contained in multivesicular bodies 
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followed by release into the cytoplasm from late endosomes [83]. Furthermore, V-
ATPases have been implicated in infection of cells by HIV. Subunit H of the V-ATPase 
appears to play a role in the internalization of the HIV receptor CD4 [84]. In addition 
to this role in entry of viruses and toxins, it has been shown that the E5 oncoprotein of 
bovine papilloma virus causes an inhibition of endosomal and Golgi acidification 
through binding to the c subunit of the V-ATPase [36]. Mutations in E5 that disrupt 
interaction with the c subunit both prevent inhibition of acidification and block the 
ability of E5 to transform cells [85]. Martinez-Zaguilan and colleagues found that 
highly invasive MB231 breast-tumour cells exhibited significant plasma membrane V-
ATPase activity in comparison to the poorly metastatic MCF7 cells [86]. It has been 
suggested that tumour-cell invasiveness could be enhanced by a low extracellular pH 
created by V-ATPases [61,87]. In these cells V-ATPases may play an additional role by 
improving drug resistance. It has been shown that drug-resistant tumour cell lines 
show increased expression of V-ATPase subunits [87]. Thus, V-ATPases could be a 
potential drug target to increase the drug sensitivity of tumours. 
Phenotypes elicited by V-ATPase mutations not found in humans 
Two isoforms of the d subunit, d1 and d2, exist in human and mice which 
exhibit high similarity [10]. The d2 isoform is expressed mainly in the kidney and at 
lower levels in heart, spleen, skeletal muscle, and testis, whereas d1 was detected in 
various tissues [88]. 
It was shown that the inactivation of Atp6v0d2 in mice results in normal 
growth and development [89]. Despite the high expression of d2 in the kidney urine 
pH was normal. However, Atp6v0d2–/– animals showed a strikingly increased bone 
mass reminiscent of osteopetrosis. Increased cartilage remnants and reduced serum 
type 1 collagen cross-linked C-terminal telopeptide indicated a decreased bone 
resorption activity. Although d2 was not detectable in osteoblasts, osteoblast number 
and bone formation rate were significantly increased. In vitro investigations revealed 
that Atp6v0d2–/– osteoclasts were much smaller due to impaired progenitor cell 
fusion. When the in vitro resorption activity of mutant osteoclasts was normalized by 
the number of multinucleated osteoclasts it was undistinguishable from wildtype. 
Therefore, the d2 subunit, in contrast to the a3 subunit (see above), does not play a 
role in acid secretion via the ruffled border, but by a yet unknown mechanism 
regulates fusion of osteoclast progenitors.  
Peri and Nuesslein-Volhard demonstrated that knock down of the V-ATPase a1 
subunit in zebra fish leads to defects in brain development due to the reduced 
phagocytotic removal of apoptotic neurons by microglial cells [63]. Normally, the 
phagolysosomes required for this process are formed by fusion of many acidic 
vesicles. The defective generation of phagolysosomes after knock down of the a1 
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subunit shows that the a1 subunit mediates fusion between phagosomes and 
lysosomes during microglial phagocytosis, a function that is independent of its proton 
pump activity.  
In Drosophila mutations in the vha-100 gene encoding the a1 subunit lead to 
impaired photoreceptor function due to a defect in synaptic transmission [77]. 
Subsequent analysis demonstrated that lack of a1 unexpectedly did not impair loading 
of synaptic vesicles with neurotransmitters, but their fusion with the presynaptic 
membrane.  
Human phenotypes arising from mutations in V-ATPase subunits 
Genetic defects in V-ATPase genes have been associated with hereditary 
human diseases. Mutations in four known genes encoding specific subunits of V-
ATPases have been identified so far.  
Infantile malignant autosomal recessive osteopetrosis (ARO)  
Infantile malignant osteopetrosis (MIM:259700) is a rare autosomal recessive 
disease with an average incidence of 1:200,000 to 1:300,000 [90]. It is characterised 
by high bone density due to a failure of osteoclasts to resorb bone. The clinical 
features comprise abnormal bone remodelling, deficient haematopoiesis, and 
neurologic impairment owing to narrowing of the foramina [90]. Bony encroachment 
can cause facial nerve entrapment resulting in facial palsy, visual impairment and 
optic atrophy, hearing loss, and difficulties with swallowing and feeding [90,91]. The 
disease is most commonly diagnosed soon after birth or within the first years of life 
with symptoms of variable severity such as anaemia caused by bone marrow failure, 
nystagmus, hepatosplenomegaly, hypertelorism, psychomotor retardation, and nasal 
congestion [92]. Seventy-five percent of patients, when untreated, die by the age of 4 
years as a consequence of recurrent infections such as osteomyelitis and pancytopenia 
[93]. The diagnosis can be made on the basis of characteristic radiologic changes [94] 
and should be confirmed by molecular genetic analysis. Diffuse sclerosis of the spine 
and long bones [95] and modelling defects at the metaphyseal ends of long bones, 
resulting in typically widened and blunted diaphyses and metaphyses (‘Erlenmeyer 
flask’ deformity) are the most typical radiographic features [94]. ‘Bone-in-bone’ 
appearance can be present in the vertebrae, phalanges, long bones, and pelvic bones. 
Mutations in the a3 subunit (ATP6V0A3, TCIRG1, MIM:604592) of the V-ATPase have 
been found to be causative for ARO [54,91]. Most mutations entail a loss of function of 
the encoded protein. Since early bone marrow transplantation provides the only 
curative treatment for malignant forms of osteopetrosis an early clinical, radiologic 
and genetic diagnosis is crucial for the prognosis [96].  
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Autosomal recessive renal tubular acidosis with and without 
sensorineural deafness  
Distal renal tubular acidosis (dRTA) is a rare genetic disease in which the 
intercalated cells in the collecting duct fail to secrete the protons required for urinary 
acid excretion. The dRTA is classified into four different types according to the mode 
of inheritance and the presence of hearing impairment. Different forms have been 
described: a) a dominant type of dRTA, b) a recessive type without hearing loss, c) a 
recessive type with early onset of sensorineural deafness (MIM:267300) and d) a 
recessive type with later onset of sensorineural deafness (MIM:602722) [97]. The 
clinical severity is very variable, ranging from compensated mild acidosis, absence of 
symptoms, and the incidental finding of kidney stones and/or renal tract calcification 
to major effects in infancy with severe acidosis, impaired growth, and early 
nephrocalcinosis causing eventual renal insufficiency in combination with progressive 
and irreversible bilateral sensorineural hearing loss [98]. If untreated, this acidosis 
may result in dissolution of bone, leading to osteomalacia and rickets. In 1999, Karet 
et al. first associated mutations in the AT6B1 gene to dRTA with sensorineural 
deafness [99]. ATP6V1B1 encodes the V-ATPase B1 subunit. Northern Blot analysis 
revealed high expression of ATP6V1B1 in human kidney and cochlea. By 
immunohistochemistry the protein was detected in the apical membrane of the renal 
-intercalated cells of the distal tubule [99]. Mutations introduce premature 
termination codons, frameshift mutations, splice-site mutations and non-conservative 
missense substitutions. Subsequently, mutations in another V-ATPase gene, 
ATP6V0A4, were identified in kindreds with recessive renal tubular acidosis [57]. The 
gene encodes subunit a4 of the vacuolar H+-ATPase, which was found to be exclusively 
expressed in foetal and adult kidney. While ATP6V1B1 mutations are associated with 
early sensorineural hearing loss (SNHL), ATP6V0A4 mutations are classically 
associated with either late-onset SNHL or normal hearing. Vargas-Poussou R. et al. 
(2006) assessed the phenotype and genotype of 39 families with recessive dRTA 
[100]. Unexpectedly, 7 out of the 21 probands with mutations in ATP6V0A4 developed 
severe hearing loss at young age. This study demonstrates that mutations in either of 
these genes may cause early deafness. 
Cutis laxa 
Recently, defects in the V-ATPase a2 subunit due to mutations in the ATP6V0A2 
gene have been shown to cause an autosomal recessive form of cutis laxa in 
combination with glycosylation defects [1,101]. 
Cutis laxa is a rare inherited disorder of the connective tissue characterized by 
excessive sagging of skin folds and decreased elasticity of the skin. Patients suffering 
from cutis laxa present with an aged appearance. Most inherited types occur in 
syndromic forms associated with variable organ involvement and severity. One of the 
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major diagnostic criteria is the detection of decreased amounts of structurally 
abnormal elastin fibres in the skin biopsy, which can, however be missing in some 
clinically similar, mostly autosomal recessively inherited cases. In most patients 
diagnosed with cutis laxa syndrome the underlying genetic cause is not known. Due to 
overlap in the phenotypes and significant clinical variability the exact clinical 
diagnosis remains challenging [102]. Dominant, recessive and x-chromosomal modes 
of inheritance have been described. 
The autosomal dominant form of cutis laxa syndrome (ADCL; MIM: 123700) is 
relatively mild, compared to the recessive neonatal form [103]. Systemic involvement 
seldom occurs except for cardiac symptoms [104]. Some patients with autosomal 
dominant inheritance carry fibulin-5 (FBLN5) gene mutations, or deletions in the 
elastin gene (ELN) [104,105]. The X-linked variant (XLCL; MIM: 304150) is due to a 
defect of the cellular copper transport and has a wide phenotypic spectrum, and a 
combination of skeletal and internal organ involvement [106]. This disorder is allelic 
to Menkes disease, and is caused by mutations in the copper transporter gene ATP7A 
[107]. 
Autosomal recessive cutis laxa 
The most severe forms of cutis laxa are inherited in an autosomal recessive 
fashion and are frequently lethal in the neonatal period (ARCL I; MIM: 219199). 
Besides cutis laxa, patients show arterial tortuosity, emphysema, diverticulae of 
urinary and gastrointestinal tract. Mutations in the fibulin-4 (FBLN4, EFEMP2) gene 
[108] or the fibulin-5 (FBLN5) gene [109,110] have been detected in children with 
ARCL I. 
 Patients classified as autosomal recessive cutis laxa type II (ARCL II, ARCL 
Debré type; MIM 219200) [111,112] have a much better clinical outcome than those 
with a severe, multisystemic form (ARCL I; MIM:219199). In ARCL II children, cutis 
laxa is associated with prenatal and postnatal growth retardation, delayed closure of 
large fontanels, congenital hip dislocation, osteoporosis, dental caries and a 
characteristic facial appearance (down-slanting palpebral fissures, broad flat nasal 
bridge, anteverted nostrils, large ears). There is a developmental delay in some of the 
cases. Osteoporosis and decreased bone density have been reported in many patients. 
Within the same clinical group there is biochemical heterogeneity: a congenital 
combined N- and O-linked disorder of glycosylation can be detected in some of the 
patients (see below) [1,101,112].  
Patients with De Barsy syndrome, included in ARCL III (MIM: 219150), show 
significant phenotype overlap with ARCL II, but no patient has been reported so far 
with combined glycosylation anomalies. The underlying genetic aetiology of this 
unique, progressive disorder is still unknown [113]. One should mention two 
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additional clinical syndromes in the clinical spectrum of ARCL syndromes. Gerodermia 
osteodysplastica (GO; MIM: 231070) [114], presents with several features similar to 
ARCL II, including congenital cutis laxa and skeletal findings, including generalized 
osteoporosis and increased fracture rate. Another similar entity is wrinkly skin 
syndrome (WSS; MIM: 278250) [114], a mild variant of ARCL II, without significant 
histological abnormalities, and a biochemical and genetic heterogeneity.  
Clinical features in ARCL II 
Recently, missense and nonsense mutations were discovered in the ATP6V0A2 
gene in several families diagnosed with autosomal recessive cutis laxa type II and 
wrinkly skin syndrome, suggesting that both are phenotypic variants of the same 
disorder [1,101,112]. ARCL II and WSS patients with a ATP6V0A2 mutation have 
generalized skin abnormalities, skeletal, neuromuscular and central nervous system 
involvement in variable degree with or without mental retardation. Their perinatal 
history is mostly normal, and generalized cutis laxa is present already at birth. Skin 
biopsy in the most severe cases demonstrates an abnormal, broken, shortened and 
fuzzy elastic fibre structure with a significantly decreased amount of elastin. The skin 
anomalies became less obvious, and sometimes disappear with age. Cardiac anomalies 
are rare. Many of the patients have congenital hip dislocations and increased joint 
laxity. The systemic involvement is very mild, including elevated liver enzyme 
activities and slightly abnormal coagulation in a very few patients. Common 
ophthalmologic abnormalities are strabismus, myopia or amblyopia. Congenital or 
progressive microcephaly is the most common associated feature in patients. 
Congenital brain malformations are extremely rare. Although developmental delay 
can be observed in the majority of the children the motor development improves in 
most cases with age. One might suspect that the motor delay was partially due to 
muscle hypotonia, and in some degree to the hyperelastic joints. Most of the children 
demonstrate a normal mental development and only a minority shows intellectual 
disability [1,101]. So far, all patients with ATP6V0A2 mutations show a combined 
defect in the biosynthesis of N- and O-linked glycans. This can easily be picked up with 
the technique of plasma transferrin isofocusing (see below in “Defects in the 
ATP6V0A2 gene lead to a combined defect in N- and O-glycosylation”). No specific 
clinical features have been found distinguishing the group of patients having the 
glycosylation abnormalities, and remaining patients within the diagnostic group of 
ARCL II. Apparently, the frequency of central nervous system malformations is 
somewhat higher in the group with CDG, but congenital brain malformations have 
been described in the group without glycosylation defect as well [101]. 
CNS abnormalities in ARCL II  
Congenital brain anomalies seldom occur in ARCL II. Motor developmental 
delay is common but the mental development is low normal in most cases A unique 
Chapter 5 
~ 108 ~ 
finding is the presence of developmental brain abnormalities in a couple of cases, such 
as migration defects.  [1]. In general, CNS symptoms are less frequent in ARCL II in 
general (but specifically in the subgroup of ATP6V0A2 mutation carriers as well) 
compared to the relatively common occurrence of cerebellar hypoplasia, spasticity, 
epilepsy, hearing and visual loss in patients diagnosed with N-glycosylation disorders. 
The detected, unique brain anomalies, representing different steps on a severity scale 
of brain developmental defect, are more comparable to the brain anomalies found in 
congenital O-mannosylation defects [115]. 
Neuronal migration is a complex developmental process. Several disorders of 
neuronal migration are known, including a group of disorders caused by defective O-
mannosyl glycan synthesis. The most severe form, Walker-Warburg syndrome (WWS; 
MIM: 236670) is a recessive disorder characterized by severe brain malformations, 
muscular dystrophy, and congenital eye abnormalities. Another two similar, but less 
fatal, diseases are the so called muscle eye brain disease, (MEB; MIM: 253280) and 
Fukuyama congenital muscular dystrophy (FCMD; MIM: 253800). 
In brain, several different proteins and glycosylated molecules have been 
hypothesized to be responsible for the occurrence of developmental defects. Failed 
interactions with extracellular matrix components may underlie the severe neuronal 
migration that causes the congenital anomalies in the MEB disease spectrum, such as 
in the currently described novel glycosylation defect. 
Glycosylation defects 
Glycosylation is one of the most variable post-translational modifications of 
proteins. It plays an important role in cell migration, pathway finding and cellular 
connectivity, as well as localisation, interaction and function of glycoproteins. Since 
50% of the proteome consists of glycoproteins that play many different roles in the 
organism, it is not surprising that inborn errors of glycosylation result in a wide 
variety of congenital malformation syndromes, collectively called congenital disorders 
of glycosylation [102]. Two types of glycosylation are known, based on the attachment 
site of the glycan on the protein: N- and O-glycosylation. 
N-glycosylation defects 
The biosynthesis of N-glycans is a multistep process taking place in different 
cellular compartments. It starts in the cytosol, where nucleotide sugars are 
synthesized from monosaccharides derived from dietary sources and recycling 
processes. Next, in the endoplasmic reticulum, a lipid-linked oligosaccharide (LLO), 
consisting of dolichol-PP-GlcNAc3-Man9-Glc3, is constructed and transferred to an 
asparagine of a nascent protein. Defects in the assembly and transfer of the LLO result 
in a congenital disorders of glycosylation type I [116]. Finally, the glycoprotein leaves 
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the ER and enters the Golgi, where N-glycans are processed through the sequential 
action of a number of specific glycosyltransferases and glycosidases in a highly 
controlled way. Defects in the processing of N-glycans result in CDG type II. Fully 
processed N-glycans present two, three or four antennae terminated by a negatively 
charged sialic acid (Figure 5.3) [116]. 
Iso-electric focusing (IEF) of plasma transferrin is an important tool in 
diagnosing patients with congenital disorders of glycosylation. Human plasma 
transferrin contains two N-glycans, each with 2 or 3 antennae, usually with a 
negatively charged terminal sialic acid (Figure 5.3). In human plasma of healthy 
individuals, the tetrasialotransferrin fraction is the most abundant form, containing 
two biantennary, fully sialylated N-glycans. When a genetic defect is present in the 
early steps of N-glycan biosynthesis, in the cytoplasm or endoplasmic reticulum, the 
flux through the biosynthetic pathway of the LLO will be overall insufficient. The 
newly built glycoproteins therefore cannot be adequately N-glycosylated. The 
transferrin molecule, normally acquiring two N-glycans, will then obtain a single or no 
N-glycan. Thus, in patients with CDG type I, the percentages of asialotransferrin (no N-
glycan) and disialotransferrin (only one fully built biantennary N-glycan) are 
increased (Figure 5.3). If the defect occurs after transfer of the oligosaccharide to the 
protein, the result is a deficient processing of the glycan antennae and 
undersialylation thereof. The defect can influence biosynthesis and transport of 
nucleotide sugars or the activity and localisation of glycosidases and glycosyl-
transferases. In addition, proper transport of the glycoprotein from ER to cis-, median 
and trans-Golgi cisternae is important for the correct sequential removal of terminal 
glucoses and mannoses and the addition of new monosaccharides to the glycan. 
Ultimately, complex N-glycans, such as those present on human transferrin, may 
present truncated antennae, thus lacking one or two sialic acids. This leads to a typical 
type II transferrin iso-electric focusing pattern, as seen in figure 5.3. Further 
biochemical analysis to find the exact diagnosis of the CDG subtype includes enzyme 
measurements, analysis of lipid linked oligosaccharides and mutation analysis [117].  
O-glycosylation defects 
The onset of O-glycosylation takes place in the ER or in the Golgi apparatus, 
after folding and oligomerisation of proteins. O-glycans are attached to the hydroxyl 
group of serine or threonine, and occasionally to hydroxylysine. In humans, mucin-
type glycans are the most common form. They are attached to the protein via a GalNAc 
and are usually limited in size (1 to 10 residues). Within the mucin-type O-glycans, 8 
core structures can be distinguished, depending on the second sugar and its glycosidic 
linkage. [118]. Like N-glycosylation, O-glycosylation starts with the biosynthesis of 
activated nucleotide sugars in the cytosol. In the ER and Golgi, O-glycans are 
assembled in a highly controlled way by the sequential action of specific, membrane-
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bound transferases, whose localisation is very important. Complex processes are 
involved in vesicular transfer between different cisternae of the Golgi and thus the 
localisation of the transferases. Defects in trafficking within the Golgi can affect 
structure and function of the whole apparatus, leading to impaired biosynthesis of 
glycoconjugates, intracellular protein sorting, and protein secretion [118].  
Wopereis et al. [119] developed a screening method to demonstrate defects in 
the biosynthesis of core 1 mucin-type O-glycans, based on the iso-electric focusing of 
serum apolipoprotein C-III (apoC-III). ApoC-III carries one glycan: a core 1 mucin-type 
O-glycan. As shown in figure 5.4, this glycan presents with two sialic acids in its fully 
synthesized form. The corresponding apoC-III isoform is called apoC-III2. Two other 
isoforms exist, based on the number of sialic acids: apoC-III0 (nonsialylated form) and 
apoC-III1 (monosialylated form) [119]. Compared to the isofocusing profile of apoC-III 
of healthy individuals, the apoC-III profile of patients with disturbed core 1 mucin-
type O-glycan biosynthesis shows increased amounts of apoC-III0 and/or apoC-III1.  
 
 
Figure 5.3: N-glycosylation of transferrin (Tf). Left: N-glycans present on tetrasialotransferrin ( = 
GlcNAc, = Man,  = Gal,  = sialic acid); right: iso-electric focusing of human plasma transferrin. Lane 
1: normal IEF profile, lane 2: type I IEF profile, characteristic for N-glycan biosynthesis defects localized 
in the cytoplasm or the ER (decreased tetrasialo-Tf, increased disialo- and monosialo-Tf), lane 3: asialo 
type II IEF profile, characteristic for Golgi based glycosylation defects (decreased tetrasialo-Tf, increase 
of all hypoglycosylated forms), lane 4: disialo type II IEF profile, characteristic for patients with cutis 
laxa due to ATP6V0A2 defect (decreased tetrasialo-Tf, increased trisialo- and disialo-Tf). The double 
banding pattern observed in the IEF profiles of lane 3 and 4 are due to a polymorphism of transferrin 
[adapted from [122]]. 
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Figure 5.4: O-glycosylation of apolipoprotein C-III. Lane 1: iso-electric focusing pattern of a control; 
lane 2: apoC-III0 profile of CDG -II patient (decreased apoC-III2, increased apoC-III0 and apoC-III1); lane 
3: apoC-III1 profile characteristic for cutis laxa patients with an ATP6V0A2 defect (decreased apoC-III2, 
increased apoC-III1). The picture also shows the probable O-glycan structure present on the apoC-III 
isoforms. The nomenclature of the two apoC-III IEF profiles derives from Wopereis et al. [122]. (= 
GalNAc,  = Gal,  = sialic acid) [adapted from [122]]. 
 
Defects in the ATP6V0A2 gene lead to a combined defect of N- and O-
glycosylation 
As described above, processing of N-glycans and mucin O-glycosylation both 
occur in the Golgi apparatus and defects in this part of the biosynthetic route are 
characterized by a type II transferrin isofocusing pattern. Some CDG type II patients 
also have an abnormal apoC-III isofocusing profile. A number of factors involved in 
glycan biosynthesis are common to the N and O-glycosylation process, such as 
nucleotide sugars and their transporters. Also, Golgi trafficking and structural 
integrity are crucial for both types of glycosylation. Combined glycosylation defects 
have been observed in several patients, including a group with mutations in one of the 
subunits of the Conserved Oligomeric Golgi (COG) complex. This octameric complex is 
essential for the structure of the Golgi complex and is thought to have a role in 
trafficking between ER and Golgi and amongst Golgi cisternae [120,121]. Based on 
transferrin iso-electric focusing patterns as well as apoC-III iso-electric focusing and 
SDS-PAGE profiles of serum from CDG type II patients, Wopereis et al. [122] defined 6 
biochemical subgroups among these patients. Surprisingly, 3 out of 4 patients of the 
subgroup showing disialotransferrin IEF and apoC-III1 profiles, displayed an ARCL II 
phenotype. These patients turned out to have a defect in the a2 subunit of the V-
ATPase [1].  
Subsequently, all patients with cutis laxa due to ATP6V0A2 mutations known to 
date have been shown to have an abnormal transferrin isofocusing profile 
[1,101,119]. The typical so-called disialo- type II transferrin isoform profile seen in 
these patients is shown in figure 5.3, lane 4 [115]. Alongside the N-glycan biosynthesis 
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defect, patients also have a core 1 mucin-type O-glycan biosynthesis defect. This is 
shown by the typical apoC-III1 profile (Figure 5.4, lane 3), characterized by decreased 
apoC-III2 and increased apoC-III1. It has been observed that patients may have a 
normal transferrin isofocusing profile in the first months of life, but develop the 
typical transferrin abnormality later on. In these patients, the apoC-III isofocusing was 
already abnormal in the first months of life [123].  
ATP6V0A2 mutations and their influence on glycosylation and elastic 
fibre formation 
While it might be that O-glycosylation defects are responsible for the brain 
abnormalities found in ARCL II in analogy to known disorders of O-glycosylation the 
connection between loss of the a2 subunit, Golgi dysfunction and the elastic fibre 
defect remains elusive.  
Also, the exact mechanism by which mutations in the V-ATPase a2 subunit 
affect glycosylation remains to be elucidated. Two major functions of the V-ATPase V0 
domain are (i) maintenance of the pH gradient along the secretory pathway by proton 
transport and (ii) the regulation of protein transport through the facilitation of vesicle 
fusion [75]. Both processes are closely related, as vesicle acidification can regulate the 
recruitment of factors involved in vesicle budding and fusion.  
Axelsson et al. [124] have proven that neutralization of the pH gradient of the 
secretory pathway result in the relocalisation of glycosyltransferases such as N-
acetylgalactosaminyltransferase 2, β1,2 N-acetylglucosaminyltransferase I and β1,4 
galactosyltransferase 1. These are normally localized in the medial/trans-Golgi and 
the trans-Golgi/TGN, respectively. Bafilomycin A1, a specific V-ATPase inhibitor, 
causes a relocalisation of these enzymes to the cell surface, while the general 
morphology of the ER and Golgi apparatus is retained. In vitro neutralization of the pH 
of whole cells with NH4Cl leads to a relocalisation of the enzymes to endosomes and 
an altered O-glycosylation of gel-forming mucins in colorectal carcinoma cells. Also, 
these cells show a structurally abnormal Golgi apparatus, consisting of fragmented 
and separate elements scattered around the nucleus. The same unusual structures 
were observed in acidification-defective breast cancer cell lines. In these cells, both N 
and O glycosylation were abnormal, as well as glycosylation of glycolipids [125]. Thus, 
alterations in the pH in the Golgi may cause changes in glycosylation in two ways: 
through the alteration of the localization of glycosyltransferases and through changes 
in the enzymatic activity. Abnormal Golgi trafficking is often paralleled by alterations 
of the cisternal structures. No major alterations were observed in Golgi morphology in 
skin fibroblasts of patients with cutis laxa due to the ATP6V0A2 defect. This is in 
accordance with experiments where V-ATPase was inhibited specifically with 
bafilomycin A1 [124]. Delayed retrograde translocation of Golgi membranes to the ER 
was observed upon brefeldin A treatment, which indicates a disturbed Golgi-ER 
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retrograde transport. This mechanism has also been described in patients with CDG 
due to a COG complex defect [126]. Therefore, defective retrograde transport seems to 
be a general mechanism that could result in abnormal N- and O-glycosylation, either 
directly or via alterations in pH of acidic organels. Disruption of the interaction 
between the a2-isoform and other proteins that regulate vesicular trafficking as 
described by Hurtado-Lorenzo et al. [50] may provide another pathophysiological 
basis for defects in vesicular transport. 
Functional defects of the elastic fibre system lead to wrinkled skin or cutis laxa. 
In the skin extracellular matrix (ECM), non-glycosylated (e.g. elastin) and glycosylated 
proteins (e.g. the fibulins, fibronectin, and collagen) have important functions in 
establishing and maintaining elastic fibres. The final structure and adequate function 
of collagen and elastin fibres is dependent on the function and anchoring of these 
essential matrix molecules. It can be speculated that either abnormal glycosylation, 
other changes in post-translational processing or simply impaired secretion of these 
important ECM proteins as a result of ATP6V0A2 mutations, leads to the cutis laxa 
phenotype. Reduced glycosylation of fibulin-5 was shown to enhance binding of the 
protein to tropoelastin and elastic fibre formation in vitro [127]. Acute treatment of 
cultured cells with several agents that disturb the pH gradient in all cellular 
compartments was shown to severely reduce tropoelastin secretion [128]. Although 
direct evidence for a role of the a2 subunit in tropoelastin-containing secretory 
vesicles is missing the localisation in the Golgi compartment make it likely that a2 
directly or indirectly influences the formation of Golgi-derived vesicles, either for 
anterograde or retrograde transport.  
In conclusion, patients presenting with an autosomal recessive cutis laxa type 
II phenotype with a combined defect in N- and O-glycosylation, have a mutation in the 
ATP6V0A2 gene. This gene encodes the a2 subunit isoform of the vacuolar H+-ATPase. 
Defects in pH regulation of acidic organels or vesicular transport within the cell are 
hypothesized to be involved in the underlying pathomechanism. Further 
investigations are necessary to elucidate the relation between V-ATPase dysfunction, 
glycosylation defects and the cutis laxa phenotype.  
ACKNOWLEDGMENTS 
This work was supported by the European Commission, contract number 
LSHM-CT2005-512131 (Euroglycanet). 
  
Table 5.1: Tissue-specific localisation and function of human V-ATPase subunits. 
Subunit 
isoform 
Gene 
name 
Chromosomal 
Localisation 
Swiss-Prot  
entry name1  
Swiss-Prot  
acc. 
number1 
Tissue Function References 
V1 domain 
A ATP6V1A13 3q13.2-q13.31 VATA_HUMAN P38606 Ubiquitous 
ATP binding and hydrolysis 
Control of ATP hydrolysis 
[129] 
B1 
B2 
ATP6V1B1 
ATP6V1B2 
2p13.1 
8p22-p21 
VATB1_HUMAN 
VATB2_HUMAN 
P15313 
P21281 
Kidney, epididymis 
Ubiquitous 
ATP binding 
Regulation of ATP hydrolysis 
[130] 
C1 
C2 
ATP6V1C1 
ATP6V1C2 
8q22.3 
Chr. 2 
VATC1_HUMAN 
VATC2_HUMAN 
P21283 
Q8NEY4 
Ubiquitous 
Placenta, lung, kidney 
Regulation of V1 – V0 interaction 
Element of peripheral stalk/stator 
[131-134] 
D ATP6V1D 14q23-q24.2 VATD_HUMAN Q9Y5K8 Ubiquitous Element of central stalk / rotor [135,136] 
E1 
E2 
ATP6V1E1 
ATP6V1E2 
22q11.1 
2p21 
VATE1_HUMAN 
VATE2_HUMAN 
P36543 
Q96A05 
Testis 
Ubiquitous 
Structural element of peripheral 
stalk / stator 
[28,132,137] 
F ATP6V1F 7q32 VATF_HUMAN Q16864 Ubiquitous Element of central stalk / rotor [138,139] 
G1 
G2 
G3 
ATP6V1G1 
ATP6V1G2 
ATP6V1G3 
9q32 
6p21.3 
1q31.3 
VATG1_HUMAN 
VATG2_HUMAN 
VATG3_HUMAN 
O75348 
O95670 
Q96LB4 
Ubiquitous 
Brain, neuronal tissue 
Kidney, epididymis 
Structural element of peripheral 
stalk / stator 
[139] 
H1 
H2 
ATP6V1H2 8q11.2 VATH_HUMAN Q9UI12 Unknown 
Regulation of ATP-hydrolysis 
Element of peripheral stalk/stator 
[31,84] 
V0 domain 
a1 
a2 
a3 
a4 
ATP6V0A1 
ATP6V0A2 
ATP6V0A33 
(TCIRG1) 
ATP6V0A4 
17q21 
12q24.31 
11q13.2 
7q33-q34 
VPP1_HUMAN 
VPP2_HUMAN 
VPP3_HUMAN 
VPP4_HUMAN 
Q93050 
Q9Y487 
Q13488 
Q9HBG4 
Neuronal tissue 
Ubiquitous 
Osteoclast 
Kidney, inner ear, epididymis 
Intracellular targeting of ATPase, 
Proton pumping across membranes 
Regulation of versicle formation, 
pH sensor and regulator 
[79,140-145] 
c ATP6V0C 16p13.3 VATL_HUMAN P27449 unknown 
Proteolipid ring, proton transfer 
Vesicle budding 
[146-148] 
c” ATP6V0B 1p32.3 VATO_HUMAN Q99437 unknown Proteolipid ring, proton transfer [149,150] 
d1 
d2 
ATP6V0D1 
ATP6V0D2 
16q22 
Chr. 8 
VA0D1_HUMAN 
VA0D2_HUMAN 
 
P61421 
Q8N8Y2 
Ubiquitous 
kidney, epididymis 
Connection of rotor with 
proteolipid ring 
[132,151-153] 
e1 
e2 
ATP6V0E1 
ATP6V0E2 
5q35.2 
7q36.1 
VA0E1_HUMAN 
VA0E2_HUMAN 
O15342 
Q8NHE4 
Unknown Unknown [43,134,154] 
1 Source: www.expasy.org/.  2Subunit H has two isoforms, generated by two different splice variants of the same gene. 3 Smith A.N. et al. [136]defined different official 
names for these subunits. In order to reflect our interest in the structure of the V-ATPase, we have chosen to retain the ATP6V* nomenclature 
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ABSTRACT  
Dysmorphic features, multisystem disease and central nervous system 
involvement are common symptoms in congenital disorders of glycosylation, 
including several recently discovered Golgi-related glycosylation defects. In search for 
discriminative features, we assessed eleven children suspected with a Golgi-related 
inborn error of glycosylation. We evaluated all genetically unsolved patients 
diagnosed with a type 2 transferrin isofocusing pattern in the period of 1999-2009. By 
combining biochemical results with characteristic clinical symptoms we used a 
diagnostic flow chart to approach the underlying defect in patients with CDG type IIx. 
According to specific symptoms and laboratory results we initiated additional, 
targeted biochemical and genetic studies. Thus, we found a distinctive spectrum of 
CDG type II-associated anomalies including sudden hearing loss, brain malformations, 
wrinkled skin and epilepsy in combination with skeletal dysplasia, dilated 
cardiomyopathy, sudden cardiac arrest, abnormal copper and iron metabolism and 
endocrine abnormalities in our patients. One patient with severe cortical 
malformations and mild skin abnormalities was diagnosed with a known genetic 
syndrome, due to an ATP6V0A2 defect. Based on our findings we recommend 
clinicians to consider CDG in patients with cardiac rhythm disorders, 
spondylodysplasia and biochemical abnormalities of the copper and iron metabolism 
even in absence of intellectual disability.  
INTRODUCTION 
The congenital disorders of glycosylation form a group of inborn errors of 
metabolism characterized by a defective biosynthesis of glycans, first described by 
Jaeken et al in 1980 [1]. A recent classification of CDGs distinguishes four major 
biochemical categories: three involving protein-glycosylation (disorders of N-linked 
glycosylation, O-linked glycosylation and combined N- and O-glycosylation) and one 
involving lipid-glycosylation [2]. Plasma transferrin isoelectric focusing is used as a 
simple and reliable biochemical screening tool for CDG associated with deficient 
sialylation [2] (Figure 6.1). Compared to healthy individuals, in patients with N-
glycosylation disorders, hypoglycosylated isoforms are elevated and 
tetrasialotransferrin is decreased. The glycosylation route comprises the cytoplasm, 
the endoplasmic reticulum and the Golgi apparatus. Depending on the localization of a 
defect, two isofocusing patterns can be distinguished: the so called type 1 pattern, 
which demonstrates increases of even (2 and 0) sialotransferrin bands, and the type 2 
pattern, which shows additional uneven (3 and 1) sialotransferrin bands [2]. This 
classification, based on the TIEF pattern, relates to N-glycosylation diseases, found by 
the initial screening test in patients with a suspected CDG. According to preceding 
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nomenclature however, not only patients with a type 2 TIEF pattern were labeled as 
CDG type II defects, but a few additional CDG forms with normal TIEF as well, based 
on their underlying defect in Golgi or Golgi-associated proteins [3]. Unsolved patients 
with type 2 TIEF pattern were labeled as CDG type IIx (MIM 212067) [4]. 
 
Figure 6.1: Left, TIEF: 1 = control, 2 = type 1 profile, 3 = type 2 disialo-profile, 4 = type 2 asialo-profile. 
Center, apo C-III: 1 = control, 2 = apo C-III1 profile, 3 = apo C-III2  profile. TIEF can be subdivided in an 
asialo- and disialo- profile, afterwards the apo C-III IEF can be subdivided in a normal, apo C-III0 -profile 
or apo C-III1-profile. On the right side, the division in subgroups is shown. 
In addition to parts of the N-glycan biosynthesis pathway, the Golgi apparatus 
houses the full mucin type O-glycan biosynthetic pathway. Plasma apolipoprotein C-III 
isofocusing has been developed to evaluate O-glycan biosynthesis [3] (Figure 6.1), a 
useful tool in combined N- and O-glycan biosynthesis defects [3]. 
Some of the CDG patients show not only abnormal N-linked, but also abnormal 
O-glycosylation. Other Golgi-related glycosylation defects, however, like muscle-eye-
brain disease, Schneckenbecken dysplasia, or multiple cartilaginous exostoses, do not 
show abnormal TIEF. Due to the emerging number of combined defects, and isolated 
O-glycosylation defects, a consensus for a novel nomenclature, based on genetic 
etiology, became essential [2].  
In the past couple of years, several novel CDG defects have been described with 
a type 2 TIEF pattern, some of them historically carrying the name CDG type II (COG7-
CDG/CDG IIe, COG1-CDG/CDG IIg, etc), while the most recently discovered types were 
labeled as COG5-CDG and COG6-CDG [2, 5-11]. Neurologic involvement is frequent in 
both CDG type I and CDG type II defects [2,3,5-11]. COG7-CDG typically presents with 
profound development delay, microcephaly, swallowing difficulties, failure to thrive 
and distal arthrogryposis [8,9] (Table 6.1). Another interesting example with 
distinctive CNS symptoms is ATP6V0A2-CDG; causing autosomal recessive cutis laxa 
syndrome type II (ARCL-type-II, MIM 219200), a disorder of sagging skin, dysmorphic 
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features, developmental delay and unique cortex malformations [5,6], and a combined 
N- and O-glycosylation defect [12-14].  
Recently the number of defects associated with a TIEF type 2 pattern has more 
than doubled [15,16]. Apart from central nervous system, hematologic and liver 
involvement in both types, the phenotype of the newly discovered defects is quite 
different from the well known clinical presentation in CDG type I (Table 6.1). Classic 
CDG type I features, like inverted nipples, hypothyroidism or strabismus are less 
common in patients with a type 2 TIEF pattern.  
In the European database EUROGLYCANET# for glycosylation disorders, 
approximately 80% of patients show a type 1 pattern. With advancing biochemical 
techniques, the primary molecular genetic defect has been elucidated in the majority 
of CDG type I cases. In contrast, no comprehensive analytical or biochemical 
techniques are available to identify and delineate the primary defects in patients with 
a TIEF type 2 pattern and suspected Golgi-related glycosylation defects. Thereby, the 
vast majority of these cases (80% of CDG type II patients based on EUROGLYCANET#, 
2010) is still classified as unsolved; CDG type IIx (MIM 212067). 
Table 6.1: Genetic, clinical, and laboratory features in the historically defined CDG type II group. 
According to the new nomenclature, the name of the gene followed by the CDG suffix is used. B= 
hematological, C=coagulopathy, CNS= Central nervous system, COG= conserved oligomeric Golgi 
complex subunit, GI=gastro-intestinal, H= heart, I=immunological, L=liver, M=muscle, R=respiratory, 
S=skeletal abnormalities, SLeX= Sialyl-Lewis X ligand. 
Genetic defect Protein Clinical features Specific laboratory  
features 
MGAT2-CDG (CDG-IIa) N-acetylglucosaminyl-
transferase II 
CNS, L, S, H, C  - 
GLS1-CDG (CDG-IIb) Glucosidase I CNS, L, S, R, GI Abnormal levels of a 
tetrasaccharide in urine 
SLC35C1/FUCT1-CDG 
(CDG-IIc) 
Solute carrier family 35, 
member C1/GDP-fucose 
transporter 1 
CNS, SS, B, I - 
B4GALT1-CDG (CDG-
IId) 
β-1,4-
galactosyltransferase 
CNS, L, C, M  Lack of SLeX expression 
in neutrophils 
SLC35A1-CDG (CDG-IIf) CMP-sialic acid 
transporter  
I, C  Lack of SLeX expression 
in neutrophils 
COG1-CDG (CDG-IIg) COG 1 CNS, L  - 
COG4-CDG  COG 4 CNS, L, R, I  - 
COG5-CDG  COG 5 CNS, L  - 
COG6-CDG COG 6 CNS, L Vitamine K deficiency 
COG7-CDG (CDG-IIe) COG 7 CNS, L, S, H, C, M I, GI,  
cutis laxa, 
hyperthermia  
- 
COG8-CDG (CDG-IIh) COG 8 CNS, L, S, C, M - 
ATP6V0A2-CDG ATP6V0A2 CNS,S, cutis laxa - 
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PATIENTS AND METHODS 
All patients were evaluated according to standard diagnostic procedures for a 
suspected disorder of protein glycosylation. Patient 1 was not fully evaluated due to 
an early lethal course. 
Clinical patient characteristics  
Clinical characteristics are summarized in Table 6.2.  
Patients 1 and 2 were brothers. They presented with recurrent infections, 
anemia, hepatosplenomegaly, severe thrombocytopenia, disturbed coagulation and 
liver function tests and increased activity of lysosomal enzymes in plasma. Patient 1 
had severe hypotonia, strabismus and developmental delay, the letter also present in 
patient 1.  
The female patient 3 showed generalized hypotonia, macrocephaly with large 
fontanel, psychomotor retardation, joint-hyperlaxity, intermittently elevated serum 
transaminases and leucopenia, without a history of infections.  
The male patient 4 showed normal development until the age of 13 years when 
he experienced a sudden cardiac arrest. He developed epilepsy and became physically 
and mentally disabled. Hemostasis and liver function were abnormal. Albuminuria 
and hypoglycemia were noted (Table 6.2).  
The male patient 5 showed multiple dysmorphic features and congenital 
genital abnormalities. He had hypothyroidism, abnormal coagulation, liver 
dysfunction, decreased serum ceruloplasmin and copper levels and elevated creatine 
kinase (CK). Subsequently he developed myopia and retinitis pigmentosa. 
Prepubertally his bilateral hearing loss required hearing aids. Right-sided sudden 
deafness occurred at the age of 13 years. Hearing was restored by cochlear implant 
and he attends a regular school.  
The patients 6 and 7 (sister and brother) showed cholestasis after birth. 
Patient 6 had elevated CK, alanine aminotransaminase and aspartate 
aminotransaminase (ASAT and ALAT) levels and disturbed clotting parameters. She 
was diagnosed at the age of 10 years with chronic liver disease, also showing mild 
dysmorphic features, relative microcephaly (Figure 6.2), generalized muscular 
hypotonia, and a severe sleeping and behavioral disorder. Her brother (patient 7) is 
additionally known with skeletal dysplasia, ptosis (Figure 6.2) and a more severe 
psychomotor retardation.  
The male patient 8 has previously been reported [17]. In the following years 
wrinkled skin on his abdomen and neck became more apparent (Figure 6.2). He 
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developed a behavioral disorder with aggression and self mutilation. Subsequently he 
showed severe myopia, sensorineural hearing loss, severe mental retardation and an 
expressive language disorder.  
The female patient 9 had a Pierre-Robin sequence (Figure 6.2), generalized 
muscular hypotonia with elevated CK, dilated cardiomyopathy and delayed motor 
development. The hypotonia improved significantly over the years. At 15 years she 
has short stature, hypogonadotrophic hypogonadism and a high normal intelligence.  
The male patient 10 had dysmorphic features, short stature and 
kyphoscoliosis. Vision was impaired due to glaucoma. His motor development was 
delayed. Severe anemia required transfusion. Currently he is 17 years old and attends 
regular school.  
Patient 11 had wrinkled skin of the abdominal region and other dysmorphic 
features (Figure 6.3d). He had a motor and speech developmental delay, and showed 
complex partial seizures. At the age of 14 years he was mentally retarded.  
Additional clinical evaluation 
Hand X-rays were performed in three patients to determine bone age, in 
accordance with the Greulich & Pyle atlas. All investigations including brain imaging 
(MRI and ultrasound), visual evoked potentials (VEP), electromyography (EMG) and 
electroencephalography (EEG), liver biopsies and skeletal imaging were performed 
upon clinical indication.  
Laboratory investigations 
Standard laboratory investigations included full blood count, transaminases 
(ALAT, ASAT), alkaline phosphatase (ALP), gamma-glutamyltransferase (γ-GT), 
infection parameters, hemoglobin, creatine kinase, lactate dehydrogenase (LDH) and 
urine reduction. 
Investigations performed upon indication were serum bilirubin, copper, 
ceruloplasmin, iron, cholesterol, triglycerides, coagulation factors, coagulation tests, 
ceruloplasmin, hormones, amino acids and activity of lysosomal enzymes in plasma. 
Upon indication organic acids and oligosaccharides were evaluated in urine. Also upon 
indication hepatitis A, B and C antibodies were evaluated. 
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Figure 6.2: a,b,e: Patient 7 presented with microcephaly, bilateral ptosis, blue sclerae, downslanting 
palpebral fissures, scapula alatae and platyspondyly;  2c, d: His sister, patient 6 showed mild 
dysmorphic features like a flat face, hypertelorism and relative microcephaly; f, g: Patient 9 presented 
with a Pierre-Robin sequence, a flat face, hypertelorism, hypogonadotropic hypogonadism and 
cardiomyopathy; 2h-l: A syndrome like presentation in patient 8 with marked hypotonia (h), cutis laxa 
(i), pes adductus with hypoplastic small toe (j), clinodactyly of the fifth finger, low insertion of the 
thumb, camptodactyly (k), and extended hypertrichosis of the back (l). 
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Figure 6.3: T1 weighed sagittal MRI images demonstrating frontal cobblestone like cortical dysgenesis 
(a) and no significant cerebellar hypoplasia in ATP6V0A2-CDG (b). T2 weighed horizontal image 
showing bilateral frontal polymicrogyria, enlarged Virchow-Robin spaces (arrow) by symmetrical 
cobblestone like cortical dysgenesis (c) and wrinkled abdominal skin (d) in patient 11. 
  
Diagnostic approach to CDG  
All patients were included with a TIEF showing a type 2 pattern. Additional 
investigation of N-linked glycosylation defects could be achieved by isofocusing of 
plasma thyroxin binding globulin (TBG) and alfa-1-antitrypsin (α1-AT ). Secondary 
causes of hypoglycosylation (galactosemia, fructosemia and presence of sialidase in 
blood) and transferrin polymorphisms as a possible cause for an abnormal TIEF 
profile, were excluded using clinical and dietary anamnesis, urine analysis, and if 
indicated by blood culture, genetic studies and plasma protein mass spectrometry. 
Lipid-linked oligosaccharides (LLO) analysis used in three inconclusive initial TIEF 
profile cases confirmed CDG type I. To evaluate Golgi-related mucin-type O-
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glycosylation defects, isoelectric focusing of apo C-III was performed as described by 
Wopereis et al [3]. The abnormal apoC-III profile can be subdivided in an ‘apo C-III0’ 
and an ‘apo C-III1’ profile [16]. The relative amounts of apo C-III isoforms were 
determined using densitometry. MALDI mass spectrometry of plasma N-glycans was 
performed in 9 patients as described by Guillard et al. [18] in order to exclude 
MGAT2-CDG (CDG-IIa), SLC35C1-CDG (CDG-IIc) and B4GALT1-CDG (CDG-IId). 
Tetrasaccharides in urine were measured to screen for GLS1-CDG [19] in five patients. 
Lack of expression of sialyl-Lewis-X ligand (SLeX) on the surface of neutrophils is 
indicative for SLC35C1-CDG and SLC35A1-CDG (CDG IIf) [20] and is performed in one 
patient. Western Blot and direct sequencing of the coding regions of all the eight COG 
subunits (COG1 - COG8) was performed in five patients. Genetic studies were 
performed in seven cases (direct gene sequencing for Pendred (MIM 274600, 
SLC26A4), Aarskog-Scott (MIM 305400, FGD1), hemochromatosis (MIM 235200, HFE) 
and Wilson disease (MIM 277900, ATP7B), methylation analysis for Prader Willi 
syndrome (MIM 176270, SNRPN), autosomal recessive cutis laxa (ARCL2A; MIM 
219200, ATP6V0A2) karyotyping and Array CGH (250K) whole genome scanning). 
RESULTS  
Table 6.2 provides an overview of clinical, biochemical and metabolic findings. 
Additional clinical investigations 
BEAP showed severe bilateral sensorineural hearing loss in patient 8 (55/65 
dB). In patient 5 the audiogram showed sensorineural deafness of the right ear and a 
hypoacusis (70 dB ) of the left ear. In three patients with muscle weakness EMG 
showed normal results. An EEG was performed in four cases, one was normal, two 
showed encephalopathy with generalized epileptic activity (patient 4 and 8) and one 
with bilateral frontotemporal focal activity, (secondary generalized) in patient 11. VEP 
was severely abnormal in patient 5 and showed a normal result in patient 10. 
MRI was performed in ten patients. Head ultrasound was performed in patient 
1. 
In five patients no abnormalities where detected (patients 1, 3, 7, 9 and 10). 
Patient 2 and 8 showed partial agenesis of the corpus callosum and patient 6 showed 
decreased myelinisation around the occipital horn of the ventricle. In patient 4, 
widened ventricles and atrophy on the left fronto-temporal cerebral quadrant were 
seen. Patient 5 showed brain atrophy and small areas of increased paraventricular 
occipital signal intensity. Patient 11 had bilateral frontal cobblestone like cortical 
dysgenesis (Figure 6.3c). 
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Histology 
In patients 1 and 2 a liver biopsy showed chronic hepatitis, micro nodular 
changes and necrosis. (In this phase the hepatitis serology did not support active 
infection). 
Biochemical investigations 
Liver function was abnormal in nine patients (Table 6.2). Patients 5 (increased 
TSH and decreased free T4) and 9 (decreased LH, FSH and oestradiol) had endocrine 
abnormalities. Full blood count abnormalities were found in patients 1, 2, 3 and 10 
(thrombopenia, leucopenia and anemia). Serum copper was diminished and iron level 
fluctuated in patient 5. Coagulation was disturbed in eight patients (decreased clotting 
factors, abnormal coagulation tests or thrombotic events). Ceruloplasmin was 
decreased in patients 5, 6 and 7. Activity of lysosomal enzymes in serum were 
measured in four patients, of which two patients showed elevated levels (patient 1 
and 2) and two showed normal levels (patient 3 and 6). 
Organic acids and oligosaccharides in urine were measured in five patients: 
results were normal in four patients (3, 5, 8 and 9) but abnormal in patient 2 with 
elevated galactose levels. Sialyl-Lewis X expression in patient 8 was normal, ruling out 
the probability of SLC35A1-CDG.  
Glycosylation analysis 
Of the eleven patients, ten had a confirmed type 2 TIEF pattern by repeated 
analysis, suggestive for a defect in the Golgi apparatus. Abnormal TIEF profiles led to 
exclusion of GLS1-CDG and SLC35C1-CDG, since these subtypes give normal TIEF 
profiles. In patient 1, IEF of transferrin and apo C-III were not performed because he 
deceased during ongoing investigations. The diasialo TIEF pattern was seen in eight 
patients and two patients showed an asialo pattern. Of the eight patients with a disialo 
pattern, two had an apoC-III0 profile and six an apo C-III1 profile, which indicates a 
combined defect in N- and O-glycosylation [16]. Of the two patients with the asialo-
TIEF pattern, one showed a normal apo C-III-profile and the second showed an apo C-
III0 profile (Figure 6.1). Lipid-linked oligosaccharides analysis is used to identify the 
underlying defects in CDG type I and is expected to be normal in CDG type II. It was 
performed in three cases were the first TIEF profiles were inconclusive (patients 2,4 
and 8), all results were normal. Mass spectrometry analysis of N-glycans was 
performed for 9 patients. The resulting spectra reflect a Golgi-related defect in 8 of the 
9 patients because of an increase in truncated glycans associated with decreased 
triantennary structures. Based on the results, MGAT2-CDG, SLC35C1-CDG and 
B4GALT1-CDG are very unlikely in all patients: no significant increase in 
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monoantennary N-glycans, or decrease in galactosylated or fucosylated glycans was 
reported.  
COG defects were analyzed in five patients (3,5,8,9 and 10) using Western Blot 
and sequencing. All results were normal. In patient 4, COG analysis was not performed 
due to the normal apo C-III profile, which excludes COG deficiencies. In patients 6 and 
7, based on consanguinity and the results of genetic linkage analysis COG defects were 
unlikely. No material was available from patients 1 and 2 for Western Blot analysis.  
In patient 5 genetic investigations ruled out Pendred syndrome (Pendred 
syndrome was suspected based of hearing loss in combination with hypothyroidism), 
Faciogenital dysplasia (Aarskog-Scott syndrome) and hemochromatosis. Array CGH 
was normal in patient 9. 
Genetic analysis 
Methylation analysis for Prader Willi syndrome and array CGH in patient 3 did 
not show any abnormalities. High resolution karyotype analysis was performed in five 
patients (patients 2, 5, 8, 9 and 10), all had normal karyotypes. The results of 
sequencing for the eight COG subunit genes were normal. In patient 5 genetic 
investigations ruled out Pendred syndrome (suspected based on hearing loss in 
combination with hypothyreoidism). Genome wide linkage analysis (homozygosity 
mapping) was performed in patients 6 and 7. This hasn’t resulted in a candidate gene 
due to abundance of large homozygous regions. We also ruled out all genes known to 
be involved in the glycosylation pathway in the homozygotic regions. ATP6V0A2 
mutation analysis was noncontributory in patient 8, and showed two novel mutations 
in a compound heterozygous form (c1101delC/c1562_1563delins9) in patient 11.  
DISCUSSION 
The surprising discovery of the ATP6V0A2 defect in autosomal recessive cutis 
laxa type II presenting as a glycosylation defect led to a rapid increase in the number 
of patients diagnosed with a type 2 TIEF pattern. This taught us that once a distinct 
phenotype is associated with CDG, systematic screening leads to large additional 
numbers of patients. To date eight patients with CDG type IIx have been published as 
case-reports [21-25], (one of these patients was diagnosed since the original report 
with COG4-CDG) [22]. This is in great contrast to the rapidly expanding CDG type IIx 
group. These genetically unsolved patients have been reported with a mild 
psychomotor retardation, infections (haemolytic uraemic syndrome), failure to thrive 
and facial dysmorphy [21], chronic diarrhea, progressive liver cirrhosis and recurrent 
infections [22], a lethal case with psychomotor retardation and bleeding tendency 
[23], an adult case with unexplained chronic hypertransaminasaemia with decreased 
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clotting factors [24], and a cohort of four patients with hypertransaminasaemia, 
coagulopathy and steatosis [25].  
The combination of liver and CNS involvement is common in CDG. In our own 
cohort 9 out of 11 patients showed liver involvement. Liver problems varied from 
slightly elevated transaminases without clinical consequence to hepatic coma leading 
to death. Central nervous symptoms are characteristic features of CDG. Interestingly 
two children in our study group showed no mental retardation. Of the two children 
with clinical epilepsy one presented with a seizures only after cardiac arrest. MRI 
changes were diagnostic in patient 11 showing cobble-stone like brain dysgenesis 
(frontal polymicrogyria, Figure 6.3). Eye involvement is well known in CDG type I, but 
unusual in CDG type II. We found ophthalmologic abnormalities including retinitis 
pigmentosa (patient 5), glaucoma (patient 10) and severe myopia (patient 8). A 
unique neurological presentation was observed in the most complex patient (patient 
5). He suffered from hypoacusis which suddenly developed to acute unilateral 
deafness. Sensorineural hearing loss has been recently associated with CDG type I in 
RFT1-CDG [26]. In CDG type II, sudden deafness had never been described before. 
Patient 8 and patient 11 had abdominal wrinkled skin/cutis laxa and CNS 
malformations. Compared to the ATP6V0A2-related phenotype, confirmed in patient 
11, but not in patient 8, the latter developed progressive skin wrinkling through the 
course of the disease, in association with sever hypermetropia, inguinal hernias, joint 
deformations and hyperthrichosis. 
Cardiomyopathy and rhythm disorders have not previously been associated 
with CDG type II. Patient 4 suffered a sudden cardiac arrest, most likely due to the 
combination of an underlying rhythm disorder (ventricular extrasystoles). Patient 9 
showed a dilated cardiomyopathy with left sided heart failure and Wolff-Parkinson-
White syndrome. Patient 10 had several skeletal and joint abnormalities (hypoplasia 
fifth ray hands, pectus excavatum, kyphoscoliosis, abnormal ossification/ lysis of 
cervical vertebrae), in combination with hernias. The features were not comparable 
with a known skeletal dysplasia [29]. Another three patients had delayed bone 
maturation, platyspondyly and/or decreased bone density, demonstrating common 
skeletal involvement in CDG type IIx. 
Patient 11 was diagnosed with a so far undescribed mutation in ATP6V0A2 
based on phenotyping combined with apo C-III results, demonstrating the success of 
our approach. Interestingly, the other patient with cutis laxa and CDG type II did not 
carry a mutation in ATP6V0A2. 
Endocrine abnormalities are common in CDG type I, especially with decreased 
TBG and total T4 levels. Patient 5 had hypothyroidism with goiter, not previously 
reported in CDG type II. Patient 9 interestingly showed a hypogonadotrophic 
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hypogonadism in combination with growth delay and decreased IgF1 levels [34]. 
Coagulopathy defined as decreased clotting factors, thrombopenia and prolonged 
bleeding time was present in seven patients. Some of these patients had bleedings 
after minimal invasive medical procedures, even with only slightly decreased clotting 
factors. CDG thus should be considered in unexplained bleeding disorders. The 
diminished serum copper and ceruloplasmin levels in two patients are unexplained, 
and might be a consequence of abnormal Golgi transport.  
Increased activities of lysosomal enzymes in plasma are present in most CDG 
type I but not in CDG type II [27], except for COG7-CDG [28]. Both patients died shortly 
after birth and showed outspoken dysmorphic features and skeletal anomalies, in 
contrast with our patients 1 and 2 who also showed increased activity of lysosomal 
enzymes. The exact mechanism leading to increased activity of lysosomal enzymes 
remains unclear.  
Mass spectrometry has a growing significance in CDG diagnostics, especially in 
MGAT2-CDG, SLC35C1-CDG and B4GALT1-CDG. Direct genetic approaches, like direct 
sequencing for known genes and homozygosity mapping, in combination with 
clinical/biochemical grouping, have been proven effective in elucidating underlying 
genetic defects (ATP6V0A2-CDG, DPM3-CDG and SRD5A3-CDG) [14,30,31]. Clinical 
phenotyping should be included early on to decide on the diagnostic approach in CDG 
patients with a type 2 pattern (Figure 6.4). Pathognomic features, such as cobble-
stone like cortical dysgenesis with skin wrinkling [13,32,33], or severe microcephaly 
with adducted thumbs [9] are key to the diagnosis. The combination of neurological 
symptoms and liver dysfunction is highly suggestive for congenital disorders of 
glycosylation, but normal psychomotor development does not exclude CDG type II. 
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Figure 6.4: Diagnostic flowchart for patients diagnosed with a type 2 TIEF pattern. Once this profile has 
been confirmed, and secondary glycosylation defects are ruled out, the pattern is matched to known 
type 2 profiles. If these do not match, isoelectric focusing of apo C-III protein is performed for Golgi 
related secretory O-mucin type defects. Mass spectrometry (MS) of plasma glycans is used to exclude 
MGAT2-CDG or B4GALT1-CDG, because these two types have distinct MS profiles. Western Blot analysis 
and sequencing of COG genes can lead to diagnosing a COG defect. The use of homozygosity mapping, 
especially in consanguineous cases and whole genome analysis can be implemented simultaneously. 
  
Table 6.2: Clinical features. Abbreviations and symbols: α1-AT= alpha1-antitrypsine, ADHD= attention deficit hyperactivity disorder,  ALP= alkaline phosphatase, 
APTT= activated partial thromboplastin time, AT-III= antithrombin-III, ASD= atrial septum defect, Bili= bilirubine, CC= corpus callosum, CK= creatinine kinase, DCM= 
dilated cardiomyopathy, F= factor, FSH= follicle stimulating hormone, FTT= failure to thrive, Fe= iron, GE=gastroenteritis, GI= gastro-intestinal, HM= hepatomegaly, IGF-
1= insulin like growth factor 1, INR= International Normalized Ratio, HSM= hepato-splenomegaly,  LDH= lactate dehydrogenase , L= left, LH= luteinizing hormone , MI= 
mitral insufficiency, PMR= psychomotor retardation,  R= right, SF= shortenings fraction, TA= transaminases, T3= triiodothyronine, T4=  thyroxine, TBG= thyroxine 
binding globuline, TI= tricuspid insufficiency, TT= thrombin time, VES=ventricular extrasystole.    
 Patient 1 ♂ Patient 2 ♂ Patient 3 ♀ Patient 4 ♂ Patient 5 ♂ 
Age of onset 3 m (deceased 15m) 5 m 3 m 13 y Neonatal 
Ethnicity/consanguinity Turkish/+ Turkish/+ Greek/suspected German/- Polish/- 
Dysmorphic features/ 
congenital anomalies 
- - macrocephaly, 
large fontanel 
- upslanting palpebral fissures, 
epicanthal folds, thin nasal bridge, 
bilateral inguinal hernias, micropenis, 
testes migrans, 
Skeletal/limb anomalies - - hyperlaxity of the 
joints 
- Clinodactyly 
PMR/hypotonia +/- -/+ +/+ +/- -/- 
Hepatic involvement HSM, liver cirrhosis, ↑TA, 
↑AP, ↑bili 
HSM, liver 
cirrhosis, ascites, 
↑TA, ↑AP, ↑bili 
↑TA, ↑AP ↑TA HM, pancreatic steatosis, ↑neonatal 
icterus , ↑TA 
Hematological 
involvement, coagulopathy 
anemia/thrombopenia, 
↑TT, ↓fibrinogen 
thrombopenia, 
↑APTT,↑TP, ↑TT. 
↑INR 
leucopenia recurrent GI-
bleedings/thrombosis. ↑APTT, 
↓FII, ↓FV, ↓FVII, ↓FIX, ↓FXI, 
↓protein C/S, ↓AT-III 
↓AT-III, ↓protein C/S 
Neurological /psychiatric 
involvement 
-/- -/- -/ADHD Focal motor seizures/- bilateral sensorineural deafness, 
sudden unilateral deafness/- 
Cerebral MRI NA agenesis CC normal slight ventriculomegaly/left 
temporal atrophy 
widening of Virchow Robin spaces 
(occipital, parietal, frontal), 
hyperintens signal (T2) occipital horns 
of lateral ventricles 
Cardiac involvement - - - sudden cardiac arrest, VES, 
normal echocardiography 
- 
Opthalmological 
involvement 
- divergent 
strabismus 
- - hypermetropia, periferal  retinal 
pigmentation 
Recurrent infections S. typhii GE, chronic 
hepatitis C infection 
chronic hepatitis C 
infection 
- - - 
Other laboratory 
abnormalities 
↑ lysosomal enzymes ↑ lysosomal 
enzymes 
 hypoglycemia,↓α1-AT, 
albuminuria 
↑↓serum copper and ceruloplasmin 
↑ CK, ↓T3, ↓FT4 
  
 
 Patient 6 ♀/ Patient 7 ♂ Patient 8 ♂ Patient 9 ♀ 
Age of onset neonatal neonatal neonatal 
Ethnicity/consanguinity Turkish/+ Czech/- German/- 
Dysmorphic features/ 
congenital anomalies 
mild microcephaly, ptosis, blue 
sclerae, downslanting 
palpebral fissures 
microcephaly, dolichocephaly, gothic 
palate, blepharophimosis, cutis laxa, 
hypertrichosis, arachnodactyly, 
duodenal atresia and intestinal 
malrotation, bilateral inguinal hernias 
Pierre-Robin sequence, hypotelorism, crowded teeth, 
short stature 
Skeletal/limb anomalies delayed bone maturation talipes equinovarus adductus, 
brachymetatarsia, congenital hip 
dysplasia, subluxation thumbs/ 
hyperlaxity joints 
delayed bone maturation 
PMR/hypotonia +/+ +/+ -/+ 
Hepatic involvement cholestasis, ↓ceruloplasmin, ↑LDH/↑TA ↑TA, ↓LDH ↑TA 
Hematological 
involvement, 
coagulopathy 
↓protein S, ↓AT-III, ↓fibrinogen, ↓FIX ↑APTT, ↑PT, anemia ↓AT-III 
Neurological /psychiatric 
involvement 
physical contact aversion hyperkinesia, dyslalia/aggression, 
self-mutilation 
-/- 
sleep disorder ataxia 
Cerebral MRI ↓ occipital 
myelinisation 
normal hypogenesis posterior CC NA 
Cardiac involvement - - DCM, MI, TI (SF 22%) 
Opthalmological 
involvement 
- ↓vision, myopia, nystagmus - 
Recurrent infections - upper respiratory tract infections - 
Other laboratory 
abnormalities 
↑CK hypoglycemias, ↑CK, ↓LH, ↓FSH, ↓IGF-
1, ↓TBG, ↓oestradiol 
- 
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ABSTRACT 
The clinical phenotype of congenital disorders of glycosylation (CDG) is very 
heterogeneous, mostly including a severe neurologic involvement and multisystem 
disease. We characterized the gene defect in a patient classified as CDG type IIx, with 
mild hepatopathy and coagulation anomalies, but a normal psychomotor development.  
Biochemical investigations, including plasma glycoprotein isoelectric focusing and N-
glycan profiling were performed, followed by enzyme measurements in fibroblasts and 
mutation analysis. Upon the discovery of the genetic defect, expression profiles were 
investigated in different human tissues. In addition, we re-evaluated the only other 
patient reported with the same defect. A galactosyltransferase defect was confirmed by 
enzyme activity measurements and a homozygous c.1031-1032insC mutation in exon 5 
of the B4GALT1 gene resulting in a truncated protein. After comparing the clinical 
presentation of the child with the current situation of the previously described 
B4GALT1-CDG patient, we re-define the clinical phenotype in B4GALT1-CDG, and explain 
this unusual presentation through tissue-specific expression of B4GALT1. By evaluating 
both patients, we demonstrate that B4GALT1-CDG presents with dysmorphic facial 
features, coagulation abnormalities and hepatic involvement, but has a good long-term 
neurological prognosis. 
INTRODUCTION 
The congenital disorders of glycosylation represent a large and rapidly growing 
family of genetic diseases. Since Jaeken’s initial description of a glycosylation disorder, 
more than 40 defects have been described in protein N-glycosylation, protein O-
glycosylation, lipid glycosylation or combinations thereof. Whereas certain defects are 
relatively common among the CDG-patients (PMM2-CDG or ALG6-CDG), other CDG 
subtypes have only been described in single patients (B4GALT1-CDG, DPM3-CDG) [1-5].  
Serum transferrin isofocusing provides a high-throughput screening of patients 
with an N-glycosylation defect. It allows distinction between defects in the cytoplasm or 
endoplasmic reticulum (CDG type I) and defects limited to the late ER and the Golgi (CDG 
type II). The development of improved analytical methods such as mass spectrometry of 
serum N-glycans in CDG type II [6] has assisted the diagnosis of these disorders. Defects 
in glycosyltransferases, such as MGAT2 or B4GALT1, result in very specific glycan 
profiles that directly lead to the genetic defect.  
In general, CDG presents as a multi-system disorder because of the ubiquitous 
expression of glycosylation enzymes. Neurologic involvement is frequent in both CDG 
type I and CDG type II defects, and several CDG type II patients show distinctive 
neurological symptoms [7-11]. COG7-CDG typically presents with profound development 
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delay, microcephaly, dysphagia, failure to thrive and distal arthrogryposis [12,13]. 
ATP6V0A2-CDG, causing autosomal recessive cutis laxa syndrome type II, is 
characterized by lax skin, dysmorphic features, developmental delay and specific cortical 
malformations [10,14]. Additional features seen in CDG type II patients include 
hematologic and hepatic involvement, epilepsy or ataxia, coagulation problems and 
dysmorphic features. Classic CDG type I features, such as inverted nipples, fat pads, low 
serum thyroxin binding globulin or strabismus are less common in patients with CDG 
type II. A growing group of patients, presenting with a wide range of clinical symptoms, 
have a genetic etiology that is yet to be identified [11]. The identification of new genes 
associated with CDGs and reports of the phenotypic breadth will allow for improved 
nosology and prognosis for families.  
In this paper, we present a tissue-restricted CDG type II defect in a patient with an 
exceptionally benign clinical presentation without neurological involvement.  
MATERIALS AND METHODS 
Plasma samples were collected from EDTA or heparin blood by centrifugation and 
stored at – 20oC. Unless stated otherwise, chemical reagents were acquired from Sigma 
Aldrich (St. Louis, USA).  
Isoelectric focusing of serum transferrin and apolipoprotein C-III was performed 
essentially as described [6,15]. Plasma N-glycan profiling of both patients was performed 
by MALDI linear ion trap mass spectrometry as described [6], using 10 μL of serum. 
Galactosyltransferase activity was measured in fibroblast homogenates using 
UDP-[3H]Gal as donor and p-nitrophenyl-N-acetyl-β-D-glucosamine (pNP-GlcNAc) as 
acceptor, using a procedure modified from [3] and [16]. To a pellet of 10 million 
fibroblasts, 75 μL lysis buffer was added (0.05% v/v Triton X-100, 150 mM NaCl and 
protease inhibitor (Roche diagnostics, Basel, Switserland) in 50 mM Tris-HCl pH 8.8) 
prior to three rounds of sonication (10 seconds, on ice). Protein concentration was 
determined by 2D Quant (GE Healthcare, Buckinghamshire, UK). Galactosyltransferase 
activity was measured by incubating 3 μg of proteins from the cell homogenate with 20 
μL buffer A (10 mM Tris-HCl pH 7.7, 250 mM sucrose, 0.5% v/v Triton X-100, 1 mM 
EDTA) and 30 μL buffer B (5.2 μL 0.5 M Tris-HCl (pH 7.4), 1.5 μL Triton X-100, 4.4 μL 0.2 
M MnCl2, 15.4 μL H2O, 2.5 μL 1 M pNP-GlcNAc in H2O, 0.44 μL 0.2 M ATP, 0.25 μL 1 mM 
UDP-galactose, 0.22 μL 0.2 μCi/μL UDP-[3H]Gal (American Radiolabeled Chemicals, Saint 
Louis, USA) for 2 hours at 37oC. After addition of 500 μL ultrapure water, the reaction 
volume was purified on Sep-Pak® Vac C18 cartridges (Waters, Milford, MA). The 
cartridge was washed with 5 mL ultrapure water before elution with 2 mL 10% aqueous 
methanol. 900 μL of eluent was dissolved in 10 mL Ultima Gold XR counting fluid (Perkin 
Elmer, Waltham, MA) and the incorporated radioactive galactose was counted in the 
B4GALT1-CDG presents as a non-neurological glycosylation disorder 
~ 147 ~ 
Liquid Scintillation Analyzer Tricarb 2810TR (Perkin Elmer). After substraction of blancs 
(identical procedure without protein from cell homogenate), the data were expressed as 
fmol UDP-[3H]Gal incorporated per μg protein per minute.  
Genomic DNA was extracted and genotyped with Affymetrix Genome-Wide 
Human SNP 250K Nsp1 arrays. Copy number analysis and exporting of SNPs were 
performed on the raw data using the Affymetrix Genotyping Console 3.0. Homozygosity 
mapping on a 250K SNP array was performed on the genomes of patient 1, her parents 
and a healthy sibling to restrict the number of candidate genes from mutation analysis. 
The genotyped SNPs were analyzed for homozygous stretches using in house algorithms. 
DNA analysis was performed on genomic DNA. The B4GALT1 gene (ENST00000379731) 
was amplified in 6 fragments (exon 1 – 6). Fragments included both DNA sequences of 
the individual exons, splice donor and splice acceptor sites. Oligonucleotide primers 
were designed from the human B4GALT1 gene sequence. Exon 5 was amplified for 
sequencing using primers 5’-GGGCTGGGTTCTGGCATGAT-3’ and 5’-
AACGCTAGCTCGGTGTCCCG-3’. Other primer sequences are available on request. The size 
of the amplification products obtained after PCR reactions were checked on 1.5 % 
agarose gel and the amplimers were subjected to DNA sequence analysis with BigDye 
terminator cycle sequencing chemistry on an Applied Biosystems ABI PRISM 3130xl 
Genetic Analyzer. The nucleotide numbering follows cDNA numbering with +1 
corresponding to the A of the ATG translation codon in the reference sequence. The 
initiation codon is codon 1. DNA from 100 healthy control individuals with similar 
ethnicity was used for comparison. 
SYBR Green-based real-time quantitative PCR (QPCR) expression analysis was 
performed on a 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, 
USA) by using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, 
USA) according to the manufacturer´s instructions. Primers were developed by the 
primer3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) [17] and 
validated as described before [18]. Primer sequences are given in Table 7.1. GUSB and 
PPIB were used as reference genes [18]. Total RNA from different human adult and fetal 
tissues was ordered from Stratagene Europe (Amsterdam, The Netherlands). Total RNA 
was transcribed into cDNA by using the iScript cDNA synthesis kit (Bio-Rad Laboratories, 
Hercules, CA, USA) according to the manufacturer’s protocol. cDNA was purified by using 
the NucleoSpin extract II kit (Macherey-Nagel, Düren, Germany) according to the 
manufacturer’s protocol. QPCR quantifications were performed in duplicate on the 
equivalent of 12.5 ng total RNA input. Experimental threshold cycles (Ct) values were 
within the range of cDNA dilutions used to validate the primers. The melt curves of all 
PCR products showed a single PCR product. All water controls were negative. Differences 
in expression of a gene of interest between two samples were calculated by the 
Chapter 7 
~ 148 ~ 
comparative Ct or 2ΔΔCt method [19,20]. Data are expressed relative to the tissue with 
lowest expression and a Ct value below 32, set at 1. 
Table 7.1. Primer sequences for the QPCR analysis of B4GALT1-2. 
Gene Gene ID Forward 5'->3' Reverse 5'->3' 
GUSB NM_000181.1 agagtggtgctgaggattgg ccctcatgctctagcgtgtc 
PPIB NM_000942.4 cggaaagactgttccaaaaac gattacacgatggaatttgctg 
B4GALT1 NM_001497.3 ctatatctcgcccaaatgctg gtgcaattcggtcaaacctc 
B4GALT2 NM_001005417.1 cgcgacaagcataacgaac agacctggtaccgcactgac 
RESULTS 
Patients clinical presentation 
Patient 1, a female child of consanguineous, healthy parents of Turkish ancestry, 
was born at term, with age appropriate growth parameters. The family history was 
unremarkable. She was evaluated for recurrent episodes of diarrhea and mild 
hepatomegaly (Table 7.2). A transient axial hypotonia improved within the first year of 
life. At age 7 years she had normal growth and psychomotor development and attended 
regular school. She had dysmorphic facial features involving hypertelorism, broad nasal 
bridge, full supra-orbital region, a long philtrum, thin upper lip, low-set ears and a 
hypoplastic antihelix. She was diagnosed with severe myopia (-5 D) but her hearing was 
normal. Laboratory investigations showed abnormal liver function (Table 7.2) and 
abnormal coagulation with decreased antithrombin III, protein C and S, and borderline 
low platelets. Galactosemia was ruled out. At the age of 9 years she has normal 
intelligence and completely normal motor performance including muscle tone and 
strength, normal motor coordination, as well as deep tendon reflexes. During metabolic 
work-up, she was diagnosed with an abnormal serum transferrin isoelectric focusing 
pattern.  
Patient 2, a male patient of Turkish ancestry was reported earlier as having 
B4GALT1-CDG [3,21]. Severe perinatal complications occurred due to bleeding diathesis. 
Laboratory investigation showed abnormal liver function, increased CK, abnormal 
coagulation with decreased antithrombin III, protein C and S, and thrombocytopenia. He 
developed a hydrocephalus secondary to a Dandy-Walker malformation requiring shunt 
placement. Mild dysmorphic facial features including low-set ears and a broad nose were 
present [3,21]. Since the original description of this patient in 2002, his growth curve 
and psychomotor development normalized. At the age of 11 years he has no 
hepatomegaly, diarrhea, nor significant neurological symptoms or mental retardation.  
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Table 7.2: Clinical features and laboratory findings presented by patients 1 and 2. 
Clinical features Patient 1 Patient 2 Remarks 
Perinatal bleeding diathesis - + Recurrent 
Axial hypotonia + + Transient 
Dandy Walker malformation - +  
Dysmorphic facial features + +  
Hepatomegaly + -  
Episodes of diarrhea + - Recurrent 
Growth retardation - -  
Myopia + +  
Laboratory findings* Patient 1 Patient 2 Reference range 
Activated partial thromboplastin time (sec) 64 74 30-43 
Antithrombin III  52% 33% 80-120% 
Protein C  40% 45% 70-140% 
Protein S 41% 46% 70-140% 
Platelets (x 109 / L) 120 139 120-350 
Creatine kinase (IU / L) 320 573 <290 
Aspartate aminotransferase (IU / L) 216 270 10-46 
*The results show the most significantly abnormal values, measured throughout the course of disease. 
Biochemical investigations 
The transferrin isofocusing pattern of the plasma from patient 1 were consistent 
with a type 2 pattern in two independent samples, characterized by a main 
asialotransferrin band and decreasing amounts of mono-, di- and trisialotransferrin, and 
almost absent tetrasialotransferrin (Figure 7.1, lane 3). ApoC-III isofocusing was normal, 
indicating that the glycosylation defect was limited to N-glycan biosynthesis (data not 
shown). Presence of sialidase in plasma as a secondary cause of undersialylation, as seen 
in patients with hemolytic uremic syndrome with a similar transferrin IEF profile, was 
excluded in patient 1. 
To obtain more insight in the N-glycosylation abnormalities, plasma N-glycan 
profiling by mass spectrometry was performed. The spectrum of a healthy person 
(Figure 7.2) is characterized by a main ion with m/z 2794 representing the biantennary, 
disialylated complex N-glycan. The triantennary, fully sialylated N-glycan (m/z 3606) 
and the biantennary monosialylated forms (m/z 2433) are also major structures [6,22]. 
In patient 1, these glycans were almost completely absent, whereas structures with no or 
single galactose moieties dominated the profile (m/z 1663, 1838, 1908, 2083, 2113, 
2229, 2287, 2474 and 2648). Over 80% of the glycans terminates in N-
acetylglucosamine, as opposed to 15% in controls (ref. interval 8 – 34%). This triggered 
the idea that a defect might be present in a β1,4-galactosyltransferase. For comparison, 
serum N-glycans from patient 2, diagnosed with B4GALT1-CDG, was measured, revealing 
a highly similar pattern (data not shown) [6].  
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Figure 7.1: Serum transferrin isoelectric focusing profiles. C. = control, PMM2 = Type 1 profile with 
increased disialo- and asialotransferrin and decreased tetrasialotransferrin, Patient 1 and 2 = Type 2 
profiles of both patients, with loss of tetrasialotransferrin and increased hypoglycosylated transferrin, 
MGAT2 = Type 2 profile of a patient with MGAT2-CDG, showing loss of tetrasialotransferrin and increased 
disialotransferrin. 
 
To confirm a galactosyltransferase deficiency, galactose transfer to pNP-GlcNAc as 
a substrate was measured, using fibroblast homogenates of patient 1. As compared to 
controls, the galactosyltransferase activity in the index patient was decreased to 5% 
(Figure 7.3). We measured the same decrease in cells from patient 2, whom is known to 
have a B4GALT1 defect, but shows a different clinical presentation (Figure 7.3). 
Genetic analysis 
In human, 7 galactosyltransferases have been described [23,24]. Homo-zygosity 
mapping was performed to restrict the number of candidate genes for mutation analysis. 
The longest homozygous stretch, not homozygous in parents or unaffected sibling, was 
detected on chromosome 9, spanning 63 Mb from 9p21.1 to 9q22.32 and included the 
B4GALT1 gene, which encodes UDP-Gal:N-acetylglucosamine β-1,4-galactosyltransferase 
I (B4GALT1; EC 2.4.1.22). B4GALT1 is a six exon gene located on chromosome 9p13, 
encoding a 398 amino acid protein. Sequencing revealed a homozygous insertion in exon 
5, c.1031-1032insC. The mutation was heterozygous in the patient’s parents and was not 
seen in the patient’s healthy sibling or in 100 controls. The mutation is identical to the 
mutation found in patient 2 [3] and creates a frameshift resulting in 6 miscoded amino 
acids followed by a premature stop codon which causes the loss of 50 C-terminal amino 
acids in the B4GALT1 protein after translation. We generated expression profiles for the 
B4GALT1 and B4GALT2 genes in several human adult and fetal tissues (Figure 7.4). 
B4GALT1 was widely expressed in all tissues, with the exception of fetal heart and brain, 
and adult brain. In contrast, B4GALT2 is very specifically expressed in fetal skeletal 
muscle, fetal brain, adult heart and adult brain. In the liver, where many serum proteins, 
including transferrin, are glycosylated, the expression of B4GALT1 is intermediate 
whereas B4GALT2 is only expressed in relatively low amounts. 
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Figure 7.2: MALDI-MS profile of serum N-glycans. The N-glycome of patient 1 is characterized by a loss of 
fully processed glycans, along with a strong increase of truncated structures lacking galactose and sialic 
acid.  = N-acetyl glucosamine,  = mannose,  = galactose,  = fucose,  = sialic acid. 
 
 
 
Figure 7.3: Transfer of UDP[3H]-Gal on pNP-GlcNAc in fibroblasts from controls (1 – 4), patient 1 (5) and 
patient 2 (6).  
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Figure 7.4: Expression of B4GALT1 and B4GALT2 in different human fetal and adult tissues. Relative 
expression levels are given as the fold change in comparison to the tissue or area with the lowest 
expression level. All fetal tissues are from 20 or 21 weeks-old embryos after gestation. 
DISCUSSION 
Patient 1 presented with a mild hepatopathy, recurrent episodes of diarrhea and 
coagulation abnormalities, and was therefore screened for a possible metabolic disorder, 
including CDGs. Plasma transferrin and apo C-III isofocusing showed an isolated N-glycan 
biosynthesis defect. MALDI-ion trap analysis of plasma N-glycans revealed a profile with 
highly increased levels of truncated glycans, consistent with a galactosylation deficiency. 
Measurement of the B4GALT activity in fibroblasts showed a 95% decrease in cells from 
both patients compared to controls, in accordance with the previous reported on patient 
2 [3]. Homozygosity mapping, a candidate gene approach and molecular analysis 
revealed a homozygous insertion c.1031-1032insC in B4GALT1. 
Previously, patient 2 had been described with an identical mutation [3,21]. Unlike 
patient 1, this boy presented with macrocephaly due to a Dandy-Walker malformation, 
hypotonia and a transient cholestatic syndrome and coagulation anomalies. This raises 
the question regarding phenotypic variability. The Dandy-Walker malformation is a 
relatively common congenital anomaly that can be associated with numerous other 
malformations of the brain, as well as extra-cranial abnormalities, whether or not in the 
context of specific syndromes. If not diagnosed already by prenatal ultrasonography, 
Dandy-Walker malformation generally presents with head enlargement in the first year 
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of life. Its enormously heterogeneous origin might explain its equally variable prognosis: 
patients may suffer from severe neurological deficits, despite early and correct 
neurosurgical management. On the other hand, up to half of the patients are reported to 
have normal cognitive development. Patient 2 had severe neurological findings during 
the first year of life, but most of the findings were secondary to progressive 
hydrocephalus. Following the initial management of the increased intracranial pressure, 
patient 2 received extensive rehabilitation and luckily showed a benign neurological 
course with gradually normalizing development. Recent clinical follow-up at age 11 was 
consistent with normal cognitive development, while motor performance was only 
slightly abnormal because of mild generalized hypotonia. Throughout several years, this 
patient showed increased CK values. No episodes of diarrhea or hepatomegaly were 
documented as in patient 1. Currently, both children have dysmorphic facial features in 
common and generalized hypotonia. Laboratory findings are consistent with disturbed 
coagulation factors and abnormal liver enzymes. Coagulation abnormalities, liver 
dysfunction and dysmorphic features are often seen in other CDG’s, including the most 
common type, PMM2-CDG. 
The seven known β-1,4-galactosyltransferases differ in kinetics, tissue expression 
and oligosaccharide acceptor specificity. B4GALT1 and B4GALT2 are considered most 
important in galactosylation of N-glycans, although others like B4GALT3 and B4GALT4 
can perform a role in N-glycan galactosylation [23,25]. B4GALT1 is a 52 kDa protein, 
anchored into the Golgi membrane [26]. The last 268 amino acids form the catalytic 
domain formed by two flexible loops. The long flexible loop, formed by amino acids I341-
H361, contains amino acids crucial for binding Mn2+ (a D-X-D motif), the UDP-Gal donor and 
the GlcNAc acceptor molecule [27]. Truncation of this loop, caused by the mutation, is likely 
to strongly decrease the enzyme function. 
Several mouse models were described presenting a B4GALT1 deficiency [28-31]. 
These were mainly characterized by growth retardation and early death. Other 
symptoms included transient skin lesions or puffy faces, pituitary insufficiency, delayed 
spermatogenesis, difficulty in delivering pups and inability to lactate. None of these 
symptoms were observed in the patients. Abnormal villi and enhanced proliferation of 
epithelial cells were observed in the small intestine of these mice, which may 
corroborate with the diarrhea seen in patient 1. There is no evidence for neurological 
defects in mice. Kido et al. suggested the existence of another functional B4GALT, 
expressed in the brain, important for galactosylation of brain proteins such as neural cell 
adhesion molecules or myelin-associated glycoprotein [32]. B4GALT2 was later defined 
as the key galactosyltransferase in neuronal development [33] and knock-out mice show 
motor learning retardation and impaired motor coordination, features which are not 
seen in either child with B4GALT1-CDG reported here [34].  
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We wished to investigate the expression of B4GALT1 and other 
galactosyltransferases throughout different human tissues, given the phenotypic 
variability. Our expression data confirm that B4GALT2 is specifically expressed in the 
brain, where the expression of B4GALT1 is relatively low [23,35,36]. Therefore, the 
mutation in B4GALT1 will likely not affect glycosylation of brain proteins, and the 
absence of psychomotor retardation could be explained by the activity of B4GALT2 in 
brain protein glycosylation.  
We describe the phenotypic and laboratory features of B4GALT1-CDG and define 
a clinical syndrome including inherited coagulation disturbance with hepatopathy, mild 
hypotonia and dysmorphic facial features. We extend the features associated with 
B4GALT1-CDG with variable presentation of diarrhea, hepatomegaly and myopia. The 
absence of mental and growth retardation may be explained by the tissue-specific 
expression of B4GALT1, which is barely present in brain. We recommend to perform 
isoelectric focusing of plasma glycoproteins in patients with mild gasto-intestinal and/or 
bleeding symptoms in combination with hepatopathy, also in the absence of neurological 
symptoms.  
 ACKNOWLEDGMENTS 
We thank Alice Jansen for technical assistance in sequencing the B4GALT1 gene. 
This work was supported by the European Commission (LSHM-CT2005-512131, 
Euroglycanet), and Metakids. 
B4GALT1-CDG presents as a non-neurological glycosylation disorder 
~ 155 ~ 
REFERENCES 
1. S.Grunewald, G.Matthijs, and J.Jaeken,  Congenital disorders of glycosylation: a review, Pediatr. Res. 52 
(2002) 618. 
2. J.Jaeken and G.Matthijs,  Congenital disorders of glycosylation: a rapidly expanding disease family, 
Annu. Rev. Genomics Hum. Genet. 8 (2007) 261. 
3. B.Hansske, C.Thiel, T.Lubke, M.Hasilik, S.Honing, V.Peters, P.H.Heidemann, G.F.Hoffmann, E.G.Berger, 
K.von Figura, and C.Körner,  Deficiency of UDP-galactose:N-acetylglucosamine beta-1,4-
galactosyltransferase I causes the congenital disorder of glycosylation type IId, J. Clin. Invest 109 
(2002) 725. 
4. D.J.Lefeber, J.Schönberger, E.Morava, M.Guillard, K.M.Huyben, K.Verrijp, O.Grafakou, A.Evangeliou, 
F.W.Preijers, P.Manta, J.Yildiz, S.Grunewald, M.Spilioti, C.van den Elzen, D.Klein, D.Hess, H.Ashida, 
J.Hofsteenge, Y.Maeda, L.van den Heuvel, M.Lammens, L.Lehle, and R.A.Wevers,  Deficiency of Dol-P-
Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the 
dystroglycanopathies, Am. J. Hum Genet 85 (2009) 76. 
5. J.Jaeken,  Congenital disorders of glycosylation, Ann. N. Y. Acad. Sci. 1214 (2010) 190. 
6. M.Guillard, E.Morava, F.L.van Delft, R.Hague, C.Körner, M.Adamowicz, R.A.Wevers, and D.J.Lefeber,  
Plasma N-Glycan Profiling by Mass Spectrometry for Congenital Disorders of Glycosylation Type II, 
Clin. Chem. 57 (2011) 593. 
7. S.Wopereis, D.J.Lefeber, E.Morava, and R.A.Wevers,  Mechanisms in protein O-glycan biosynthesis and 
clinical and molecular aspects of protein O-glycan biosynthesis defects: a review, Clin. Chem. 52 (2006) 
574. 
8. E.Morava, H.Wosik, J.Karteszi, M.Guillard, M.Adamowicz, J.Sykut-Cegielska, K.Hadzsiev, R.A.Wevers, 
and D.J.Lefeber,  Congenital disorder of glycosylation type Ix: review of clinical spectrum and 
diagnostic steps, J. Inherit. Metab Dis. 31 (2008) 450. 
9. F.Foulquier, E.Vasile, E.Schollen, N.Callewaert, T.Raemaekers, D.Quelhas, J.Jaeken, P.Mills, 
B.Winchester, M.Krieger, W.Annaert, and G.Matthijs,  Conserved oligomeric Golgi complex subunit 1 
deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II, Proc. Natl. 
Acad. Sci. U. S. A 103 (2006) 3764. 
10. E.Morava, D.J.Lefeber, Z.Urban, L.de Meirleir, P.Meinecke, K.G.Gillessen, J.Sykut-Cegielska, 
M.Adamowicz, I.Salafsky, J.Ranells, E.Lemyre, J.van Reeuwijk, H.G.Brunner, and R.A.Wevers,  Defining 
the phenotype in an autosomal recessive cutis laxa syndrome with a combined congenital defect of 
glycosylation, Eur. J. Hum. Genet. 16 (2008) 28. 
11. M.Mohamed, M.Guillard, S.B.Wortmann, S.Cirak, E.Marklova, H.Michelakakis, E.Korsch, M.Adamowicz, 
B.Koletzko, F.J.v.Spronsen, K.E.Niezen-Koning, G.Matthijs, T.Gardeitchik, D.Kouwenberg, R.Zeevaert, 
B.C.Lim, R.Wevers, D.Lefeber, and E.Morava,  Clinical and diagnostic approach in unsolved CDG 
patients with a type 2 transferrin pattern, Biochim. Biophys. Acta 1812 (2011) 691. 
12. X.Wu, R.A.Steet, O.Bohorov, J.Bakker, J.Newell, M.Krieger, L.Spaapen, S.Kornfeld, and H.H.Freeze,  
Mutation of the COG complex subunit gene COG7 causes a lethal congenital disorder, Nat. Med. 10 
(2004) 518. 
13. E.Morava, R.Zeevaert, E.Korsch, K.Huijben, S.Wopereis, G.Matthijs, K.Keymolen, D.J.Lefeber, L.de 
Meirleir, and R.A.Wevers,  A common mutation in the COG7 gene with a consistent phenotype 
including microcephaly, adducted thumbs, growth retardation, VSD and episodes of hyperthermia, Eur. 
J. Hum. Genet. 15 (2007) 638. 
14. U.Kornak, E.Reynders, A.Dimopoulou, J.van Reeuwijk, B.Fischer, A.Rajab, B.Budde, P.Nurnberg, 
F.Foulquier, D.Lefeber, Z.Urban, S.Grunewald, W.Annaert, H.G.Brunner, H.van Bokhoven, R.Wevers, 
E.Morava, G.Matthijs, L.van Maldergem, and S.Mundlos,  Impaired glycosylation and cutis laxa caused 
by mutations in the vesicular H+-ATPase subunit ATP6V0A2, Nat. Genet. 40 (2008) 32. 
15. S.Wopereis, S.Grunewald, K.M.Huijben, E.Morava, R.Mollicone, B.G.van Engelen, D.J.Lefeber, and 
R.A.Wevers,  Transferrin and apolipoprotein C-III isofocusing are complementary in the diagnosis of N- 
and O-glycan biosynthesis defects, Clin. Chem. 53 (2007) 180. 
Chapter 7 
~ 156 ~ 
16. I.van Die, A.van Tetering, W.E.Schiphorst, T.Sato, K.Furukawa, and D.H.van den Eijnden,  The acceptor 
substrate specificity of human beta4-galactosyltransferase V indicates its potential function in O-
glycosylation, FEBS Lett. 450 (1999) 52. 
17. S.Rozen and H.Skaletsky,  Primer3 on the WWW for general users and for biologist programmers, 
Methods Mol. Biol. 132 (2000) 365. 
18. A.P.de Brouwer, H.van Bokhoven, and H.Kremer,  Comparison of 12 reference genes for normalization 
of gene expression levels in Epstein-Barr virus-transformed lymphoblastoid cell lines and fibroblasts, 
Mol. Diagn. Ther. 10 (2006) 197. 
19. K.J.Livak and T.D.Schmittgen,  Analysis of relative gene expression data using real-time quantitative 
PCR and the 2(-Delta Delta C(T)) Method, Methods 25 (2001) 402. 
20. M.W.Pfaffl,  A new mathematical model for relative quantification in real-time RT-PCR, Nucleic Acids 
Res. 29 (2001) e45. 
21. V.Peters, J.M.Penzien, G.Reiter, C.Körner, R.Hackler, B.Assmann, J.Fang, J.R.Schaefer, G.F.Hoffmann, and 
P.H.Heidemann,  Congenital disorder of glycosylation IId (CDG-IId) -- a new entity: clinical 
presentation with Dandy-Walker malformation and myopathy, Neuropediatrics 33 (2002) 27. 
22. M.Guillard, J.Gloerich, H.J.Wessels, E.Morava, R.A.Wevers, and D.J.Lefeber,  Automated measurement of 
permethylated serum N-glycans by MALDI-linear ion trap mass spectrometry, Carbohydr. Res. 344 
(2009) 1550. 
23. M.Amado, R.Almeida, T.Schwientek, and H.Clausen,  Identification and characterization of large 
galactosyltransferase gene families: galactosyltransferases for all functions, Biochim. Biophys. Acta 
1473 (1999) 35. 
24. T.Hennet,  The galactosyltransferase family, Cell Mol. Life Sci. 59 (2002) 1081. 
25. S.Guo, T.Sato, K.Shirane, and K.Furukawa,  Galactosylation of N-linked oligosaccharides by human beta-
1,4-galactosyltransferases I, II, III, IV, V, and VI expressed in Sf-9 cells, Glycobiology 11 (2001) 813. 
26. P.K.Qasba, B.Ramakrishnan, and E.Boeggeman,  Structure and function of beta -1,4-
galactosyltransferase, Curr. Drug Targets. 9 (2008) 292. 
27. E.E.Boeggeman, B.Ramakrishnan, and P.K.Qasba,  The N-terminal stem region of bovine and human 
[beta]1,4-galactosyltransferase I increases the in vitro folding efficiency of their catalytic domain from 
inclusion bodies, Protein Expression and Purification 30 (2003) 219. 
28. M.Asano, K.Furukawa, M.Kido, S.Matsumoto, Y.Umesaki, N.Kochibe, and Y.Iwakura,  Growth 
retardation and early death of beta-1,4-galactosyltransferase knockout mice with augmented 
proliferation and abnormal differentiation of epithelial cells, EMBO J. 16 (1997) 1850. 
29. Q.Lu, P.Hasty, and B.D.Shur,  Targeted mutation in beta1,4-galactosyltransferase leads to pituitary 
insufficiency and neonatal lethality, Dev. Biol. 181 (1997) 257. 
30. M.Kido, M.Asano, Y.Iwakura, M.Ichinose, K.Miki, and K.Furukawa,  Normal levels of serum 
glycoproteins maintained in beta-1, 4-galactosyltransferase I-knockout mice, FEBS Lett. 464 (1999) 
75. 
31. J.Chen, L.Lu, S.Shi, and P.Stanley,  Expression of Notch signaling pathway genes in mouse embryos 
lacking beta4galactosyltransferase-1, Gene Expr. Patterns. 6 (2006) 376. 
32. M.Kido, M.Asano, Y.Iwakura, M.Ichinose, K.Miki, and K.Furukawa,  Presence of polysialic acid and HNK-
1 carbohydrate on brain glycoproteins from beta-1,4-galactosyltransferase-knockout mice, Biochem. 
Biophys. Res. Commun. 245 (1998) 860. 
33. N.Sasaki, H.Manya, R.Okubo, K.Kobayashi, H.Ishida, T.Toda, T.Endo, and S.Nishihara,  beta4GalT-II is a 
key regulator of glycosylation of the proteins involved in neuronal development, Biochem. Biophys. 
Res. Commun. 333 (2005) 131. 
34. T.Yoshihara, K.Sugihara, Y.Kizuka, S.Oka, and M.Asano,  Learning/memory impairment and reduced 
expression of the HNK-1 carbohydrate in beta4-galactosyltransferase-II-deficient mice, J. Biol. Chem. 
284 (2009) 12550. 
35. T.Sato, K.Furukawa, H.Bakker, D.H.van den Eijnden, and I.van Die,  Molecular cloning of a human cDNA 
encoding beta-1,4-galactosyltransferase with 37% identity to mammalian UDP-Gal:GlcNAc beta-1,4-
galactosyltransferase, Proc. Natl. Acad. Sci. U. S. A 95 (1998) 472. 
B4GALT1-CDG presents as a non-neurological glycosylation disorder 
~ 157 ~ 
36. N.W.Lo, J.H.Shaper, J.Pevsner, and N.L.Shaper,  The expanding beta 4-galactosyltransferase gene family: 
messages from the databanks, Glycobiology 8 (1998) 517. 
Chapter 7 
~ 158 ~ 
 
 
 ~ 159 ~ 
 
 
 
 
 
CHAPTER 8 
SUMMARY AND OUTLOOK 
 ~ 160 ~ 
 
Summary and outlook 
~ 161 ~ 
The congenital disorders of glycosylation are a rapidly growing group of 
disorders. With the inclusion of defects affecting the various glycosylation pathways, 
close to 50 disorders can now be categorized as CDG. Among these, the disorders 
affecting N-glycosylation of proteins, possibly in combination with other glycosylation 
pathways, are most abundant.  
Clinically, CDG patients present with a very wide spectrum of symptoms. 
Whereas some patients show mild features, others are severly affected or die at a 
young age. Based on the general symptoms such as failure to thrive, developmental 
delay, coagulation anomalies or gastro-intestinal malfunction, it is challenging for a 
physician to suspect CDG. Nevertheless, even though the symptoms may be common, 
physicians should be encouraged to request CDG screening. Transferrin isoelectric 
focusing (TIEF) provides a first line diagnostic tool for the detection of CDG. This 
plasma protein carries two N-glycans, each terminated by two sialic acids. Based on 
the TIEF pattern and the position of the defect along the N-glycan biosynthesis 
pathway, most CDG can be classified as ‘type I’ or ‘type II’. Additional investigations 
are needed to pinpoint the exact defective step in the glycan biosynthesis.  
CDG type I are caused by a defective enzyme in the cytosol or endoplasmic 
reticulum. This leads to a defective build-up of a lipid-linked oligosaccharide, resulting 
in a protein lacking one or more complete N-glycan chains. Measurement of the 
activity of various enzymes or accumulation of lipid-linked oligosaccharide (LLO) 
intermediates in fibroblasts, or analysis of polyprenols in plasma, can be performed to 
investigate the defective step. Great care must be taken to avoid confusing a real 
glycosylation defect with a secondary cause of hypoglycosylation, such as 
galactosemia or fructosemia. An additional complicating factor in the diagnosis of 
CDG, when a type 1 TIEF pattern is obtained, is the occurrence of transferrin protein 
polymorphisms, also called variants. Combinations of two variants in a person may 
result in a TIEF pattern suggestive of CDG; yet, neuraminidase treatment of the 
transferrin prior to IEF usually allows exclusion of such polymorphism. In such cases, 
two disctinct asialotransferrin bands are visible on the gel. Nevertheless, in chapter 4, 
we present individuals with a distinctive type 1 TIEF pattern with a 
tetrasialo:disialotransferrin ratio of 1:1 and almost no asialotransferrin. After 
neuraminidase digestion, only one band was visible as would be indicative for a true 
CDG. In order to better understand the distinctive IEF pattern, ESI-MS analysis of the 
transferrin peptides was performed. This revealed a mutation of one of the 
asparagines onto which the N-glycans are normally attached. In case 1, the second 
glycan attachment site, Asn630, was mutated into a threonine, and in case 2, the first 
glycan attachment site, Asn432 was mutated into a histidine. Thus, we have shown a 
potential application of mass spectrometry in the diagnosis of CDG, when a type 1 IEF 
pattern is obtained.  
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CDG type II defects affect the processing of glycan chains on the glycoprotein. 
Usually, these proteins do carry their N-glycan chains, yet are not fully terminated. 
This mostly results in lack of terminal sialic acids, and possibly other glycan moieties. 
With the explosion of the number of proteins known to be deficient in CDG type II, it 
was important to improve diagnostic methods. By performing analysis of serum N-
glycans, we expected to observe specific glycans, or glycan features, which could be 
indicative of the defect. As in CDG type I, it is also important to exclude secondary 
causes of a type 2 TIEF pattern, without real glycosylation defect.  
As shown in Chapter 2, we started by optimizing a method for analysis of 
plasma N-glycans from healthy blood donors. These glycans were released by PNGase 
F digestion, permethylated and purified, then measured on a MALDI linear ion trap 
instrument (vMALDI-LTQ, Thermo Fisher Scientific). This mass spectrometer has the 
advantage of high-throughput measurement and multistage sequencing analysis, 
allowing confirmation of glycan structures. We focused on automated data acquisition 
and reproducibility of the measurement. Data acquisition was improved by use of an 
appropriate matrix, α-cyano-4-hydroxycinnamic acid (CHCA), optimisation of the 
instrument settings, and development of a script to automatically extract peak 
intensities. The control serum N-glycan profile is characterized by high peaks at m/z 
2794 and m/z 2432, representing the biantennary, di- and monosialylated complex N-
glycans respectively. Other major glycans are their fucosylated equivalents (m/z 2967 
and 2606), as well as triantennary, trisialylated N-glycans (m/z 3606 and 3778). All 
structures were confirmed by MS2 and MS3 sequencing, which revealed both core and 
antennal fucosylation. Reproducibility analysis showed that the variability of the 
measurement was acceptable, yet that sample processing still required attention.  
Based on our prior experience, we improved the sample preparation procedure 
and measurement (Chapter 3). We extended the set of glycans used for quantitative 
analysis to 38 structures, and defined a number of glycan features to compare samples 
from healthy individuals with respect to patient samples. Using plasma samples with 
normal TIEF pattern (10 adults and 9 children, age 0 – 14 y.), we set up reference 
intervals which were compared to the N-glycome features of patients with a Golgi-
related CDG or a secondary cause of hypoglycosylation. The CHCA matrix was 
replaced by a mixture of 2,5-dihydroxybenzoic acid and N,N-dimethyl aniline, 
providing a more  homogeneous crystallization surface. Comparison of glycan features 
between control and patient samples showed that almost all patient samples had 
increased truncation of their glycans. Glycosyltransferase defects presented a very 
distinctive N-glycan spectrum, in accordance with the defective enzyme: MGAT2-CDG 
was characterized by the presence of monoantennary complex glycans, whereas the 
N-glycans of the B4GALT1-CDG showed high levels of undergalactosylation. Deficient 
GDP-Fuc transporter in SLC35C1-CDG resulted in evident hypofucosylation, yet we 
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could not detect hyposialylation in SLC35A1-CDG, which is due to a CMP-NeuAc 
transporter. The Golgi trafficking defects COG7-CDG and ATP6V0A2-CDG result in an 
increase of truncated N-glycans, confirming that the N-glycan processing is affected at 
different levels along the biosynthetic route. To investigate the possibilities to exclude 
secondary causes of hypoglycosylation, we analyzed the N-glycome of patients with a 
secondary cause of hypoglycosylation (one with isolated liver failure, one with 
citrullinemia type 1 and one with hemophagocytic lymphohistiocytosis). This showed 
truncation of the glycans and decreased amounts of triantennary glycans, yet the most 
obvious observation was a markedly higher fucosylation status: over 50% of all 
quantified glycans were fucosylated. In a patient with sialidase in the blood, high 
levels of glycans lacking their sialic acid capping were measured. In contrast to Golgi 
trafficking defects and other secondary causes of hypoglycosylation, there was no 
decrease of triantennary structures or increased fucosylation.  
Thus, we showed that plasma N-glycan fingerprinting could help in the 
diagnosis of glycosylation defects and that some differences could be defined in the 
features of the quantified glycans, in accordance with the defect. Therefore, we 
proceeded to the measurement of more than 40 samples presenting a type 2 TIEF 
pattern. Most samples showed an increase of truncated glycans: two thirds of the 
samples showed undersialylation and one third showed additional 
undergalactosylation. No samples showed such increased fucosylation that it would 
suggest a secondary cause of hypoglycosylation. Also, no samples showed features 
suggestive of the presence of sialidase in blood. Half of the samples presented an 
increase in the amount of hybrid structures, which was previously seen in COG-CDG. 
This may be indicative of a Golgi trafficking defect. Only in two cases, mass 
spectrometry lead to the identification of the CDG type II gene defect; a general 
sialylation deficiency due to limiting amounts of CMP-sialic acid and a 
galactosyltransferase defect. 
In this last patient, we found a striking increase of undergalactosylated N-
glycans. We first suspected either a defect in the biosynthesis or transport of UDP-
galactose, or a galactosyltransferase defect (Chapter 7). As galactosemia was ruled 
out and the mucin O-glycans were normal, we excluded UDP-Gal biosynthesis and 
transport defects and focused on galactosyltransferase activity. Galactose transfer 
activity to a pNP-GlcNAc acceptor was found to be decreased by 95% in the patient’s 
fibroblasts, as compared to controls. By homozygosity mapping, a region was found to 
be homozygous in the patient and heterozygous in her parents and healthy siblings, 
which contained the gene encoding UDP-Gal:N-acetylglucosamine β-1,4-
galactosyltransferase (B4GALT1). Mutation analysis of this gene revealed a 
homozygous insertion, c.1031-1032insC which creates a frameshift leading to a 
premature stop codon. Previously, another patient had been described with this same 
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mutation [1,2], yet his clinical presentation at the time of diagnosis was very different. 
Our patient presented mainly with hepatointestinal and coagulation problems yet 
with normal psychomotor development, whereas the first B4GALT1-CDG patient was 
described with macrocephaly due to a Dandy-Walker malformation, hypotonia, a 
transient cholestatic syndrome and coagulation anomalies. An update on his physical 
condition revealed that his psychomotor development and his growth parameters had 
normalized. Expression analysis of the galactosyltransferase isoforms B4GALT1 and 
B4GALT2 showed brain specific expression for B4GALT2 and non-neurological 
expression of B4GALT1, in line with the restricted clinical presentation.  
The clinical presentation of CDG patients is further reviewed in Chapter 6, 
where we focus on the diagnostic approach of patients with a type 2 TIEF pattern. 
Besides central nervous system malfunction, coagulation anomalies and hepatopathy, 
the phenotype of newly discovered defects covers a much wider range than the more 
common clinical pattern in CDG type I.  Eleven genetically unsolved patients were 
assessed, who all have a suspected Golgi-related glycosylation defect. Besides common 
clinical features such as liver involvement or mental retardation, some clinical 
features were observed which are uncommon or undescribed in CDG type II: eye 
abnormalities (retinitis pigmentosa, glaucoma, and severe myopia), hearing loss, 
progressive skin wrinkling and cardiomyopathy. Based on particular symptoms and 
laboratory measurements, targeted biochemical and genetic studies were initiated. 
After detection of a type 2 TIEF pattern, additional investigation of a glycosylation 
defect included the following procedures: isofocusing of other plasma glycoproteins, 
exclusion of secondary causes of hypoglycosylation such as galactosemia or 
fructosemia, isofocusing of apo C-III, MALDI mass spectrometric analysis of plasma N-
glycans and measurement of tetrasaccharides in urine. Due to limited sample 
availability, not all analyses could be performed in all patients. Based on these 
investigations, MGAT2-CDG, SLC35C1-CDG, B4GALT1-CDG and GSL1-CDG could be 
excluded. In five patients, a COG-CDG was excluded by direct sequencing of the genes 
and Western Blot analysis. In one patient, mutation analysis of the ATP6V0A2 gene 
revealed two novel mutations in a compound heterozygous form.  In all other patients, 
the exact defect remains to be found.  
In a number of patients presenting with lax skin and combined defects of N- 
and O-glycosylation, mutations were found in the gene encoding the a2 subunit of the 
vacuolar H+-ATPase. When located in the membrane of the Golgi, this pump is 
important for acidification of the Golgi vesicles along the secretory pathway, as well as 
for Golgi trafficking through the formation and fusion of vesicles. In Chapter 5, we 
review the structure of the pump, its function in different cell types and its regulation. 
Different phenotypes are described, arising from mutations in V-ATPase subunits, 
with the emphasis on autosomal recessive cutis laxa type II, as seen in our patients. 
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Nevertheless, the connection between the loss of the a2 subunit, Golgi dysfunction and 
the elastic fibre defects remains unclear. Possibly, alterations in the pH of the Golgi 
may cause glycosylation defects through mislocalization of the glycosyltransferases 
and through changes in enzymatic activity. Impairment of the trafficking, also seen in 
COG-CDG, seems to result in abnormal N- and O-glycosylation. By extention, 
abnormally glycosylated proteins of the extracellular matrix (such as fibulins, 
fibronectins or collagen), or impaired secretion of these proteins, may lead to the cutis 
laxa phenotype. Further investigations are currently performed in order to solve this 
query. 
OUTLOOK 
The knowledge about CDG is constantly increasing. With the inclusion of O-
glycosylation defects, defects of lipid glycosylation and glycosylphosphatidylinositol 
anchor glycosylation, and defects in multiple glycosylation pathways, the number of 
CDG’s has boomed in the last years. It is our conviction that, at this point, only the tip 
of the “CDG-iceberg” is known and that many more defects may be expected. With the 
advances in diagnostic methods, such as mass spectrometry and innovations in the 
field of genetics, it has become possible to screen patients which could not be solved 
by any of the other techniques presented in the diagnostic flowchart (Figure 6.4).  
Transferrin isoelectric focusing currently remains the first line screening 
approach, yet mass spectrometry has now proven to be a useful tool in the diagnosis 
of certain types of glycosylation defects and exclusion of secondary causes of 
hypoglycosylation. Recent improvements in whole exome sequencing have allowed 
further investigation of patients showing a type 1 or type 2 TIEF profile. Nevertheless, 
this is still a costly technique, with complex data interpretation. Mass spectrometry 
has the potential to confirm a suspected defect, identified through whole genome 
sequencing, at the biochemical level. 
Observation of the new B4GALT1-CDG patient, the cohort of CDG type IIx 
patients, and patients with a known defect, illustrate that CDG should be considered in 
patients with a much wider range of clinical symptoms than previously expected. Mild 
clinical features and the absence of psychomotor retardation or intellectual disability 
should not exclude CDG. TIEF should be performed in patients with mild gastro-
intestinal or coagulation abnormalities, in combination with hepatopathy, in patients 
with cardiomyopathy or cardiac rhythm disorders, spondylodysplasia and 
biochemical abnormalities of the copper or iron metabolism.  
It is becoming more and more apparent that some glycosylation disorders are 
restricted to specific cells or tissues. Recently, a mutation in the β-galactoside-α2,3-
sialyltransferase-III (ST3GAL3) was described, which leads to mental retardation 
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without other physical symptoms [3]. We expect that a wide range of tissue-specific or 
cell type-specific defects will become apparent as the diagnostic methods improve. 
Glycan profiling by mass spectrometry has the potential to detect glycosylation 
anomalies in cells such as fibroblast or leukocytes, tissues such as liver or muscle, or 
body fluids such as cerebrospinal fluid.  
Knowledge and easy detection of the defects is of great importance to the 
medical community, in order to provide genetic counselling and prenatal testing. 
While awaiting treatment, understanding of the pathomechanisms is essential for 
management of the disease.  
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De congenitale defecten in glycosylering (CDG), of glycosyleringsziektes, zijn 
een snel groeiende groep ziektes. Wanneer defecten in de verschillende 
glycosyleringsroutes in beschouwing worden genomen, kan men thans bijna 50 
verschillende ziektes onderscheiden. De meest voorkomende defecten treffen de N-
glycosylering van eiwitten, al dan niet in combinatie met andere glycosyleringstypes.  
CDG-patiënten vertonen een brede scala aan klinische verschijnselen. Sommige 
patiënten zijn slecht licht aangedaan, terwijl anderen ernstige afwijkingen vertonen of 
op jonge leeftijd overlijden. De algemene symptomen zoals langzame groei, 
ontwikkelings-achterstand, bloedstollingsafwijkingen or maag- en darmstoornissen 
maken het moeilijk voor clinici om de diagnose ‘glycosyleringsziekte’ te stellen. Toch 
worden zij geadviseerd om CDG screening in te zetten wanneer deze verschijnselen 
voorkomen. Isoelektrische focusering van transferrine (TIEF) is thans de meest 
gebruikte screeningsmethode om glycosyleringsziektes op te sporen. Dit plasma-eiwit 
draagt twee N-glycanen die elk eindigen op twee siaalzuren. Op basis van het TIEF 
profiel en de positie langs de N-glycaan biosynthese route, kan men voor de meeste 
CDGs onderscheid maken tussen ‘type I’ of ‘type II’. Bijkomend onderzoek is dan 
noodzakelijk om het exacte defect in de glycaanbiosynthese te bepalen.  
CDG type I worden veroorzaakt door een enzymatisch defect in het cytosol of 
het endoplasmatisch reticulum. Dit leidt tot een slechte opbouw van een lipid-gelinkt 
oligosaccharide (LLO) waardoor het eiwit een of meer volledige N-glycanen mist. Om 
het exacte defect te bepalen, kan men metingen uitvoeren van enzymactiviteiten en 
opstapeling van LLO intermediairen in fibroblasten, of polyprenolen in plasma 
analyseren. Het is belangrijk om eerst secundaire oorzaken van hypoglycosylering, 
zoals fructose of galactosemie, uit te sluiten. Bovendien wordt de diagnose van CDG 
type I gecompliceerd door het voorkomen van transferrine eiwit polymorfismen, 
genaamd varianten. De combinatie van twee varianten in een persoon kan aanleiding 
geven tot een TIEF patroon dat een CDG suggereert. Door het transferrine vóór de 
isofocusering te behandelen met neuraminidase, kunnen polymorfismes meestal 
worden uitgesloten, omdat er in aanwezigheid van een polymorfisme twee 
asialotransferrine banden zichtbaar zijn op de gel. In hoofdstuk 4 onderzoeken we 
een paar situaties waarbij een duidelijk type 1 TIEF profiel te zien is, met een 1:1 
verhouding van tetrasialo-:disialotransferrine, en bijna geen asialotransferrine. Na 
neuraminidasebehandeling was er slechts één band zichtbaar, wat zou wijzen op een 
CDG type I. Om dit patroon beter te begrijpen, werden de transferrinepeptiden 
gemeten met ESI-massaspectrometrie. Hiermee werd een mutatie gevonden van een 
van de asparagines waarop een N-glycaan gebonden had moeten zijn. In het eerste 
geval was dit de tweede glycosyleringssite, Asn630, die gemuteerd was tot een 
threonine. In het tweede geval was Asn432 gemuteerd tot een histidine. Op deze wijze 
Chapter 9 
~ 170 ~ 
hebben we de toegevoegde waarde bewezen van massaspectrometrie in de diagnose 
van CDGs met type 1 TIEF profiel.  
CDGs type II defecten treffen de bewerking van glycanen nadat ze op het eiwit 
zijn overgebracht, waardoor ze niet helemaal afgewerkt worden. Dit leidt 
hoofdzakelijk tot een tekort aan terminale siaalzuren, en mogelijk bijkomende suikers. 
Het explosief toenemend aantal gekende defecten in CDG type II heeft geleid tot de 
noodzaak om nieuwe diagnostische methoden te ontwikkelen. Door serum N-glycanen 
te analyseren, verwachten wij specifieke glycanen of glycaaneigenschappen te kunnen 
onderscheiden die wijzen op het defect. Net als bij CDG type I is het tevens belangrijk 
om secundaire oorzaken van een type 2 TIEF profiel uit te sluiten.  
Hoofdstuk 2 beschrijft het opzetten en optimaliseren van een methode voor 
analyse van N-glycanen uit plasma van gezonde bloeddonoren. Deze glycanen werden 
met behulp van het enzym PNGase F van hun eiwit gescheiden, gepermethyleerd en 
gezuiverd. Vervolgens werden ze gemeten op een MALDI linear ion trap 
massaspectrometer (vMALDI-LTQ, Thermo Fischer Scientific). Dit instrument heeft 
het voordeel dat een groot aantal monsters gemeten kunnen worden, en de 
glycaanstructuren bevestigd kunnen worden door sequentieanalyse. De nadruk werd 
gelegd op automatiseren van de dataopnamen en de reproduceerbaarheid van de 
meting. Het serum N-glycaanprofiel van gezonde mensen wordt bepaald door hoge 
pieken bij m/z 2794 en m/z 2432: dit zijn respectievelijk de biantennaire, di- en 
monogesialyleerde complexe N-glycanen. Ook hun gefucosyleerde equivalenten (m/z 
2967 en 2606) en triantennaire, trigesialyleerde N-glycanen (m/z 3606 en 3778) zijn 
prominent aanwezig. Reproduceerbaarheidsanalyses geven aan dat de variabiliteit 
van de meting binnen aanvaardbare grenzen ligt, maar dat het opwerken van de 
monsters nog aan verbetering toe is.  
De verbeteringen in opwerking en meting worden voorgesteld in hoofdstuk 3. 
Nu werd een set van 38 glycanen gebruikt voor kwantitatieve analyse. Bovendien 
werd een aantal glycaaneigenschappen gedefinieerd, zodat monsters van gezonde 
mensen vergeleken konden worden met monsters van patiënten. Plasma monsters 
met normaal TIEF profiel (10 volwassenen en 9 kinderen, leeftijd 0 – 14 j.) werden 
gebruikt om referentie intervals op te stellen voor deze glycaaneigenschappen. Deze 
werden vergeleken met de profielen van plasma N-glycanen van patiënten met een 
Golgi-gerelateerd CDG of een secundaire oorzaak van hypoglycosylering. Bijna alle 
patiëntmonsters vertonen een verhoging van onafgewerkte glycanen. 
Glycosyltransferase defecten tonen zeer kenmerkende profielen, conform het defect: 
het profiel van een MGAT2-CDG patiënt wordt gedomineerd door de monoantennaire 
complexe glycaan, terwijl de N-glycanen van een B4GALT1-CDG patiënt hoge 
ondergalactosylering tonen. Een deficiënte GDP-fucose transporter bij een SLC35C1-
CDG leidt tot duidelijk verlaagde fucosylering. Echter, er werd geen verlaagde 
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sialylering gezien bij SLC35A1-CDG, veroorzaakt door een defect CMP-siaalzuur 
transporter. Golgi transport defecten, zoals gezien in COG7-CDG en ATP6V0A2-CDG, 
leiden tot een algemene afknotting van de glycanen. Dit bewijst dat de bewerking van 
glycanen op verschillende niveaus wordt beïnvloed langs de biosynthese route. Bij 
patiënten met een secundaire oorzaak van hypoglycosylering observeert men een 
verhoogde afknotting van glycanen en een verlaagde hoeveelheid triantennaire 
structuren, maar vooral een opvallende verhoging van de fucosylering: meer van 50% 
van de gekwantificeerde glycanen zijn gefucosyleerd. In een patiënt die aanwezigheid 
van neuraminidase in het bloed vertoont, werden hoge hoeveelheden ongesialyleerde 
glycanen gemeten, zonder verlaging in de hoeveelheid triantennaire structuren of 
verhoogde fucosylering. 
Op deze manier hebben we aangetoond dat plasma N-glycaan analyse kan 
helpen in het stellen van diagnoses bij glycosyleringsziektes. Veertig monsters met 
type 2 TIEF profiel werden opgewerkt en gemeten. De meeste N-glycaan profielen 
vertonen verhoogde afknotting van glycanen: twee derde toonde enkel verlaagde 
sialylering en één derde ook verlaagde galactosylering. Geen enkel monster toonde 
een dergelijke hoge fucosylering dat een secundaire oorzaak werd vermoeden, of 
eigenschappen die duiden op neuraminidase in het bloed. De helft van de monsters 
vertoonde een verhoging van de hybride structuren, wat eerder gezien was in COG-
CDG. Dit zou kunnen wijzen op een Golgi transport defect. In twee gevallen leidde de 
massaspectrometrie tot het identificeren van een CDG type II defect: een algemeen 
sialyleringsdefect ten gevolge van een tekort aan CMP-siaalzuur, en een 
galactosyltransferasedefect.  
 In deze laatste patiënt werd een opvallende verhoging van 
ondergegalactosyleerde N-glycanen gevonden. Dit was vermoedelijk het gevolg van 
een defect in biosynthese of transport van UDP-galactose, of een galactosyltransferase 
defect (hoofdstuk 7). Galactosemie werd uitgesloten en de mucine O-glycanen waren 
normaal. Daarom werden biosynthese- en transportdefecten achterwege gelaten om 
te focusen op een transferase defect. De transfer van galactose naar een pNP-GlcNAc 
acceptor bleek 95% verlaagd, in vergelijking met controles. Genetische analyse leidde 
tot het vinden van een homozygote insertie, c.1031-1032insC, in het B4GALT1-gen, 
coderend voor UDP-Gal:N-acetyl-glucosamine β-1,4-galactosyltransferase. Dit geeft 
aanleiding tot een premature stop codon. In het verleden werd een andere patiënt 
beschreven met dezelfde mutatie [1,2], maar zijn klinische presentatie op het moment 
van de diagnose was zeer verschillend. Onze patiënt vertoonde hoofdzakelijk lever- en 
darmproblemen en afwijkende bloedstolling. De eerste B4GALT1-CDG patiënt, 
daarentegen, vertoonde macrocephalie ten gevolge van een Dandy-Walker 
malformatie, hypotonie, een transient cholestatisch syndroom en bloedstollings-
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afwijkingen. Echter, recente klinische informatie over deze patiënt leerde ons dat zijn 
psychomotore ontwikkeling en groeiparameters genormaliseerd waren.  
 In hoofdstuk 6 wordt de klinische presentatie van 11 CDG patiënten 
verzameld. Hierbij wordt gefocused op de diagnostiek van patiënten met een type 2 
TIEF profiel. Hieruit blijkt dat naast problemen van het centrale zenuwstelsel, 
bloedstollingsafwijkingen en leverafwijkingen, een veel bredere scala aan symptomen 
wordt gezien in deze patiënten dan men in CDG type I observeert. Elf genetisch 
onopgeloste patiënten met een vermoedelijk Golgi transport-gerelateerd defect 
werden onderzocht. Naast de veel voorkomende klinische eigenschappen zoals 
leverafwijkingen en mentale retardatie, werden ook andere symptomen gezien die 
zeldzaam of onbekend waren bij CDG type II: oogafwijkingen, doofheid, progessieve 
rimpeling van de huid en cardiomyopathie. Op basis van specifieke symptomen en 
laboratoriumonderzoek werden doelgerichte biochemische en genetische studies 
ingezet. Een type 2 TIEF profiel gaf aanleiding tot de volgende mogelijke onderzoeken: 
isofocusering van andere plasmaglycoproteïnen, uitsluiten van secundaire oorzaken 
van hypoglycosylering, isofocusering van apo C-III, MALDI massaspectrometrie van 
plasma N-glycanen en meting van tetrasacchariden in urine. Op basis van de 
resultaten werden MGAT2-CDG, SLC35C1-CDG, B4GALT1-CDG en GSL1-CDG 
uitgesloten. In 5 patiënten werd COG-CDG uitgesloten op basis van directe sequencing 
van genen en Western Blot analyse. In een patiënt leidde mutatie analyse van het 
ATP6V0A2 gen tot het vinden van twee nieuwe compound heterozygote mutaties. In 
alle andere patiënten moet het exacte defect nog gevonden worden.  
In een aantal patiënten met cutis laxa en gecombineerde N- en O-
glycosylerings-defecten werden mutaties gevonden in het gen dat de a2 subunit van 
de vacuolar H+-ATPase codeert. Wanneer deze in de Golgimembraan voorkomt, zorgt 
de ATPase voor verzuring van de Golgicompartimenten en voor transport door 
afsplitsing en fusie van vesicles. In hoofdstuk 5 wordt de structuur van deze pomp 
beschreven, alsook zijn functie in verschillende celtypes en de regulering ervan. 
Verschillende phenotypes worden beschreven die het gevolg zijn van gekende 
mutaties in de ATPase subunits. De nadruk wordt gelegd op autosomaal recessieve 
cutis laxa type II, die in onze patiënten te zien is. Het is thans nog onduidelijk wat het 
verband is tussen het verlies van de a2 subunit, Golgi defecten en de defecten van de 
elastische vezels van de huid. Mogelijk zorgt een verandering van pH in het Golgi 
ervoor dat glycosyltransferases verkeerd gelocaliseerd zijn, of niet optimaal werken, 
met glycosyleringsdefecten tot gevolg. Afwijkend transport, zoals ook gezien wordt in 
COG-CDG, kan ook aanleiding geven tot de N- en O-glycosyleringsdefecten. Als gevolg 
zouden essentiële glycoproteïnen van de extracellulaire matrix (zoals fibulines, 
fibronectines en collageen) niet goed geglycosyleerd kunnen worden, of niet op de 
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correcte manier buiten de cel gebracht worden, wat zou leiden tot het cutis laxa 
fenotype. Meer onderzoek wordt hier nog aan besteed.  
VOORUITZICHTEN 
De kennis van CDG wordt steeds groter. Met inbegrip van O-glycosylerings-
defecten, defecten van lipide glycosylering en glycosylphosphatidylinositol anker 
glycosylering, en defecten in meerdere routes, is het aantal gekende defecten enorm 
gestegen in de laatste jaren. Wij zijn er van overtuigd dat we thans slecht de top van 
de ‘CDG-ijsberg’ kennen, en dat vele nieuwe defecten in de komende jaren ontdekt 
zullen worden. Dankzij de vooruitgang van diagnostische methodes zoals 
massaspectrometrie en genetische analyses is het mogelijk geworden om patiënten te 
screenen die niet opgelost kunnen worden aan de hand van de technieken die 
voorgesteld worden in het standaard diagnostisch traject (figuur 6.4).  
Transferrine isofocusing is nog steeds de meest gebruikte screeningsmethode, 
maar massaspectrometrie heeft bewezen een nuttige toepassing te zijn in de diagnose 
van bepaalde glycosyleringsdefecten en het uitsluiten van secundaire oorzaken van 
hypoglycosylering. Recente vooruitgangen in whole exome sequencing laten toe om 
patiënten met een type 1 of type 2 TIEF verder te onderzoeken, maar het is een 
prijzige techniek en de interpretatie van de gegevens is complex. Door middel van 
massaspectrometrie kan men een mogelijk defect, gevonden met whole exome 
sequencing, bevestigen op biochemisch niveau.  
Observatie van de nieuwe B4GALT1-CDG patiënt, de CDG type IIx patiënten, 
alsook patiënten met een gekend defect, wijzen er op dat veel meer symptomen 
voorkomen in CDG-patiënten dan tot nu toe werd aangenomen. Milde klinische 
presentaties en de afwezigheid van psychomotore retardatie of intellectuele 
achterstand zijn geen reden om CDG uit te sluiten. TIEF zou ook uitgevoerd moeten 
worden bij milde aandoeninging van  maag en darmen, of bloedstollingsafwijkingen in 
combinatie met leveraandoeningen, in patiënten met cardiomyopathie of 
hartritmestoornissen, spondylodysplasie en biochemische afwijkingen van koper en 
ijzermetabolisme.  
Het is steeds duidelijker dat sommige glycosyleringsafwijkingen beperkt 
blijven tot specifieke cellen of weefsels. Recent werd een mutatie ontdekt in het β-
galactoside-α2,3-sialyltransferase-III (ST3GAL3), die leidt tot mentale retardatie 
zonder andere symptomen [3]. We vermoeden dat er menig cel- of weefselspecifieke 
defecten bekend zullen worden naarmate de diagnostische methodes ontwikkeld 
worden. Glycaan profiling door massaspectrometrie zou glycosyleringsafwijkingen 
kunnen aantonen in cellen zoals fibroblasten of leukocyten, in weefsels zoals lever of 
spier, en in liquor.  
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Kennis en een snelle detectie van CDG is van groot belang voor de medische 
wereld, zodat genetisch advies verstrekt kan worden, bij voorbeeld bij prenaal 
onderzoek. In afwachting van therapie en behandelmethoden, is het belangrijk om de 
pathomechanismen van glycosyleringsziektes te begrijpen om de ziekteverschijnselen 
onder controle te kunnen houden.  
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